日本臨牀　73/増刊7　免疫性神経疾患

出版社： 日本臨牀社
発行日： 2015-09-20
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 免疫性神経疾患―基礎・臨床研究の最新知見―
電子書籍版： 2015-09-20 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

20,350 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

20,350 円(税込)

購入する

目次

  • 日本臨牀　73/増刊7　免疫性神経疾患

    ―目次―

    特集　免疫性神経疾患―基礎・臨床研究の最新知見―

    I．総　　　論
    　1　免疫性神経疾患研究の歴史と展望
    　2　免疫性神経疾患の発症要因
    　3　免疫性神経疾患と免疫系
    　4　病態形成
    　5　免疫性神経疾患の動物モデル

    II．免疫性中枢神経疾患
    　1　多発性硬化症(MS)
    　2　視神経脊髄炎(NMO)
    　3　急性散在性脳脊髄炎(ADEM)
    　4　溶連菌感染と関連した自己免疫性神経疾患と
    　　　　　抗大脳基底核抗体
    　5　Bal 病 (同心円硬化症)
    　6　アトピー性脊髄炎
    　7　横断性脊髄炎

    III．中枢・末梢連合脱髄症
    　1　中枢・末梢連合脱髄症の概念・疫学
    　2　中枢・末梢連合脱髄症と抗ニューロファシン抗体
    　3　中枢・末梢連合脱髄症の病態・診断・治療

    IV．免疫性末梢神経疾患
    　1　Guillain-Barr 症候群(GBS)とFisher症候群(FS)
    　2　慢性炎症性脱髄性多発根ニューロパチー(CIDP)
    　3　多巣性運動ニューロパチー(MMN)
    　4　抗MAG抗体陽性ニューロパチー
    　5　Crow-Fukase(POEMS)症候群
    　6　急性自律性感覚性ニューロパチー
    　7　自己免疫性自律神経節障害
    　　　(autoimmune autonomic ganglionopathy: AAG)

    V．免疫性筋疾患
    　1　重症筋無力症(MG)　
    　2　HTLV-1関連脊髄症(HAM)　
    　3　多発筋炎・皮膚筋炎・封入体筋炎・壊死性筋症

    VI．その他の免疫性神経疾患
    　1　自己免疫性脳炎・脳症
    　2　膠原病および類縁疾患に伴う神経・筋障害
    　3　傍腫瘍性神経症候群

    VII．特　　　論
    　1　多発性硬化症とセマフォリン4
    　2　Tumefactive multiple sclerosisとコネキシン
    　3　NLRP3 インフラマゾームと多発性硬化症/EAE
    　4　抗myelin oligodendrocyte glycoprotein (MOG) 抗体
    　5　多発性硬化症とmicroRNA
    　6　多発性硬化症における髄鞘再生戦略
    　7　医療経済学的視点からみた多発性硬化症治療の課題
    　8　分子標的治療とprogressive multifocal
    　　　　　leukoencephalopathy
    　9　免疫性神経疾患患者の妊娠・出産時の対応と治療

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 総論

P.11 掲載の参考文献
1) 小副川学, 松岡健 : 多発性硬化症の臨床疫学. 多発性硬化症の診断と治療 (吉良潤一編), p11-18, 新興医学出版社, 2008.
 
2) Polman CH, et al : Diagnostic criteria for multiple sclerosis : 2010 revisions to the McDonald criteria. Ann Neurol 69 : 292-302, 2011.
 
3) Fang L, et al ; South Japan Multiple Sclerosis Genetics Consortium : Interleukin-7 receptor alpha gene polymorphism influences multiple sclerosis risk in Asians. Neurology 76 : 2125 -2127, 2011.
 
4) Lennon VA, et al : A serum autoantibody marker of neuromyelitis optica : distinction from multiple sclerosis. Lancet 364 : 2106, 2004.
PubMed
5) Lennon VA, et al : IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202 : 473-477, 2005.
 
6) Misu T, et al : Loss of aquaporin 4 in lesions of neuromyelitis optica : distinction from multiple sclerosis. Brain 130 : 1224, 2007.
PubMed
7) Takano R, et al : Astrocytic damage is far more severe than demyelination in NMO : a clinical CSF biomarker study. Neurology 75 : 208-216, 2010.
PubMed
8) Chihara N, et al : Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 108 : 3701-3706, 2011.
PubMed
9) Miyamoto K, et al : A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413 : 531, 2001.
PubMed
10) Hoch W, et al : Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7 : 365-368, 2001.
 
11) Shigemoto K, et al : Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest 116 : 1016, 2006.
PubMed
12) Higuchi O, et al : Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69 : 418-422, 2011.
PubMed
13) Lennon VA, et al : Autoantibodies bind solubilized calcium channel-omega-conotoxin complexes from small cell lung carcinoma : a diagnostic aid for Lambert-Eaton myasthenic syndrome. Mayo Clin Proc 64 : 1498-1504, 1989.
PubMed
14) Fukunaga H, et al : Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci USA 80 : 7636-7640, 1983.
 
15) Braun PE, et al : Myelin-associated glycoprotein is the antigens for a monoclonal IgM in polyneuropathy. J Neurochem 39 : 1261-1265, 1982.
PubMed
16) Ariga T, et al : Characterization of sulfated glucuronic acid containing glycolipids reacting with IgM M-proteins in patients with neuropathy, J Biol Chem 262 : 848-853, 1987.
PubMed
17) Ilyas M et al : Serum antibodies to gangliosides in Guillain-Barre syndrome. Ann Neurol 23 : 440-447, 1988.
 
18) Feasby TE, et al : An acute axonal form of Guillain-Barre polyneuropathy. Brain 109 : 1115-1126, 1986.
PubMed
19) Yuki N, et al : A bacterium lipopolysaccharide that elicits Guillain-Barre syndrome has a GMI ganglioside-like structure. J Exp Med 178 : 1771, 1993.
 
20) Chiba A, et al : Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 31 : 677, 1992.
PubMed
21) Saida T, et al : Experimental allergic neuritis induced by sensitization with galactocerebroside. Science 204 : 1103, 1979.
PubMed
22) Nagai Y, et al : Ganglioside syndrome, a new autoimmune neurologic disorder, experimentally induced with brain gangliosides. Neurosci Lett 2 : 107, 1976.
PubMed
23) Kusunoki S, et al : Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurol 39 : 424, 1996.
PubMed
24) Yuki N, et al : Animal model of axonal Guillain-Barre syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 49 : 712, 2001.
PubMed
25) Kaida K, et al : Ganglioside complexes as new target antigens in Guillain-Barre syndrome. Ann Neurol 56 : 567, 2004.
PubMed
26) Dyck PJ, et al : Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 50 : 621-637, 1975.
PubMed
27) Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) : report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 41 : 617-618, 1991.
 
28) Joint Task Force of the EFNS and the PNS : European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy : Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision. J Peripher Nerv Syst 15 : 1-9, 2010.
 
29) Pestronk A, et al : Atreatable multifocal motor neuropathy with antibodies to GMIganglioside. Ann Neurol 24 : 73 -78, 1988.
 
30) Kaji R, et al : Multifocal demyelinating motor neuropathy : cranial nerve involvement and immunoglobulin therapy. Neurology 42 : 506, 1992.
PubMed
31) Miyashiro A, et al : Are multifocal motor neuropathy patients underdiagnosed? An epidemiological survey in Japan. Muscle Nerve 49 : 357-361, 2014.
PubMed
32) Joint Task Force of the EFNS and the PNS : European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy : report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. J Peripher Nerv Syst 15 : 295-301, 2010.
PubMed
33) Osame M, et al : Chronic progressive myelopathy associated with elevated antibodies to HTLV-1 and adult T cell leukemia like cells. Ann Neurol 21 : 117, 1987.
PubMed
34) Nakanishi T, et al : The Crow-Fukase syndrome : A study of 102 cases in Japan. Neurology 34 : 712, 1984.
PubMed
35) Watanabe O, et al : Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve 21 : 1390, 1998.
PubMed
36) Kuwabara S, et al : Neurologic improvement after peripheral blood stem cell transplantation in POEMS syndrome. Neurology 71 : 1691, 2008.
PubMed
37) Dalmau J, et al : Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 61 : 25-36, 2007.
PubMed
38) 亀井聡 : 若年女性に好発する急性非ヘルペス性脳炎 (Acute Juvenile Female Non-Herpetic Encephalitis : AJFNHE). 神経研究の進歩 48 : 827-836, 2004.
 
39) Liguori R, et al : Morvan's syndrome : peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 124 : 2417-2426, 2001.
 
40) Lai M, et al : Investigation of LGII as the antigen in limbic encephalitis previously attributed to potassium channels : a case series. Lancet Neuro 19 : 776-785, 2010.
 
41) Irani SR, et al : Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated lprotein and contactin-associated protein-2 in limbic encephalitis Morvan's syndrome and acquired neuromyotonia. Brain 133 : 2734-2748, 2010.
 
42) Sano F, et al : Peripheral nerve pericytes modify the blood-nerve barrier function and tight junctional molecules through the secretion of various soluble factors. J Cell Physiol 226 : 255-266, 2011.
 
43) Mizuno T, et al : Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid-β neurotoxicity. Am J Pathol 179 : 2016-2027, 2011.
 
P.20 掲載の参考文献
1) Sadovnick AD, et al : A population-based study of multiple sclerosis in twins : Update. Ann Neurol 33 : 281-285, 1993.
PubMed
2) Sadovnick AD, et al : Evidence for genetic basis of multiple sclerosis. The Canadian Collaborative Study Group. Lancet 347 : 1728-1730, 1996.
 
3) Olerup O, Hillert J : HLA class II-associated genetic susceptibility in multiple sclerosis : a critical evaluation. Tissue Antigens 38 : 1-15, 1991.
PubMed
4) Haines JL, et al : Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The Multiple Sclerosis Genetics Group. Hum Mol Genet 7 : 1229-1234, 1998.
PubMed
5) Oksenberg JR, et al : Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet 74 : 160-167, 2004.
 
6) Isobe N, et al : Genetic risk variants in African Americans with multiple sclerosis. Neurology 81 : 219-227, 2013.
PubMed
7) Barcellos LF, et al : Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 15 : 2813-2824, 2006.
PubMed
8) Sawcer S, et al : Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476 : 214-219, 2011.
 
9) Marrosu MG, et al : Dissection of the HLA association with multiple sclerosis in the founder isolated population of Sardinia. Hum Mol Genet 10 : 2907-2916, 2001.
PubMed
10) Rioux JD, et al : Mapping of multiple susceptibility variants within the MHC region for 7 immunemediated diseases. Proc Natl Acad Sci USA 106 : 18680-18685, 2009.
PubMed
11) Zephir H, et al : Is neuromyelitis optica associated with human leukocyte antigen? Mult Scler 15 : 571-579, 2009.
PubMed
12) Brum DG, et al : HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis. Mult Scler 16 (1) : 21-29, 2010.
PubMed
13) Deschamps R, et al : Different HLA class II (DRB1 and DQB1) alleles determine either susceptibility or resistance to NMO and multiple sclerosis among the French Afro-Caribbean population. Mult Scler 17 : 24-31, 2011.
 
14) Kira J, et al : Western versus Asian types of multiple sclerosis : immunogenetically and clinically distinct disorders. Ann Neurol 40 : 569-574, 1996.
PubMed
15) Yamasaki K, et al : HLA-DPB1*0501 -associated opticospinal multiple sclerosis : clinical, neuroimaging and immunogenetic studies. Brain 122 : 1689-1696, 1999.
PubMed
16) Ono T, et al : Molecular analysis of HLA class I (HLA-A and-B) and HLA class II (HLA-DRB1) genes in Japanese patients with multiple sclerosis (Western type and Asian type). Tissue Antigens 52 : 539-542, 1998.
 
17) Yoshimura S, et al : Genetic and infectious profiles of Japanese multiple sclerosis patients. PLoS One 2012 ; 7 (11) : e48592. doi : 10.1371/journal. pone. 0048592. Epub 2012 Nov 9.
 
18) Yoshimura S, et al : Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin-4 antibody status. J Neurol Neurosurg Psychiatry 84 : 29-34, 2013.
PubMed
19) Qiu W, et al : HLA-DR allele polymorphism and multiple sclerosis in Chinese populations : a metaanalysis. Mult Scler 17 : 382-388, 2011.
PubMed
20) Kira J : Genetic and environmental factors underlying the rapid changes in epidemiological and clinical features of multiple sclerosis and neuromyelitis optica in Japanese. Clin Exp Neuroimmunol 4 : 261-273, 2013.
 
21) Beecham AH, et al : Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 45 : 1353-1360, 2013.
PubMed
22) Isobe N, et al : Genetic studies of multiple sclerosis and neuromyelitis optica : current status in European, African American, and Asian populations. Clin Exp Neuroimmunol 5 : 61-68, 2014.
 
23) Fang L, et al : Interleukin-7 receptor alpha gene polymorphism influences multiple sclerosis risk in Asians. Neurology 76 : 2125-2127, 2011.
PubMed
24) Ainiding G, et al : Interleukin 2 receptor α chain gene polymorphisms and risks of multiple sclerosis and neuromyelitis optica in southern Japanese. J Neurol Sci 337 : 147-150, 2014.
 
25) Fukazawa T, et al : Association of vitamin D receptor gene polymorphism with multiple sclerosis in Japanese. J Neurol Sci 166 : 47-52, 1999.
PubMed
26) Niino M, et al : No association of vitamin D-binding protein gene polymorphisms in Japanese patients with MS. J Neuroimmunol 127 : 177-179, 2002.
 
27) Niino M, et al : Estrogen receptor gene polymorphism in Japanese patients with multiple sclerosis. J Neurol Sci 179 (S1-2) : 70-75, 2000.
 
28) Fukazawa T, et al : CTLA-4 gene polymorphism is not associated with conventional multiple sclerosis in Japanese. J Neuroimmunol 159 : 225-229, 2005.
 
29) Niino M, et al : Genetic polymorPhisms of osteopontin in association With multiple sclerosis in Japanese patients. J Neuroimmunol 136 : 125-129, 2003.
PubMed
30) Miyagishi R, et al : C-C chemokine receptor 2 gene polymorphism in Japanese patients with multiple sclerosis. J Neuroimmunol 145 : 135-138, 2003.
PubMed
31) Callea L, et al : Platelet activating factor is elevated in cerebral spinal fluid and plasma of patients with relapsing-remitting multiple sclerosis. J Neuroimmunol 94 : 212-221, 1999.
PubMed
32) Osoegawa M, et al : Platelet-activating factor receptor gene polymorphism in Japanese patients with multiple sclerosis. J Neuroimmunol 161 : 195-198, 2005.
PubMed
33) Fadok VA, et al : Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 101 : 890-898, 1998.
PubMed
34) Osoegawa M, et al : Platelet-activating factor acetylhydrolase gene polymorphism and its activity in Japanese patients with multiple sclerosis. J Neuroimmunol 150 : 150-156, 2004.
PubMed
35) Kurtzke JF, et al : Validity of the epidemics of multiple sclerosis in the Faroe Islands. Neuroepidemiology 7 : 190-227, 1988.
PubMed
36) Lucas RM, et al : Epstein-Barr virus and multiple sclerosis. J Neurol Neurosurg Psychiatry 82 : 1142-1148, 2011.
PubMed
37) Pakpoor J, et al : The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus : a meta-analysis. Mult Scler 19 : 162-166, 2013.
 
38) Li, et al : Helicobacter pylori is a potential protective factor against conventional type multiple sclerosis in the Japanese population. J Neuroimmunol 184 : 227-231, 2007.
 
39) Li W, et al : Association of anti-Helicobacter pylori neutrophil-activating protein antibody response with anti-aquaporin-4 autoimmunity in Japanese patients with multiple sclerosis and neuromyelitis optica. Mult Scler 15 : 1411-1421, 2009.
PubMed
40) Pedrini MJ, et al : Helicobacter pylori infection as a protective factor against multiple sclerosis risk in females. J Neurol Neurosurg Psychiatry 86 : 603-607, 2015.
PubMed
41) Bagos PG, et al : Chlamydia pneumoniae infection and the risk of multiple sclerosis : a metaanalysis. Mult Scler 12 : 397-411, 2006.
PubMed
42) Tanaka M, et al : Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis. Neurology 71 : 974-981, 2008.
PubMed
43) Matsushita T, et al : Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One 8 (4) : e61835, 2013.
PubMed
44) Marrie RA : Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol 3 : 709-718, 2004.
PubMed
45) Koch-Henriksen N, et al : Why does the north-south gradient of incidence of multiple sclerosis seem to have disappeared on the northern hemisphere? J Neurol Sci 311 : 58-63, 2011.
PubMed
46) Kira J : Multiple sclerosis in the Japanese population. Lancet Neurol 2 : 117-127, 2003.
PubMed
47) Pierrot-Deseilligny C, Souberbielle JC : Is hypovitaminosis D one of the environmental risk factors for multiple sclerosis? Brain 133 : 1869-1888, 2010.
PubMed
48) Niino M, et al : Decreased serum vitamin D levels in Japanese patients with multiple sclerosis. J Neuroimmunol 279 : 40-45, 2015.
PubMed
49) Berg-Hansen P, et al : High prevalence and no latitude gradient of multiple sclerosis in Norway. Mult Scler 20 : 1780-1782, 2014.
PubMed
50) O'Gorman C, Broadley SA : Smoking and multiple sclerosis : evidence for latitudinal and temporal variation. J Neurol 261 : 1677-1683, 2014.
PubMed
51) Sabouri AH, et al : Differences in viral and host genetic risk factors for development of human T-cell lymphotropic virus type 1 (HTLV-1) -associated myelopathy/tropical spastic paraparesis between Iranian and Japanese HTLV-1-infected individuals. J Gen Virol 86 : 773-781, 2005.
PubMed
52) Avidan N, et al : Genetic basis of myasthenia gravis-a comprehensive review. J Autoimmun 52 : 146-153, 2014.
PubMed
53) Renton AE, et al : A genome-wide association study of myasthenia gravis. JAMA Neurol 72 : 396-404, 2015.
PubMed
54) Suzuki S, et al : Heterogeneous immunogenetic background in Japanese adults with myasthenia gravis. J Neurol Sci 189 : 59-64, 2001.
PubMed
55) Horiki T, et al : Combinations of HLA-DPB1 and HLA-DQB1 alleles determine susceptibility to early-onset myasthenia gravis in Japan. Autoimmunity 19 : 49-54, 1994.
 
56) Zhu WH, et al : HLA-DQA1*03 : 02/DQB1*03 : 03 : 02 is strongly associated with susceptibility to childhood-onset ocular myasthenia gravis in Southern Han Chinese. J Neuroimmunol 247 : 81-85, 2012.
 
57) Xie YC, et al : Association between HLA-DRB1 and myasthenia gravis in a northern Han Chinese population. J Clin Neurosci 18 : 1524-1527, 2011.
 
58) Koga M, et al : Guillain-Barre and Fisher's syndromes subsequent to Campylobacter jejuni enteritis are associated with HLA-B54 and Cw1 independent of anti-ganglioside antibodies. J Neuroimmunol 88 : 62-66, 1998.
 
59) Geleijns K, et al : HLA. class II alleles are not a general susceptibility factor in Guillain-Barre syndrome. Neurology 64 : 44-49, 2005.
 
60) Vaughan RW, et al : Major histocompatibility complex class I and class II polymorphism in chronic idiopathic demyelinating polyradiculoneuropathy. J Neuroimmunol 27 : 149-153, 1990.
 
61) McCombe PA, et al : Studies of HLA associations in male and female patients with Guillain-Barre syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). J Neuroimmunol 180 : 172-177, 2006.
PubMed
62) Mrad M, et al : Association of HLA-DR/DQ polymorphism with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in Tunisian patients. Transfus Apher Sci 49 : 623-626, 2013.
PubMed
63) Iijima M, et al : Single nucleotide polymorphism of TAG-1 induences Mg responsiveness of Japanese patients with CIDP. Neurology 73 : 1348-1352, 2009.
PubMed
64) Pang SY, et al : Single-nucleotide polymorphism of transient axonal glycoprotein-1 and its correlation with clinical features and prognosis in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 17 : 72-75, 2012.
PubMed
65) Notturno F, et al : Susceptibility to chronic inflammatory demyelinating polyradiculoneuropathy is associated to polymorphic GA repeat in the SH2D2A gene. J Neuroimmunol 197 : 124-127, 2008.
 
P.32 掲載の参考文献
1) Akira S, et al : Pathogen recognition and innate immunity. Cell 124 : 783-801, 2006.
PubMed
2) Jacob CO, et al : Identification of IRAKI as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci USA 106 : 6256-6261, 2009.
 
3) Andersson A, et al : Pivotal advance : HMGB1 expression in active lesions of human and experimental multiple sclerosis. J Leukoc Biol 84 : 1248-1255, 2008.
PubMed
4) Prinz M, et al : Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest 116 : 456-464, 2006.
 
5) Touil T, et al : Cutting Edge : TLR3 stimulation suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN-beta. J Immunol 177 : 7505-7509, 2006.
 
6) Malhotra S, et al : NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis. Brain 138 : 644-652, 2015.
 
7) Pashenkov M, et al : Two subsets of dendritic cells are present in human cerebrospinal fluid. Brain 124 : 480-492, 2001.
PubMed
8) Stasiolek M, et al : Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain 129 : 1293-1305, 2006.
PubMed
9) Bielekova B, et al : Regulatory CD56 (bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 103 : 5941-5946, 2006.
PubMed
10) Axtell RC, et al : Type I interferons : beneficial in Th1 and detrimental in Th17 autoimmunity. Clin Rev Allergy Immunol 44 : 114-120, 2013.
PubMed
11) Axtell RC, et al : T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 16 : 406-412, 2010.
PubMed
12) Mars LT, et al : Cutting edge : Valpha 14-J alpha 281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice. J Immunol 168 : 6007-6011, 2002.
 
13) Araki M, et al : Th2 bias of CD4+ NKT cells derived from multiple sclerosis in remission. Int Immunol 15 : 279-288, 2003.
PubMed
14) Miyamoto K, et al : A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413 : 531-534, 2001.
PubMed
15) Miyazaki Y, et al : Mucosal-associated invariant T cells regulate Th1 response in multiple sclerosis. Int Immunol 23 : 529-535, 2011.
PubMed
P.41 掲載の参考文献
1) Comabella M, Khoury SJ : Immunopathogenesis of multiple sclerosis. Clin Immunol 142 : 2-8, 2012.
PubMed
2) CroUy ST : Follicular helper cell differentiation, function, and roles in disease. Immunity 41 : 529-542, 2014.
 
3) Kleinewietfeld M, Hafler DA : Regulatory T cells in autoimmune neuroinflammation. Immunol Rev 259 : 231-244, 2014.
PubMed
4) Peters A, et al : The many faces of Th17 cells. Curr Opin Immunol 23 : 702-706, 2011.
PubMed
5) Laan M, Peterson P : The many faces of aire in central tolerance. Front Immunol 4 : 326, 2013.
PubMed
6) Aharoni R, et al : Age dependent course of EAE in Aire-/-mice. J Neuroimmunol 262 : 27-34, 2013.
PubMed
7) Su MA, et al : Defective autoimmune regulator-dependent central tolerance to myelin protein zero is linked to autoimmune peripheral neuropathy. J Immunol 188 : 4906-4912, 2012.
PubMed
8) Berrih-Aknin S : Myasthenia Gravis : paradox versus paradigm in autoimmunity. J Autoimmun 52 : 1-28, 2014.
PubMed
9) Pepper M, Jenkins MK : Origins of CD4 (+) effector and central memory T cells. Nat Immunol 12 : 467-471, 2011.
PubMed
10) Cua DJ, et al : Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421 : 744-748, 2003.
PubMed
11) Sallusto F, et al : T-cell trafficking in the central nervous system. Immunol Rev 248 : 216-227, 2012.
PubMed
12) Sato W, et al : CCR2 (+) CCR5 (+) Tcells produce matrix metalloproteinase-9 and osteopontin in the pathogenesis of multiple sclerosis. J Immunol 189 : 5057-5065, 2012.
 
13) Stromnes IM, et al : Differential regulation of central nervous system autoimmunity by T (H) 1 and T (H) 17 cells. Nat Med 14 : 337-342, 2008.
 
14) Axtell RC, et al : Thelper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 16 : 406-412, 2010.
 
15) Mitsdoerffer M, et al : Immunology of neuromyelitis optica : a T cell-B cell collaboration. Ann NY Acad Sci 1283 : 57-66, 2013.
 
16) Dalakas MC : Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol 7 : 507-517, 2011.
PubMed
17) Miyara M, et al : Functional delineation and ditiferentiation dynarnics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30 : 899-911, 2009.
PubMed
18) Thiruppathi M, et al : Functional defect in regulatory T cells in myasthenia gravis. Ann NY Acad Sci 1274 : 68-76, 2012.
PubMed
19) Chi LJ, et al : Impairment of circulating CD4+ CD25+ regulatory T cells in patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 13 : 54-63, 2008.
PubMed
P.49 掲載の参考文献
1) Vincent A, et al : Autoantibodies associated with diseases of the CNS : new developments and future challenges. Lancet Neurol 10 : 759-772, 2011.
PubMed
2) Probst C, et al : Anti-neuronal autoantibodies : Current diagnostic challenges. Mult Scler Relat Disord 3 : 303-320, 2014.
PubMed
3) Jarius S, et al : Neuromyelitis optica : clinical features, immunopathogenesis and treatment. Clin Exp Immunol 176 : 149-164, 2014.
PubMed
4) Kaida K, Kusunoki S : Antibodies to gangliosides and ganglioside complexes in Guillain-Barre syndrome and Fisher syndrome : mini-review. J Neuroimmunol 223 : 5-12, 2010.
PubMed
5) Vernino S, et al : Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy. Auton Neurosci 146 : 3-7, 2009.
 
6) Jayawant S, et al : Autoimmune myasthenia gravis. Handb Clin Neurol 113 : 1465-1468, 2013.
PubMed
7) Dalakas MC : Pathophysiology of inflammatory and autoimmune myopathies. Presse Med 40 : 237-247, 2011.
 
8) Rosenfeld MR, Dalmau J : Diagnosis and management of paraneoplastic neurologic disorders. Curr Treat Options Oncol 14 : 528-538, 2013.
PubMed
9) Adamus G : Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy. Autoimmun Rev 8 : 410-414, 2009.
PubMed
10) Dalmau J, Rosenfeld MR : Autoimmune encephalitis update. Neuro Oncol 16 : 771-778, 2014.
PubMed
11) Vincent A : Developments in autoimmune channelopathies. Autoimmun Rev 12 : 678-681, 2013,
PubMed
12) Malter MP, et al : Outcome of hmbic encephaUds with VGKC-complex antibodies : relation to antigenic specificity. J Neurol 261 : 1695-1705, 2014.
 
13) Kayser MS, Dalmau J : Anti-NMDA receptor encephalitis, autoimmunity, and psychosis. Schizophr Res 2014 Oct 25. pii : S0920-9964 (14) 00546-5. [Epub ahead of print]
 
14) Hoftberger R, et al : Encephalitis and GABAB receptor antibodies : novel findings in a new case series of 20 patients. Neurology 81 : 1500-1506, 2013.
 
15) Yoneda M, et al : High prevalence of serum autoantibodies against the amino terminal of alpha-enolase in Hashimoto's encephalopathy. J Neuroimmunol 185 : 195-200, 2007.
PubMed
P.56 掲載の参考文献
1) Sano Y, Kanda T : Blood-neural barrier : overview and latest progress. Clin Exp Neuroimmunol 4 : 220-227, 2013.
 
2) Derfuss T, et al : Natalizumab therapy for multiple sclerosis. Semin Neurol 33 : 26-36, 2013.
PubMed
3) Kanda T : Biology of the blood-nerve barrier and its alteration in immune mediated neuropathies. J Neurol Neurosurg Psychiatry 84 : 208-212, 2013.
PubMed
4) Kermode AG, et al : Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain 113 : 1477-1489, 1990.
PubMed
5) 清水文崇, 神田隆 : 血液脳関門と神経免疫疾患. BRAIN and NERVE 65 : 165-176, 2013.
 
6) Minagar A, et al : Serum from patients with multiple sclerosis downregulates occludin and VE-cadherin expression in cultured endothelial cells. Mult Scler 9 : 235-238, 2003.
PubMed
7) Shimizu F, et al : Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier. PLoS One 9 : e92872, 2009.
 
8) Bradl M, et al : Neuromyelitis optica : pathogenicity of patient immunoglobulin in vivo. Ann Neurol 66 : 630-643, 2009.
PubMed
9) Shimizu F, et al : Sera from neuromyelitis optica patients disrupt the blood-brain barrier. J Neurol Neurosurg Psychiatry 83 : 288-297, 2012.
PubMed
10) Tasaki A, et al : Autocrine MMP-2/9 secretion increases the BBB permeability in neuromyelitis optica. J Neurol Neurosurg Psychiatry 85 : 419-430, 2014.
PubMed
11) Saito K, et al : Blood-brain barrier destruction determines Fisher/Bickerstaff clinical phenotypes : an in vitro study. J Neurol Neurosurg Psychiatry 84 : 756-765. 2013.
 
12) Kanda T, et al : A fulminant case of Guillain-Barre syndrome : topographic and fibre size related analysis of demyelinating changes. J Neurol Neurosurg Psychiatry 52 : 857-864, 1989.
PubMed
13) Shimizu F, et al : Severity and patterns of blood-nerve barrier breakdown in patients with chronic inflammatory demyelinating polyradiculoneuropathy : correlations with clinical subtypes. PLoS One 9 : e104205, 2014.
PubMed
14) Kaji R, et al : Pathological findings at the site of conduction block in multifocal motor neuropathy. Ann Neurol 33 : 152-158, 1993.
PubMed
15) Shimizu F, et al : Sera from patients with multifocal motor neuropathy disrupt the blood-nerve barrier. J Neurol Neurosurg Psychiatry 85 : 526-537, 2014.
PubMed
P.64 掲載の参考文献
1) Altman J : Are new neurons formed in the brains of adult mammals? Science 135 : 1127-1128, 1962.
PubMed
2) Kaplan MS, Hinds JW : Neurogenesis in the adult rat : electron microscopic analysis of light radioautographs. Science 197 : 1092-1094, 1977.
PubMed
3) Reynolds BA, Weiss S : Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 255 : 1707-1710, 1992.
PubMed
4) Ming GL, Song H : Adult neurogenesis in the mammalian brain : significant answers and significant questions. Neuron 70 : 687-702, 2011.
PubMed
5) Rasmussen S, et al : Reversible neural stem cell niche dysfunction in a model of multiple sclerosis. Ann Neurol 69 : 878-891, 2011.
 
6) Pluchino S, et al : Persistent inflammation alters the function of the endogenous brain stem cell compartment. Brain 131 : 2564-2578, 2008.
PubMed
7) Zheng LS, et al : Mechanisms for interferon-α-induced depression and neural stem cell dysfunction. Stem Cell Reports 3 : 73-84, 2014.
 
8) Kaneko N, et al : Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. Neuropsychopharmacology 31 : 2619 -2626, 2006.
 
9) Garrido-Mesa N, et al : Minocycline : far beyond an antibiotic. Br J Pharmacol 169 : 337-352, 2013.
PubMed
10) Zabad RK, et al : The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes : a pilot study. Mult Scler 13 : 517-526, 2007.
PubMed
11) Siegert RJ, Abernethy DA : Depression in multiple sclerosis : a review. J Neurol Neurosurg Psychiatry 76 : 469-475, 2005.
PubMed
12) Gould E, et al : Neurogenesis in the dentate gyrus of the adult tree shrew is regulated by psychosocial stress and NMDA receptor activation. J Neurosci 17 : 2492 -2498, 1997.
 
13) Hitoshi S, et al : Antidepressant drugs reverse the loss of adult neural stem cells following chronic stress. J Neurosci Res 85 : 3574-3585, 2007.
PubMed
14) Santarelli L, et al : Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301 : 805-809, 2003.
PubMed
15) Moriguchi A, et al : The fifth exon of the myelin proteolipid protein-coding gene is not utilized in the brain of jimpy mutant mice. Gene 55 : 333-337, 1987.
 
16) Kagawa T, et al : Glial cell degeneration and hypomyelination caused by overexpression of myelin proteolipid protein gene. Neuron 13 : 427-442, 1994.
PubMed
17) Shimizu T, et al : Olig2-lineage cells preferentially differentiate into oligodendrocytes but their processes degenerate at the chronic demyelinating stage of proteolipid protein-overexpressing mouse. J Neurosci Res 91 : 178-186, 2013.
PubMed
18) Chang A, et al : Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 346 : 165-173, 2002.
PubMed
19) Burt RK, et al : Autologous non-myeloablative haemopoietic stem cell transplantation in relapsingremitting multiple sclerosis : a phase I/II study. Lancet Neurol 8 : 244-253, 2009.
PubMed
20) Pluchino S, et al : Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 422 : 688-694, 2003.
 
P.72 掲載の参考文献
1) Heppner FL, et al : Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med 11 (2) : 146-152, 2005.
PubMed
2) Yamasaki R, et al : Differential roles of microglia and monocytes in the inflamed central nervous system. J Exp Med 211 (8) : 1533-1549, 2014.
PubMed
3) Li H, et al : Tumor necrosis factor-α promotes granulocyte-macrophage colony-stimulating factor-stimulated microglia to differentiate into competent dendritic cell-like antigen-presenting cells. Clin Exp Neuroimmunol 2 : 1-11, 2011.
 
4) Keir ME, et al : PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26 : 677-704, 2008.
PubMed
5) Kawanokuchi J, et al : Production and functions of IL-17 in microglia. J Neuroimmunol 194 : 54-61, 2008.
PubMed
6) Lehman SM, et al : An unconventional role for miRNA : let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat Neurosci 15 : 827-835, 2012.
 
7) Zehnter SP, et al : Constitutive expression of a costimulatory ligand on antigen-presenting cells in the nervous system drives demyelinating disease. FASEB J 17 : 1910-1912, 2003.
 
8) Werner P, et al : Multiple sclerosis : altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 244 : 169-180, 2001.
 
9) 錫村明生 : 神経細胞死におけるミクログリアの役割. 細胞工学 30 (10) : 1042-1045, 2011.
Medical*Online
10) Pohl M, et al : Tcell-activation in neuromyelitis optica lesions play a role in their formation. Acta Neuropathol Commun 1 (1) : 85, 2013.
 
11) Satoh J, et al : Neuromyelitis optica/Davic's disease : gene expression profiling of brain lesions. Neuropathology 28 (6) : 561-576, 2008.
 
12) Matsushita T, et al : Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis opitca, relapsing remitting or primary progressive multiple sclerosis. PLos One 8 (4) : e61835, 2013.
PubMed
13) Lee Y, et al : Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 487 (7408) : 443-448, 2012.
PubMed
P.80 掲載の参考文献
1) Freund J, et al : IMMUNIZATION AGAINST MALARIA : VACCINATION OF DUCKS WITH KILLED PARASITES INCORPORATED WITH ADJUVANTS. Science 102 (2643) : 200-202, 1945.
PubMed
2) Carnegie P, Lumsden C : Encephalitogenic peptides from spinal cord. Nature 209 (5030) : 1354-1355, 1966.
PubMed
3) 山村隆 : 実験的自己免疫性脳脊髄炎. 最新医学 52 : 59-64, 1997.
 
4) Tuohy VK, et al : Myelin proteolipid protein-induced experimental allergic encephalomyelitis : variations of disease expression in different strains of mice. J Immunol 140 : 1868-1873, 1988.
PubMed
5) Linington C, et al : T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system. Eur J Immunol 23 : 1364-1372, 1993.
PubMed
6) Simmons SB, et al : Modeling the heterogeneity of multiple sclerosis in animals. Trends Immunol 34 : 410-422, 2013.
PubMed
7) Yu M, et al : A predictiable sequential determinant spreading cascade invariably accompanies pregression of experimental autoimmune encephalomyelitis : a basis for peptide-specific therapy after onset of clinical disease. J Exp Med 183 : 1777-1788, 1996.
 
8) Goverman J : Role of distinct effector cell subsets in CNS autoimmune diseases. 12th International Cogress of Neuroimmunology (Mainz) : Plenary session 3, 2014.
 
9) Stromnes IM, et al : Differential regulation of central nervous system autoimmunity by TH1 and TH17 cells. Nat Med 14 : 337-342, 2008.
PubMed
10) Goverman J, et al : Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 72 : 551-560, 1993.
 
11) Mix E, et al : Animal models of multiple sclerosis-Potentials and limitations. Prog Neurobiol 92 : 386-404, 2010.
PubMed
12) Roos RP : Pathogenesis of Theiler's murine encephalomyelitis virus-induced disease. Molecular Biology of Picornaviruses (ed by Semler BL Wimmer E), p427-435, ASM Press, Washington DC, 2002.
 
13) Miller SD, et al : Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat Med 3 : 1133-1136, 1997.
PubMed
14) Stavrou S, et al : Different strains of Theiler's murine encephalomyelitis virus antagonize different sites in the type I interferon pathway. J Virol 84 : 9181-9189, 2010.
PubMed
15) Praet J, et al : Cellular and molecular neuropathology of the cuprizone mouse model : Clinical relevance for multiple sclerosis. Neurosci Biobehav Rev 47 : 485-505, 2014.
PubMed
P.87 掲載の参考文献
1) Lennon VA, et al : A serum autoantibody marker of neuromyelitis optica : distinction from multiple sclerosis. Lancet 364 : 2106-2112, 2004.
PubMed
2) Misu T, et al : Loss of aquaporin-4 in active perivasucular lesions in neuromyelitis optica : a case report. Tohoku J Exp Med 209 (3) : 269-275, 2006.
 
3) Bradl M, et al : Neuromyelitis optica : pathogenicity of patient immunoglobulin in vivo. Ann Neurol 66 : 630-643, 2009.
PubMed
4) Bennett JL, et al : Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 66 : 617-629, 2009.
PubMed
5) Kinoshita M, et al : Neuromyelitis optica : Passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun 386 : 623-627, 2009.
PubMed
6) Hinson SR, et al : Pathologic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 69 : 2221-2231, 2007.
PubMed
7) Kinoshita M, et al : Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. Neuroreport 20 : 508-512, 2009.
PubMed
8) Hinson SR, et al : Aquaporin-5-binding autoantibodies impair glutamate transport by down-regulating EAAT2. J Exp Med 2005 (11) : 2472-2481, 2008.
 
9) Saadoun S, et al : Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133 : 349-361, 2010.
PubMed
10) Nishiyama S, et al : A case of NMO seropositive for aquaporin-4 antibody more than years before onset. Neurology 72 (22) : 1960-1961, 2009.
 
11) Kinoshita M, et al : Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells. Biochem Biophys Res Commun 394 : 205-210, 2010.
PubMed
12) Saadoun S, et al : Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol 71 : 323-333, 2012.
 
13) Zang H, et al : Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J Clin Invest 123 (5) : 2306-2316, 2013.
 
14) Kitic M, et al : Intrastriatal injection of interleukin-1 beta triggers formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats. Acta Neuropathol Commun 1 (1) : 5, 2013.
PubMed
15) Tradtrantip L, et al : Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 71 (3) : 314-322, 2012.
PubMed
16) Zang H, et al : Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59. J Autoimmun 53 : 64-77, 2014.
 
17) Sato DK, et al : Distinction between MOG antibody-positive and AQP4 antibody-positive NMO specrum disorders. Neurology 82 (6) : 474-481, 2014.
 
18) Saadoun S, et al : Neuromyelitis optica MOG IgG causes reversible lesions in mouse brain. Acta Neuropathol Commun 2 (1) : 35, 2014.
 
19) Krishnamoorthy G, et al : Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J Clin Invest 116 : 2385-2392, 2006.
 
P.96 掲載の参考文献
1) Waksman BH, et al : Allergic neuritis : An experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvants. J Exp Med 102 : 213-236, 1955.
PubMed
2) Smith ME, et al : Experimental allergic neuritis in the Lewis rat. J Neuropathol Exp Neurol 38 : 377-391, 1979.
 
3) Miyamoto K, et al : Heterozygous null mutation of myelin PO protain enhances susceptibility to autoimmune neuritis targeting PO peptide. Eur J Immunol 33 : 656-665, 2003.
 
4) Kusunoki S, et al : Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurol 39 : 424-431, 1996.
PubMed
5) Kusunoki S, et al : Degeneration of rabbit sensory neurons induced by passive transfer of anti-GD1b antiserum. Neurosci Lett 273 : 33-36, 1999.
PubMed
6) Nagai Y, et al : Ganglioside syndrome, a new autoimmune neurologic disorder, experimentally induced with brain gangliosides. Neurosci Lettt 2 : 107-111, 1976.
PubMed
7) Takada K et al : Apoptosis of primary sensory neurons in GD1b-induced sensory ataxic neuropathy. Exp Neurol 209 : 279-283, 2008.
PubMed
8) Hitoshi S, et al : Rabbit experimental sensory ataxic neuropathy : anti-GD1b antibody-mediated trkC downregulation of dosal root ganglia neurons. Neurosci Lett 260 : 157 -160, 1999.
 
9) Yuki N, et al : Animal model of axonal Guillain-Barre syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 49 : 712-720, 2001.
PubMed
10) Susuki K, et al : Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 27 : 3956-3967, 2007.
PubMed
11) Nishimoto Y, et al : Immunoglobulin improves a model of acute motor axonal neuropathy by preventing axonal degeneration. Neurology 62 : 1939-1944, 2004.
 
12) Saida T, et al : Experimental allergic neuritis induced by sensitization with galactocerebrocide. Science 204 : 1103-1106, 1979.
PubMed
13) Samukawa M, et al : Clinical features in Guillain-Barre syndrome with anti-Gal-C antibody. J Neurol Sci 337 : 55-60, 2014.
 
14) Kusunoki S, et al : Anti-Gal-C antibodies in GBS subsequent to mycoplasma infection : evidence of molecular mimicry. Neurology 57 : 736-738, 2001.
 
15) Halstead SK, et al : Eculizmub prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 131 : 1197-1208, 2008.
 
16) Vedeler CA, et al : The expression of CD59 in experimental allergic neuritis. J Neurol Sci 165 : 154-159, 1999.
PubMed
P.104 掲載の参考文献
1) Landis SC, et al : A call for transparent reporUng to optimize the predictive value of prechnical research. Nature 490 : 187-191, 2012.
 
2) Phillips WD, et al : Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis. Exp Neurol 270 : 29-40, 2015.
PubMed
3) Kusner LL, et al : Guidelines for pre-clinical assessment of the acetylcholine receptor-specific passive transfer myasthenia gravis model-Recommendations for methods and experimental designs. Exp Neurol 270 : 3-10, 2015.
PubMed
4) Tuzun E, et al : Guidelines for standard preclinical experiments in the mouse model of myasthenia gravis induced by acetylcholine receptor immunization. Exp Neurol 270 : 11-17, 2015.
PubMed
5) Losen M, et al : Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors-Recommendations for methods and experimental designs. Exp Neurol 270 : 18-28, 2015.
PubMed
6) Drachman DB : Autonomic "myasthenia" : the case for an autoimmune pathogenesis. J Clin Invest 111 : 797-799, 2003.
PubMed
7) Patrick J, Lindstrom J : Autoimmune response to acetylcholine receptor. Science 180 : 871-872, 1973.
PubMed
8) Toyka KV, et al : Myasthenia gravis : passive transfer from man to mouse. Science 190 : 397-399, 1975.
 
9) Shigemoto K, et al : Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest 116 : 1016-1024, 2006.
PubMed
10) Cole RN, et al : Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol 63 : 782-789, 2008.
PubMed
11) Mori S, Shigemoto K : Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis. Autoimmun Rev 12 (9) : 912-917, 2013.
PubMed
12) Mori S, et al : Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. Am J Pathol 180 : 798-810, 2012.
 
13) van der Neut Kolfschoten M, et al : Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317 : 1554-1557, 2007.
PubMed
14) Mori S, et al : Divalent and monovalent autoantibodies cause dysfunction of MuSK by distinct mechanisms in a rabbit model of myasthenia gravis. J Neuroimmunol 244 : 1-7, 2012.
 
15) Klooster R, et al : Muscle-specinc kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 135 (Pt 4) : 1081-1101, 2012.
 
16) Mori S, et al : 3, 4-Diaminopyridine improves neuromuscular transmission in a MuSK antibody-induced mouse model of myasthenia gravis. J Neuroimmunol 245 : 75-78, 2012.
 
17) Higuchi O, et al : Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69 : 418-422, 2011.
PubMed
18) Shen C, et al : Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest 123 (12) : 5190-5202, 2013.
PubMed
19) Rodriguez Cruz PM, et al : Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases. Exp Neurol 270 : 66-71, 2015.
PubMed
P.113 掲載の参考文献
1) Arahata K, Engel AG : Monoclonal antibody analysis of mononuclear cells in myopathies. I : Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 16 (2) : 193-208, 1984.
 
2) Nishio J, et al : Clonal biases of peripheral CD8 T cell repertoire directly reflect local inflammation in polymyositis. J Immunol 167 : 4051-4058, 2001.
PubMed
3) Kohyama K, Matsumoto Y : C-protein in the skeletal muscle induces severe autoimmune polymyositis in Lewis rats. J Neuroimmunol 98 : 130-135, 1999.
PubMed
4) Sugihara T, et al : A new murine model to define the critical pathologic and therapeutic mediators of polymyositis. Arthritis Rheum 56 : 1304-1314, 2007.
 
5) Goebels N, et al : Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest 97 : 2905-2910, 1996.
PubMed
6) Sugihara T, et al : Definitive engagement of cytotoxic CD8 T cells in C-protein induced myositis, a murine model of polymyositis. Arthritis Rheum 62 : 3088-3092, 2010.
 
7) Hirakata M, et al : Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase. Arthritis Rheum 56 : 1295-1303, 2007.
PubMed
8) Lundberg I, et al : Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum 43 : 336-348, 2000.
PubMed
9) Kuru S, et al : Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol 99 : 585-588, 2000.
PubMed
10) Chevrel G, et al : Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NF-kappaB nuclear translocation, and class I MHC expression in muscle cells : in vitro regulation with specific cytokine inhibitors. Ann Rheum Dis 64 : 1257-1262, 2005.
PubMed
11) Sugihara T, et al : Interleukin-1 and tumor necrosis factor alpha blockade treatment of experimental polymyositis in mice. Arthritis Rheum 64 : 2655-2662, 2012.
PubMed
12) Okiyama N, et al : Therapeutic effects of IL-6 blockade on a murine model of polymyositis that does not require IL-17A. Arthritis Rheum 60 : 2505-2512, 2009.
 
13) Okiyama N, et al : T lymphocytes and muscle condition act like seeds and soil in a murine polymyositis model. Arthritis Rheum 64 : 3741-3749, 2012.
 
14) Gomez-Merino D, et al : Effects of chronic exercise on cytokine production in white adipose tissue and skeletal muscle of rats. Cytokine 40 : 23-29, 2007.
PubMed
15) Lira FS, et al : Chronic exercise decreases cytokine production in healthy rat skeletal muscle. Cell Biochem Funct 27 : 458-461, 2009.
PubMed
16) Girgenrath M, et al : TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J 25 : 5826-5839, 2006.
PubMed
17) Griffin CA, et al : Chemokine expression and control of muscle cell migration during myogenesis. J Cell Sci 123 : 3052-3060, 2010.
PubMed
18) Lyon MG, et al : Predisposing factors in polymyositis-dermatomyositis : results of a nationwide survey. J Rheumatol 16 : 1218-1224, 1989.
PubMed
19) Kimura N, Hirata S, Miyasaka N, et al : Injury and subsequent regeneration of muscles for activation of local innate immunity to facilitate development and relapse of autoimmune myositis in C57BL/6 mice. Arthritis Rheumatol 67 : 1107-1116, 2015.
PubMed

II 免疫性中枢神経疾患

P.122 掲載の参考文献
1) Noonan CW, et al : Prevalence estimates for MS in the United States and eVidence of an increasing trend for women. Neurology 58 : 136-138, 2002.
PubMed
2) Bamett MH, et al : Progressive increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia : a 35-year study. J Neurol Sci 213 : 1-6, 2003.
 
3) Wallin MT, et al : Multiple sclerosis in US veterans of the Vietnam era and later military service : race, sex, and geography. Ann Neurol 55 : 65-77, 2004.
PubMed
4) Kuroiwa Y, et al : Nationwide survey of multiple sclerosis in Japan. Clinical analysis of 1,084 cases. Neurology 25 : 845-851, 1975.
PubMed
5) Shibasaki H, et al : Nationwide survey of multiple sclerosis in Japan : reappraisal of clinical features. J Trop Geo Neurol 2 : 73-82, 1992.
 
6) Osoegawa M, et al : Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese : nationwide survey results over 30 years. Mult Scler 15 : 159-173, 2009.
PubMed
7) Cocco E, et al : Anticipation of age at onset in multiple sclerosis : a Sardinian cohort study. Neurology 62 : 1794-1798, 2004.
PubMed
8) Ishizu T, et al : Heterogeneity and continuum of multiple sclerosis phenotypes in Japanese according to the results of the fourth nationwide survey. J Neuol Sci 280 : 22-28, 2009.
 
9) Ebers GC : Environmental factors and multiple sclerosis. Lancet Neurol 7 : 268-277, 2008.
PubMed
10) Kira J : Multiple sclerosis in the Japanees population. Lancet Neurol 2 : 117-127, 2003.
PubMed
11) Houzen H, et al : Increased prevalence, incidence, and female predominance of multipIe sclerosis in northern Japan. J Neurol Sci 323 : 117-122, 2012.
 
12) Alonso A, Hernan MA : Temporal trends in the incidence of multiple sclerosis. A systematic review. Neurology 71 : 129-135, 2008.
PubMed
13) Duan S, et al : Vitamin D status and the risk of multiple sclerosis : a systematic review and metaanalysis. Neurosci Lett 570 : 108-113, 2014,
PubMed
14) Niino M, et al : Association of serum vitamin D levels in Japanese patients with multiple sclerosis. Clin Exp Neuroimmunol 4 : 193-200, 2013.
 
15) Niino M, et al : Decreased serum vitamin D levels in Japanese patients with multiple sclerosis. J Neuroimmunol 279 : 40 -45, 2015.
 
16) Yazdanbakhsh M, et al : Allergy, parasites, and the hygiene hypothesis. Science 296 : 490-494, 2002.
PubMed
17) Li W, et al : Helicobacter pylori is a potential protective factor against conventional type multiple sclerosis in the Japanese population. J Neuroimmunol 184 : 227-231, 2007,
 
18) Li W, et al : Association of anti-Helicobacter pylori neutrophil-activating protein antibody response with anti-aquaporin-4 autoimmunity in Japanese patients with multiple sclerosis and neuromyelitis optica. Mult Scler 15 : 1411-1421, 2009.
PubMed
19) Yoshimura S, et al : Genetic and infectious profiles influence cerebrospinal fluid IgG abnormality in Japanese multiple sclerosis patients. PLos ONE 9 (4) : e95367, 2014.
PubMed
20) Pedrini MJ, et al : Helicobacter pylori infection as a protective factor against multiple sclerosis risk in females. J Neurol Neurosurg Psychiatry 86 : 603-607, 2015.
PubMed
21) Dobson R, et al : Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes : a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry 84 (8) : 909-914, 2013.
PubMed
22) Niino M, et al : Latitude and HLA-DRB1 alleles independently affect the emergence of cerebrospinal fluid IgG abnormality in multiple sclerosis. Mult Scler, 2015 Jan 12. pii : 1352458514560924. [Epub ahead of print]
 
23) Lennon VA, et al : A serum autoantibody marker of neuromyelitis optica : distinction from multiple sclerosis. Lancet 364 : 2106-2112, 2004.
PubMed
24) Lennon VA, et al : IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202 : 473-477, 2005.
 
25) Wingerchuk DM, et al : Revised diagnostic criteria for neuromyelitis optica. Neurology 66 : 1485-1489, 2006.
PubMed
26) Masaki K, et al : Connexin 43 astrocytopathy linked to rapidly progressive multiple sclerosis and neuromyelitis optica. PLoS One 8 (4) : e61835, 2013.
 
27) Kappos L, et al : Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis : a 3-year follow-up analysis of the BENEFIT study. Lancet 370 : 389-397, 2007.
PubMed
28) Polman CH, et al : Diagnostic criteria for multiple sclerosis : 2005 revisions to the "McDonald Criteria". Ann Neurol 58 : 840-846, 2005.
 
29) Polman CH, et al : Diagnostic criteria for multiple sclerosis : 2010 revisions to the McDonald Criteria. Ann Neurol 69 : 292-302, 2011.
 
30) Chong H, et al : Proposed modifications to the McDonald criteria for use in Asia. Mult Scler 15 : 887-888, 2009.
 
P.129 掲載の参考文献
1) Kira J : Multiple sclerosis in the Japanese population. Lancet Neurol 2 : 117-127, 2003.
PubMed
2) Koch-Henriksen N, Serensen PS : The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 9 : 520-532, 2010.
 
3) Osoegawa M, et al : Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese : nationwide survey results over 30 years. Mult Scler 15 : 159-173, 2009.
PubMed
4) Multiple Sclerosis International Federation : Epidemiology of MS. In : Atlas of MS 2013, p 8-11, Multiple Sclerosis International Federaion, London, 2013.
 
5) Ishizu T, et al : Heterogeneity and continuum of multiple sclerosis phenotypes in Japanese according to the results of the fourth nationwide survey, J Neurol Sci 280 (1-2) : 22-28, 2009,
 
6) International Multiple Sclerosis Genetics Consortium, et al : Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476 : 214-219, 2011.
 
7) International Multiple Sclerosis Genetics Consortium (IMSGC), Beechan AH, et al : Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 45 : 1353-1360, 2013.
 
8) Kira J, et al : Western versus Asian types of multiple sclerosis immunogenetically and clinically distinct disorders. Ann Neurol 40 : 569-574, 1996.
PubMed
9) Yamasaki K et al : HLA-DPB1*0501-associated opticospinal multiple sclerosis : clinical, neuroimaging and immunogenetic studies. Brain 122 : 1689-1696, 1999.
PubMed
10) Yoshimura S, et al : Genetic and infectious profiles of Japanese multiple sclerosis patients. PLoS One 7 : e48592, 2012.
PubMed
11) Niino M, et al : Decreased serum vitamin D levels in Japanese patients with multiple sclerosis. J Neuroimmunol 279 : 40-45, 2015.
PubMed
12) Yoshimura S, et al : Genetic and infectious profiles influence cerebrospinal fluid IgG abnormality in Japanese multiple sclerosis patients. PLoS One 9 : e95367, 2014.
PubMed
13) Li W, et al : Helicobacter pylori infection is a potential protective factor against conventional multiple sclerosis in the Japanese population. J Neuroimmunol 184 (1-2) : 227-231, 2007.
 
14) Yoshimura S, et al : Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status. J Neurol Neurosurg Psychiatry 84 : 29-34, 2013.
PubMed
15) Yoshimura S, et al : Bacterial infectious burden and prevalence of idiopathic central nervous system demyelinating diseases in Japanese. Clin Exp Neuroimmunol 4 : 351-352, 2013.
 
P.135 掲載の参考文献
1) Lublin FD, Reingold SC : Defining the clinical course of multiple sclerosis : results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46 : 907-911, 1996.
PubMed
2) Lublin FD, et al : Defining the clinical course of multiple sclerosis : the 2013 revisions. Neurology 83 : 278-286, 2014.
PubMed
3) Vukusic S, Confavreux C : Natural history of multiple sclerosis : risk factors and prognostic indicators, Curr Opin Neurol 20 : 269-274, 2007.
PubMed
4) Tremlett H, et al : New perspectives in the natural history of multiple sclerosis. Neurology 74 : 2004-2015, 2010.
PubMed
5) Ramsaransing GS, De Keyser J : Benign course in multiple sclerosis : a review. Acta Neurol Scand 113 : 359-369, 2006.
PubMed
6) Correale J, et al : Benign multiple sclerosis : a new definition of this entity is needed. Mult Scler 18 : 210-218, 2012.
PubMed
7) Vukusic S, Confavreux C : Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci 206 : 135-137, 2003.
PubMed
8) Confavreux C, Vukusic S : The clinical course of multiple sclerosis. Handb Clin Neurol 122 : 343-369, 2014.
PubMed
9) Leray E, et al : Evidence for a two-stage disability progression in multiple sclerosis. Brain 133 : 1900-1913, 2010.
PubMed
10) Kurtzke JF : Rating neurologic impairment in multiple sclerosis : an expanded disability status scale (EDSS). Neurology 33 : 1444-1452, 1983.
PubMed
11) Kurtzke JF : On the evaluation of disability in multiple sclerosis. Neurology 11 : 686-694, 1961.
PubMed
12) Bronnum-Hansen H, et al : Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 127 : 844-850, 2004.
PubMed
P.140 掲載の参考文献
1) Smith KJ, McDonald WI : The pathophysiology of multiple sclerosis : the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci 354 (1390) : 1649-1673, 1999.
PubMed
2) Frohman TC, et al : Uhthoff s phenomena in MS-clinical features and pathophysiology. Nat Rev Neurol 9 (9) : 535-540, 2013.
PubMed
3) Confavreux C, Vukusic S : Natural history of multiple sclerosis : a unifying concept. Brain 129 (Pt 3) : 606-616, 2006.
 
4) Langer-Gould A, et al : Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis : a systematic review. Arch Neurol 63 (12) : 1686-1691, 2006.
PubMed
5) Rae-Grant AD : Unusual symptoms and syndromes in multiple sclerosis. Continuum (Minneap Minn) 19 (4 Multiple Sclerosis) : 992-1006, 2013.
 
6) McGowan G, et al : The Pulfrich phenomenon ; clumsiness and collisions which can be ameliorated. Pract Neurol 11 (3) : 173-176, 2011.
PubMed
7) Marrie RA, et al : A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. Mult Scler 21 : 342-349, 2015.
PubMed
8) Chiaravalloti ND, DeLuca J : Cognitive impairment in multiple sclerosis. Lancet Neurol 7 (12) : 1139-1151, 2008.
PubMed
9) Rocca MA, et al : Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol 14 (3) : 302-317, 2015.
PubMed
10) Jacobs LD, et al : Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343 (13) : 898-904, 2000.
 
11) Ziemssen T : Multiple sclerosis beyond EDSS : depression and fatigue. J Neurol Sci 277 (Suppl 1) : S37-41, 2009.
 
12) Hadjimichael O, et al : Fatigue characteristics in multiple sclerosis : the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes 6 : 100, 2008.
PubMed
13) Metz LM, et al : The effect of immunomodulatory treatment on multiple sclerosis fatigue. J Neurol Neurosurg Psychiatry 75 (7) : 1045-1047, 2004.
PubMed
14) Mitchell AJ, et al : Quality of life and its assessment in multiple sclerosis : integrating Physical and psychological components of wellbeing. Lancet Neurol 4 (9) : 556-566, 2005.
PubMed
P.147 掲載の参考文献
1) Lassmann H, et al : Immunopathology of multiple sclerosis : report on an international meeting held at the institute of neurology of the University of Vienna. J Neuroimmunol 86 : 213-217, 1998.
 
2) Lucchinetti C : Multiple sclerosis pathology during early and late disease phases : pathogenic and clinical relevance. In : Immune Regulation and Immunotherapy in Autoimmune Disease (ed by Zhang J), p 214-264, Springer, New York, 2007.
 
3) Prineas JW, et al : Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 50 : 646-657, 2001.
PubMed
4) Kutzelnigg A, et al : Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128 : 2705-2712, 2005.
PubMed
5) Lassmann H, et al : Progressive multiple sclerosis : pathology and pathogenesis. Nat Rev Neurol 8 : 647-656, 2012.
PubMed
6) Hametner S, et al : Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol 74 : 848-861, 2013.
 
7) Lucchinetti C, et al : Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 365 : 2188-2197, 2011.
PubMed
8) Howell OW, et al : Meningeal innammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 134 : 2755-2771, 2011.
 
9) Bartholomaus I, et al : Effector T cell interactions with meningeal vascular structures in nascent auto, immune CNS lesions. Nature 462 : 94-98, 2009.
 
10) Kivisakk P, et al : Localizing central nervous system immune surveillance : meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Ann Neurol 65 : 457-469, 2009.
PubMed
11) Magliozzi R, et al : Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130 : 1089-1104. 2007.
PubMed
12) Magliozzi R, et al : A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 68 : 477-493, 2010.
PubMed
13) Bo L, et al : Intracortical multiple sclerosis lesions are not associated with increased lymphocyte inmtration. Mult Scler 9 : 323-331, 2003.
 
14) Bo L, et al : Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 62 : 723-732, 2003.
PubMed
15) Merkler D, et al : A new focal EAE model of cortical demyelination : multiple sclerosis-1ike lesions with rapid resolution of inflammation and extensive remyelination, Brain 129 : 1972-1983, 2006.
 
16) Gardner C, et al : Cortical grey matter demyelination can be induced by elevated pro-inflammatory cytokines in the subarachnoid space of MOG-immunized rats. Brain 136 : 3596-3608, 2013.
PubMed
17) Lucchinetti C, et al : Heterogeneity of multiple sclerosis lesions : implications for the pathogenesis of demyelination. Ann Neurol 47 : 707-717, 2000.
PubMed
18) Metz I, et al : Pathologic heterogeneity persists in early active multiple sclerosis lesions. Ann Neurol 75 : 728-738, 2014.
PubMed
19) Barnett MH, et al : Relapsing and remitting multiple sclerosis : pathology of the newly forming lesion. Ann Neurol 55 : 458-468, 2004.
PubMed
20) Matsuoka T, et al : Reappraisal of aquaporin-4 astrocytopathy in Asian neuromyeUtis op6ca and multiple sclerosis patients. Brain Pathol 21 : 516-532, 2011.
PubMed
21) Masaki K, et al : Connexin 43 astrocytopathy linked to rapidly progressive multiple sclerosis and neuromyelitis optica. PLOS ONE 8 : e72919, 2013.
PubMed
22) Ozawa K, et al : Patterns of oligodendroglia pathology in multiple sclerosis. Brain 117 : 1311-1322, 1994.
PubMed
23) Lucchinetti C, et al : A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain 122 : 2279-2295, 1999.
PubMed
24) Henderson AP, et al : Multiple sclerosis : distribution of infiammatory cells in newly forming lesions. Ann Neurol 66 : 739-753, 2009.
 
25) Matsuoka T, et al : Aquaporin-4 astrocytopathy in Balo's disease. Acta Neuropathol 120 : 651-660, 2010,
PubMed
26) Masaki K, et al : Extensive loss of connexins in Balo's disease : evidence for an auto-antibody-independent astrocytopathy via impaired astrocyte-oligodendrocyte/myelin interaction. Acta Neuropathol 123 : 887-900, 2012.
PubMed
27) Ferguson B, et al : Axonal damage in acute multiple sclerosis lesions. Brain 120 : 393-399, 1997.
PubMed
28) Trapp BD, et al : Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338 : 278-285, 1998.
PubMed
29) Nikic I, et al : A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med 17 : 495-499, 2011.
PubMed
30) Pfeifenbring S, et al : Extensive acute axonal damage in pediatric multiple sclerosis lesions. Ann Neurol 77 : 655-667, 2015.
PubMed
31) Barkhof F, et al : Remyelinated lesions in multiple sclerosis : magnetic resonance image appearance. Arch Neurol 60 : 1073-1081, 2003.
PubMed
32) Patrikios P, et al : Remyelination is extensive in a subset of multiple sclerosis patients. Brain 129 : 3165-3172, 2006.
 
33) Masaki K : Early disruption of glial communication via connexin gap junction in multiple sclerosis, Balo's disease and neuromyelitis optica. Neuropathology. 2015 May 28. doi : 10.1111/neup. 12211. [Epub ahead of print]
 
P.156 掲載の参考文献
1) Zilkha KJ : Chemistry of blood in multiple sclerosis. In : Handbook of Clinical Neurology, Vol. 9 (ed by Vinken PJ, Bruyn GW), p 320 -323, North-Holland, Amsterdum, 1970.
 
2) Harandi AA, et al : Vitamin D and multiple sclerosis. Iran J Neurol 13 : 1-6, 2014.
PubMed
3) Nakatsuji Y, et al : Elevation of Sema4A implicates Th cell skewing and the efficacy of IFN-β therapy in multiple sclerosis. J Immunol 188 : 4858-4865, 2012.
 
4) Ziemann U, et al : Development of biomarkers for multiple sclerosis as a neurodegenerative disorder. Prog Neurobiol 95 : 670-685, 2011.
PubMed
5) Fishman RA : Cerebral Fluid in Disease of the Nervous System, 2nd ed, WB Saunders, Philadelphia, 1992.
 
6) Uzawa A, et al : CSF high-mobility group box l is associated with intrathecal inflammation and astrocytic damage in neuromyelitis optica. J Neurol Neurosurg Psychiatry 84 : 517-522, 2013.
 
7) 田中正美ほか : 髄液IgG indexの日本人正常値. 神経内科 72 : 337-338, 2010.
 
8) 大封昌子ほか : 多発性硬化症・視神経脊髄炎日本人患者での脳脊髄液オリゴクローナルバンドの解析. 神経内科 77 : 537-541, 2012.
 
9) Tumani H, et al ; BioMS Study Group : Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis 35 : 117-127, 2009.
 
10) Uzawa A, et al : Cytokine and chemokine profiles in neuromyelitis optica : significance of interleukin-6. Mult Scler 16 : 1443-1452, 2010.
PubMed
11) Miller A, et al : Bio-markers of disease activity and response to therapy in multiple sclerosis. Clin Neurol Neurosurg 106 : 249-254, 2004.
PubMed
12) Kanesaka T, et al : Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 77 : 185-188, 2006.
PubMed
13) Gajofatto A, et al : Clinical, MRI, and CSF markers of disability progression in multiple sclerosis. Dis Markers 35 : 687-699, 2013.
PubMed
14) Hoglund K, Salter H : Molecular biomarkers of neurodegeneration. Expert Rev Mol Diagn 13 : 845-861, 2013.
PubMed
15) Buck D, Hemmer B : Biomarkers of treatment response in multiple sclerosis. Expert Rev Neurother 14 : 165-172, 2014.
PubMed
P.164 掲載の参考文献
1) Polman CH, et al : Diagnostic criteria for multiple sclerosis : 2010 Revisions to the McDonald criteria. Ann Neurol 69 : 292-302, 2011.
 
2) Doggrell SA : Good results for early treatment of clinically isolated syndrome prior to multiple sclerosis with interferon beta-1b and glatiramer group. Expert Opin Pharmacother 11 : 1225-1230, 2010.
 
3) Loevner LA, et al : Microscopic disease in normal-appearing white matter on conventional MR images in patients with multiple sclerosis : assessment with magnetization-transfer measurements. Radiology 196 : 511-515, 1995.
PubMed
4) Miki Y, et al : Differences between relapsing-remitting and chronic progressive multiple sclerosis as determined with quantitative MR imaging. Radiology 210 : 769-774, 1999.
PubMed
5) Miki Y, et al : Relapsing-remitting multiple sclerosis : longitudinal analysis of MR images-lack of correlation between changes in T2 lesion volume and clinical findings. Radiology 213 : 395-399, 1999.
PubMed
6) Miki Y, et al : Computer-assisted quantitation of enhancing lesions in multiple sclerosis : correlation with clinical classification. AJNR Am J Neuroradiol 18 : 705-710, 1997.
PubMed
7) Saida T, et al : Interferon beta-1b is effective in Japanese RRMS patients : a randomized, multicenter study. Neurology 64 : 621-630, 2005.
PubMed
8) Filippi M, Agosta F : Imaging biomarkers in multiple sclerosis. J Magn Reson Imaging 31 : 770-788, 2010.
PubMed
9) Banwell B, et al : Multiple sclerosis in children : clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol 6 : 887-902, 2007.
PubMed
10) Horowitz AL, et al : The ovoid lesion : a new MR observation in patients with multiple sclerosis. AJNR Am J Neuroradiol 10 : 303-305, 1989.
PubMed
11) Palmer S, et al : Subcallosal striations : early findings of multiple sclerosis on sagittal, thin-section, fast FLAIR MR images. Radiology 210 : 149-153, 1999.
PubMed
12) Miki Y, et al : Isolated U-fiber involvement in MS : preliminary observations. Neurology 50 : 1301-1306, 1998.
PubMed
13) Nielsen AS, et al : Focal cortical lesion detection in multiple sclerosis : 3 tesla DIR versus 7 tesla FLASH-T2*. J Magn Reson Imaging 35 : 537-542, 2011.
PubMed
14) Sethi V, et al : Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI. J Neurol Neurosurg Psychiatry 83 : 877-882, 2012.
PubMed
15) Sethi V, et al : MS cortical lesions on DIR : not quite what they seem? PLoS ONE 8 : e78879, 2013.
PubMed
16) Ge Y, et al : Dirty-appearing white matter in multiple sclerosis : volumetric MR imaging and magnetization transfer ratio histogram analysis. AJNR Am J Neuroradiol 24 : 1935-1940, 2003,
PubMed
17) Vrenken H, et al : Diffusely abnormal white matter in progressive multiple sclerosis : in vivo quantitative MR imaging characterization and comparison between disease types. AJNR Am J Neuroradiol 31 : 541-548, 2010.
PubMed
18) Truyen L, et al : Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 47 : 1469-1476, 1996.
PubMed
19) Roccatagliata L, et al : Multiple sclerosis : hyperintense dentate nucleus on unenhanced T1-weighted MR images is associated with the secondary progressive subtype. Radiology 251 : 503-510, 2009.
PubMed
20) Kasahara S, et al : Hyperintense dentate nucleus on unenhanced T1-weighted MR images is associated with a history of brain irradiation. Radiology 258 : 222-228, 2011.
PubMed
21) Kanda T, et al : High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images : relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 270 : 834-841, 2014.
PubMed
22) Kanda T, et al : High Signal Intensity in Dentate Nucleus on Unenhanced T1-weighted MR Images : Association with Linear versus Macrocyclic Gadolinium Chelate Administration. Radiology 275 : 803-809, 2015.
PubMed
23) Barkhof F, et al : Relapsing-remitting multiple sclerosis : sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR Am J Roentgenol 159 : 1041-1047, 1992.
PubMed
24) Masdeu JC, et al : Open-ring imaging sign : highly specific for atypical brain demyelination. Neurology 54 : 1427-1433, 2000.
PubMed
25) Metafratzi Z, et al : Conventional MRI and magnetisation transfer imaging of tumour-like multiple sclerosis in a child. Neuroradiology 44 : 97-99, 2002.
 
26) Lucchinetti CF, et al : Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 131 : 1759-1775, 2008.
PubMed
27) Kim HS, et al : Added value and diagnostic performance of intratumoral susceptibility signals in the differential diagnosis of solitary enhancing brain lesions : preliminary study. AINR Am J Neuroradiol 30 : 1574-1579, 2009.
 
28) Cha S, et al : Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions. AJNR Am J Neuroradiol 22 : 1109-1116, 2001.
PubMed
29) Pilz G, et al : Tumefactive MS lesions under fingolimod : a case report and literature review. Neurology 81 : 1654-1658, 2013.
PubMed
30) Matsuoka T, et al : Aquaporin-4 astrocytopathy in Balo's disease. Acta Neuropathol 120 : 651-660, 2010.
PubMed
31) Masuda H, et al : Anti-aquaporin-4 antibody-seronegative NMO spectrum disorder with Balo's concentric lesions. Intern Med 52 : 1517-1521, 2013.
 
32) Karaarslan E, et al : Balo's concentric sclerosis : clinical and radiologic features of five cases. AJNR Am J Neuroradiol 22 : 1362-1367, 2001.
PubMed
33) Nakamura M, et al : Preferential spinal central gray matter involvement in neuromyelitis optica. J Neurol 255 : 163-170, 2008.
PubMed
34) Hickman SJ, et al : The optic nerve sheath on MRI in acute optic neuritis. Neuroradiology 47 : 51-55, 2005.
PubMed
35) Filippi M, Rocca MA : MR imaging of multiple sclerosis. Radiology 259 : 659-681, 2011.
PubMed
36) Rocca MA, et al : Imaging the optic nerve in multiple sclerosis. Mult Scler 11 : 537-541, 2005.
PubMed
37) Loblad KO, et al : MR imaging in muhiple sclerosis : review and recommendations for current practice. AJNR Am J Neuroradiol 31 : 983-989, 2010.
 
38) Seewann A, et al : Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology 78 : 302-308, 2012.
PubMed
39) Tsuchiya K, et al : Diffusion-weighted MR imaging in multiple sclerosis : comparison with contrastenhanced study. Eur J Radiol 31 : 165-169, 1999.
PubMed
40) Sai A, et al : Diffusion-weighted imaging thermometry in multiple sclerosis. J Magn Reson Imaging 40 : 649-654, 2014.
PubMed
41) Yoshida M, et al : Diffusional kurtosis imaging of normal-appearing white matter in multiple sclerosis : preliminary clinical experience. Jpn J Radiol 31 : 50-55, 2013.
PubMed
42) Haacke EM, et al : Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. J Magn Reson Imaging 29 : 537-544, 2009.
PubMed
43) Ge Y, et al : Diminished visibility of cerebral venous vasculature in multiple sclerosis by susceptibilityweighted imaging at 3.0 Tesla. J Magn Reson Imaging 29 : 1190-1194, 2009.
 
44) Tourdias T, et al : Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium-and superparamagnetic iron oxide-enhanced MR imaging. Radiology 264 : 225-233, 2012.
PubMed
45) Bloomgren G, et al : Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366 : 1870-1880, 2012.
PubMed
46) Wattjes MP, Barkhof F : Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. Curr Opin Neurol 27 : 260-270, 2014.
PubMed
47) Yousry TA, et al : Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 72 : 779-787, 2012.
PubMed
48) Wattjes MP, et al : MRI pattern in asymptomatic natalizumab-associated PML. J Neurol Neurosurg Psychiatry 86 : 793-798, 2015.
PubMed
49) Ito S, et al : "Cloud-like enhancement" is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol 66 : 425-428, 2009.
PubMed
50) Asgari N, et al : Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO) : a population-based, descriptive study. BMC Neurology 13 : 33-39, 2013.
PubMed
51) Lim Y-M, et al : First-ever optic neuritis : distinguishing subsequent neuromyelitis optica from multiple sclerosis. Neurol Sci 35 : 781-783, 2014.
PubMed
52) Krupp LB, et al : Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 68 : S7-12, 2007.
 
53) Mader I, et al : Acute haemorrhagic encephalomyelitis (AHEM) : MRI findings. Neuropediatrics 35 : 143-146, 2004.
PubMed
54) Callen DJA, et al : Role of MRI in the differentiation of ADEM from MS in children. Neurology 72 : 968-973, 2009.
PubMed
P.171 掲載の参考文献
1) Polman CH, et al : Diagnostic criteria for multiple sclerosis : 2010 revisions to the McDonald criteria. Ann Neurol 69 : 292-302, 2011.
 
2) Kamm CP, et al : Multiple sclerosis : current knowledge and future outlook. Eur Neurol 72 : 132-141, 2014.
PubMed
3) 萩原綱一ほか : 多発性硬化症の電気生理診断学. 多発性硬化症の診断と治療 (吉良潤一編), p66-72, 新興医学出版社, 2008.
 
4) Gronseth GS, Ashman EJ : Practice parameter : the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review) : Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 54 : 1720-1725, 2000.
 
5) 飛松省三 : 早わかり誘発電位 (2) -視覚誘発電位と聴覚脳幹誘発電位-. 臨床脳波 47 : 638-648, 2005.
Medical*Online
6) Watanabe A, et al : Multimodality-evoked potential study of anti-aquaporin-4 antibody-positive and-negative multiple sclerosis patients. J Neurol Sci 281 : 34-40, 2009.
PubMed
7) 飛松省三 : 誘発電位の利用の仕方. MS Frontier 3 : 47-50, 2014.
Medical*Online
8) 黒川智美ほか : 臨床研究の進歩 検査・診断法の進歩 電気生理学的診断法. 日本臨牀 61 : 1347-1354, 2003.
 
9) Andersson T, Siden A : Multimodality evoked potentials and neurological phenomenology in patients with multiple sclerosis and potentially related conditions. Electromyogr Clin Neurophysiol 31 : 109-117, 1991.
PubMed
10) Leocani L et al : Multimodal evoked potentials to assess the evolution of multiple sclerosis : a longitudinal study. J Neurol Neurosurg Psychiatry 77 : 1030-1035, 2006.
PubMed
11) Kira J, et al : Primary progressive versus relapsing remitting multiple sclerosis in Japanese patients : a combined clinical, magnetic resonance imaging and multimodality evoked potential study. J Neurol Sci 117 : 179-185, 1993.
PubMed
12) Fuhr P, Kappos L : Evoked potentials for evaluation of multiple sclerosis. Clin Neurophysiol 112 : 2185-2189, 2001.
PubMed
13) Landi D, et al : Oral fingolimod reduces glutamate-mediated intracortical exitability in relapsingremitting multiple sclerosis. Clin Neurophysiol 126 : 165-169, 2015.
 
14) Fuhr P, Schindler C : Clinical neurophysiology in multiple sclerosis-from diagnostic tool to biomarker. Clin Neurophysiol 126 : 7-9, 2015.
PubMed
15) Tewarie P, et al : Functional brain networks : Linking thalamic atrophy to clinical disability in multiple sclerosis, a multimodal fMRI and MEG study. Hum Brain Mapp 36 : 603-618, 2015.
PubMed
P.179 掲載の参考文献
1) Polman CH, et al : Diagnostic criteria for multiple sclerosis : 2010 revisions to the McDonald criteria. Ann Neurol 69 : 292-302, 2011.
 
2) Miller DH, et al : Differential diagnosis of suspected multiple sclerosis : a consensus approach. Mult Scler 14 : 1157-1174, 2008.
PubMed
3) 多発性硬化症治療ガイドライン2010 [日本神経学会/日本神経免疫学会/日本神経治療学会 (監), 「多発性硬化症治療ガイドライン」作成委員会 (編)], pxvii-xx, 医学書院, 2010.
 
4) 富岳亮ほか : 多発性硬化症の臨床病型と診断基準, 鑑別診断. 日本臨牀 72 : 1957 -1963, 2014.
 
5) Dalton CM, et al : Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 52 : 47-53, 2002.
PubMed
6) Schumacher FA, et al : Problems of experimental trails of therapy in multiple sclerosis. Ann NY Acad Sci 122 : 552-568, 1965.
 
7) Poser CM, et al : New diagnostic criteria for multiple sclerosis : guidelines for research protocols. Ann Neurol 1 : 227-231, 1983.
 
8) Paty DW, et al : MRI in the diagnosis of MS : a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding and CT. Neurology 38 : 180-185, 1988.
 
9) Barkhof F, et al : Comparison of MR imaging criteria at first presentation to predict conversion to clinically definite MS. Brain 120 : 2059-2069, 1997.
 
10) Fazekas F, et al : Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 38 : 1822-1825, 1988.
PubMed
11) Tintore M, et al : Isolated demyelinating syndromes : comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. Am J Neuroradiol 21 : 702-706, 2000.
PubMed
12) Thompson AJ, et al : Diagnostic criteria for primary progressive multiple sclerosis. Ann Neurol 6 : 831-835, 2000.
PubMed
13) McDonald WI, et al : Recommended diagnostic criteria for multiple sclerosis : guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50 : 121-127, 2001,
PubMed
14) Polman CH, et al : Diagnostic criteria for multiple sclerosis : 2005 revisions to the "McDonald Criteria". Ann Neurol 58 : 840-846, 2005.
 
15) Swanton JK, et al : Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 77 : 830-833, 2006.
PubMed
16) Swanton JK, et al : MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes : a multicenter retrospective study. Lancet Neurol 6 : 677-686, 2007.
PubMed
17) Rovira A, et al : A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. Arch Neurol 5 : 287-292, 2009.
 
18) Montalban X, et al : MRI criteria for MS in patients with clinically isolated syndromes. Neurology 74 : 427-434, 2010.
PubMed
19) Yeh EA, et al : Pediatric multiple sclerosis. Nat Rev Neurol 5 : 621-631, 2009.
PubMed
20) Chabas D, et al : Vanishing MS T2bright lesions before puberty. Neurology 71 : 1090-1093, 2008.
PubMed
21) Banwell B, et al : Multiple sclerosis in children : clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol 6 : 887-902, 2007.
PubMed
22) 難病情報センターホームページ. [http://www.nanbyou.or.jp/]
 
P.186 掲載の参考文献
1) 多発性硬化症治療ガイドライン2010 (「多発性硬化症治療ガイドライン」作成委貝会編), 医学書院, 2010.
 
2) Minds診療ガイドライン作成の手引き2007 (福井次矢ほか編), 医学書院, 2007.
 
3) Matsui M, et al : Japanese guidelines for fingolimod in multiple sclerosis : Putting into practice. Clin Exp Neuroimmunol 5 : 34-48, 2014.
 
4) Polman CH, et al : Diagnostic criteria for multiple sclerosis : 2010 revisions to the MacDonald criteria. Ann Neurol 69 : 292-302, 2011.
 
5) 松井真, 長山成美 : 多発性硬化症の診断. 日本臨牀 71 : 811-816, 2013.
Medical*Online
6) Kira J : Multiple sclerosis in the Japanese population. Lancet Neurol 2 : 117-127, 2003.
PubMed
7) McDonald I, Compston A : The symptoms and signs of multiple sclerosis. In : McAlpine's Multiple Sclerosis, 4th ed (ed by Confavreux C, ct al), p 287-346, Churchill Livingstone, London, 2006.
 
8) Qiu W, et al : Spinal cord involvement of multiple sclerosis : A correlative MRI and high-resolution HIA-DRB1genotyping study. J Neurol Sci 300 : 114-119, 2011.
 
9) 吉良潤一 : 多発性硬化症 : 日本における最近の動向. 日本醫事新報 4301 : 53-59, 2006.
Medical*Online
10) Matsuoka T, et al : Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 130 : 1206-1223, 2007.
PubMed
11) Beck RW, et al : A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 326 : 581-588, 1992.
PubMed
12) Keegan M, et al : Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366 : 579-582, 2005.
PubMed
13) Langer-Gould A, et al : Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol 66 : 958-963, 2009.
PubMed
14) Kappos L, et al : A placebo-controlled trial of oral fingorimod in relapsing multiple sclerosis. N Engl J Med 362 : 387-401, 2010.
 
15) Mehling M, et al : Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 75 : 403-410, 2010.
PubMed
P.190 掲載の参考文献
1) Durelli L, et al : High -dose intravenous methylprednisolone in the treatment of multiple sclerosis : clinical-immunologic correlations. Neurology 36 : 238-243, 1986.
PubMed
2) Milligan NM, et al : A double-blind controlled trial of high-dose methylprednisolone in patients with multiple sclerosis : 1. Clinical effects. J Neurol Neurosurg Psychiatry 50 : 511-516, 1987.
PubMed
3) Sellebjeg F, et al : Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 51 : 529-534, 1998.
 
4) Miller DM, et al : A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbation. Mult Scler 6 : 267-273, 2000.
PubMed
5) Filipovic Grcic P, et al : Responsiveness of walking-based outcome measures after multiple sclerosis relapses following steroid pulses. Med Sci Monit 17 : CR704-710, 2011.
PubMed
6) Piri Cinar B, et al : Evaluation of clinical parameters during and after treatment of attack in patients with clinically isolated syndrome : comparison of the results with that of multiple sclerosis patients. Clin Neurol Neurosurg 155 : 2432-2437, 2013.
 
7) Iseri P, et al : The effect of pulse methylprednisolone plus theophylline treatment on clinical, pulmonary and inflammatory markers in relapses of multiple sclerosis. Balkan Med J 30 : 33-36, 2013.
PubMed
8) Martinelli V, et al : A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Neurology 73 : 1842-1848, 2009.
 
9) Morrow SA, et al : The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology 63 : 1079-1080, 2004.
PubMed
10) Pozzilli C, et al : Corticosteroid treatment. J Neurol Sci 223 : 47-71, 2004.
PubMed
11) Sloka JS, Stefanelli M : The mechanism of action methylprednisolone in the treatment of multiple sclerosis. Mult Scler 11 : 425-432, 2005.
PubMed
12) Schweingruber N, et al : Mechanisms of glucocorticoids in the control of neuroinflammation. J Neuroendocrinol 24 : 174-182, 2012.
PubMed
13) Morrow SA, et al : MS patients report excellent compliance with oral prednisone for acute relapses. Can J Neurol Sci 39 : 352-354, 2012.
PubMed
14) Vasheghani-Farahani A, et al : Incidence of various cardiac arrhythnias and conduction disturbances due to high dose intravenous methylprednisolone in patients with multiple sclerosis. J Neurol Sci 309 : 75-78, 2011.
PubMed
15) 多発性硬化症治療ガイドラインン2010, 第1版 (日本神経学会/日本神経免疫学会/日本神経治療学会監, 「多発性硬化症治療ガイドライン」作成委員会編), p 26, 医学書院, 2010.
 
16) Yen EA : Current therapeutic options in pediatric multiple sclerosis. Curr Treat Options Neurol 13 : 544-559, 2011.
 
P.195 掲載の参考文献
1) Weiner HL, et al : Double-blind study of true vs sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 39 : 1143-1149, 1989.
PubMed
2) Rodriguez M, et al : Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology 43 : 1100-1104, 1993.
PubMed
3) Weinshenker BG, et al : A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46 : 878-886, 1999.
PubMed
4) Keegan M, et al : Plasma exchange for severe attacks of CNS demyelination : predictors of response. Neurology 58 : 143-146, 2002.
PubMed
5) Keegan M, et al : Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366 : 579-582, 2005.
PubMed
6) Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology : Evidence-based guideline update : Plasmapheresis in neurologic disorders. Neurology 76 : 294-300, 2011.
 
7) Schmitt E, et al : Immunoadsorption with phenylalanine-immobilized polyvinylalcohol versus plasma exchange -A controlled pilot study in multiple sclerosis. Ther Plasmapheresis 12 : 239-242, 1993.
 
8) 多発性硬化症治療ガイドライン2010 (「多発性硬化症治療ガイドライン」作成委員会編), 医学書院, 2010.
 
P.202 掲載の参考文献
1) Neighbour PA, et al : Interferon responses of leukocytes in multiple sclerosis. Neurology 31 : 561-566, 1981.
PubMed
2) Jacobs L et al : Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 214 : 1026-1028, 1981.
PubMed
3) Camenga DL, et al : Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis. Arch Neurol 43 : 1239-1246, 1986.
PubMed
4) Interferon-alpha and transfer factor in the treatment of multiple sclerosis : adouble-blind, placebo-controlled trial. AUSTIMS Research Group. J Neurol Neurosurg Psychiatry 52 : 566-574, 1989.
 
5) Panitch HS, et al : Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1 : 893-895, 1987.
PubMed
6) Jacobs L, et al : Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis. Lancet 2 : 1411-1413, 1986.
PubMed
7) The IFNB Multiple Sclerosis Study Group : Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 : 655-661, 1993.
 
8) Saida T, et al : Interferon beta-1b is effective in Japanese RRMS patients : a randomized, multicenter study. Neurology 64 : 621-630, 2005.
PubMed
9) Jacobs LD, et al : Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39 : 285-294, 1996.
 
10) PRISMS Study Group : Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352 : 1498-1504, 1998.
 
11) The IFNB Multiple Sclerosis Study Group : Interferon beta-1b in the treatment of multiple sclerosis : final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 45 : 1277-1285, 1995.
 
12) Durelli L, et al : Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis : results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359 : 1453-1460, 2002.
PubMed
13) Panitch H, et al : Randomized, comparative study of interferon beta-1a treatment regimens in MS : The EVIDENCE Trial. Neurology 59 : 1496-1506, 2002.
PubMed
14) O'Connor P, et al : 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis : a prospective, randomised, multicentre study. Lancet Neurol 8 : 889-897, 2009.
 
15) Clanet M, et al : A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 59 : 1507-1517, 2002.
PubMed
16) Calabresi PA, et al ; ADVAVCE Study Investigators : Pegylated interferon beta-1afor relapsing-remitting multiple sclerosis (ADVANCE) : a randomised, phase 3, double-blind study. Lancet Neurol 13 (7) : 657-665, 2014.
 
17) Leary SM, et al : Interferon beta-1a in primary progressive MS : an exploratory, randomized, controlled trial. Neurology 60 : 44-51, 2003.
PubMed
18) Montalban X : Overview of European pilot study of interferon beta-1b in primary progressive multiple sclerosis. Mult Scler 10 : S62-S64, 2004.
PubMed
19) European Study Group on Interferon β-1b in Secondary Progressive MS : Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 352 : 1491-1497, 1998.
 
20) The North American Study Group on Interferon beta-1b in Secondary Progressive MS : Interferon beta-1b in secondary progressive MS Results from a 3-year controlled study. Neurology 63 : 1788-1795, 2004.
 
21) Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group : Randomized controlled trial of interferon-beta-1a in secondary progressive MS : Clinical results. Neurology 56 : 1496-1504, 2001.
 
22) Andersen O, et al : Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 75 : 706-710, 2004.
PubMed
23) Cohen JA, et al : Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 59 : 679-687, 2002.
PubMed
24) Jacobs LD, et al : Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343 : 898-904, 2000.
 
25) Comi G, et al : Effect of early interferon treatment on conversion to definite multiple sclerosis : a randomised study. Lancet 357 : 1576-1582, 2001.
PubMed
26) Kappos L, et al : Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67 : 1242-1249, 2006.
 
27) Comi G, et al : Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX) : a phase 3 randomised controlled trial. Lancet Neurol 11 : 33-41, 2012.
PubMed
28) Kinkel RP, et al : IM interferon beta-la delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 66 : 678-684, 2006.
 
29) Kinkel RP, et al : Association betWeen immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes : a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance, Arch Neurol 69 : 183-190, 2012.
PubMed
30) Kappos L, et al : Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis : a 3-year follow-up analysis of the BENEFIT study. Lancet 370 : 389-397, 2007.
PubMed
31) Kappos L, et al : Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis : 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 8 : 987-997, 2009.
PubMed
32) Edan G, et al : Long-term impact of interferon beta-1b in patients with CIS : 8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry 85 : 1183-1189, 2014.
PubMed
33) PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group : PRISMS-4 : Long-term e伍cacy of interferon-beta-1a in relapsing MS. Neurology 56 : 1628-1636, 2001.
 
34) Kappos L, et al : Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 67 : 944-953, 2006.
PubMed
35) Ebers GC, et al : Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry 81 : 907-912, 2010.
 
36) Confavreux C, Vukusic S : Age at disability milestones in multiple sclerosis. Brain 129 : 595-605, 2006.
PubMed
37) Rudick RA, et al : Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 53 (8) : 1698-1704, 1999.
 
38) Filippi M, et al : Interferon beta-la for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis : a randomised, double-blind, placebo-controlled trial. Lancet 364 : 1489-1496, 2004.
 
39) Nakatsuji Y, et al : Elevation of Sema4A implicates Th cell skewing and the efficacy of IFN-β therapy in multiple sclerosis. J Immunol 188 : 4858-4865, 2012.
 
P.210 掲載の参考文献
1) 千葉健治, 吉井成彦 : 新規多発性硬化症治療薬フィンゴリモド塩酸塩 (イムセラ(R) /ジレニア(R)) の薬理学的特性および臨床効果. 日薬理誌 139 : 265-273, 2012.
Medical*Online
2) Cohen JA, Chun J : Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 69 : 759-777, 2011.
PubMed
3) Sanford M : Fingolimod : a review of its use in relapsing-remitting multiple sclerosis. Drugs 74 : 1411-1433, 2014.
PubMed
4) Mueller SN, et al : Memory T cell subsets, migration patterns, and tissue residence. Annu Rev Immunol 31 : 137-161, 2013.
PubMed
5) Saida T, et al : A randomized, controlled trial of fingolimod (FIY720) in Japanese patients with multiple sclerosis. Mult Scler 18 : 1269-1277, 2012.
PubMed
6) 新医薬品の「使用上の注意」の解説 ジレニアカプセル 0.5mg (第3版), ノバルティスファーマ株式会社, 2012年4月作成.
 
7) Lindsey JW, et al : Sudden unexpected death on fingolimod. Mult Scler 18 : 1507-1508, 2012.
PubMed
8) Arvin AM, et al : Varisella-zoster virus infections in patients treated with fibgolimod : risk assessment and consensus recommendations for management. JAMA Neurol 72 : 31-39, 2015.
PubMed
9) Schwb N, et al : L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 81 : 865-871, 2013.
 
10) Ricklin ME, et al : T-cell response against varicella-zoster virus in fingolimod-treated MS patients. Neurology 81 : 174-181, 2013.
PubMed
11) Langer-Gould AM : The pill times 2 : what every woman with multiple sclerosis should know. Neurology 82 : 645-655, 2014.
 
12) Kira J, et al : Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months : results of a phase 2 observational extension. BMC Neurol 14 : 21, 2014.
PubMed
P.214 掲載の参考文献
1) 田中正美 : 免疫抑制剤の用い方. アクチュアル脳・神経疾患の臨床 最新アプローチ 多発性硬化症と視神経脊髄炎 (吉良潤一編), p217-223, 中山書店, 2012.
 
2) 田中正美, 越智香保 : 視神経脊髄炎へのタクロリムス療法の注意点神経内科82 : 238, 2015.
 
3) Keene DL, et al : Monoclonal antibodies and progressive multifocal leukoencephalopathy. Can J Neurol Sci 38 : 565-571, 2011.
PubMed
4) Mealy MA, et al : Comparison of relapse and treatment failure rates among patients with neuromyelitis optica : multicenter study of treatment efficacy. JAMA Neurol 71 : 324-330, 2014.
PubMed
5) 小森美華ほか : 日本人多発性硬化症患者に. 対するミトキサントロン治療の検討. 臨床神経 47 : 401-406, 2007.
 
6) Handel AE, Ramagopalan SV : Multiple sclerosis and risk of cancer : a meta-analysis. J Neurol Neurosurg Psychiatry 81 : 1413-1414, 2010.
 
7) Lebrun C, et al : Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler 14 : 399-405, 2008.
PubMed
8) Kingwell E, et al : Assessment of cancer risk with β-interferon treatment for multiple sclerosis. J Neurol Neurosurg Psychiatry 85 : 1096-1102, 2014.
 
9) Lebrun C, et al : Cancer and multiple sclerosis in the era of disease-modifying treatments. J Neurol 258 : 1304-1311, 2011.
PubMed
10) Ricklin ME, et al : T-cell response against varicella-zoster virus in fingolimod-treated MS patients. Neurology 81 : 174-181, 2013.
PubMed
11) Araki M, et al : Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica : a pilot study. Neurology 82 : 1302-1306, 2014.
PubMed
12) Dalakas MC : Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies. J Peripher Nerv Syst 17 (Suppl 2) : 34-39, 2012,
 
13) Dimachkie MM, et al : Idiopathic infiammatory myopathies. Neurol Clin 32 : 595-628, 2014.
 
14) Hughes RA et al : Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev (1) : CD003280, 2003.
PubMed
15) Muppidi S, Vernino S : Paraneoplastic neuropathies. Continuum (Minneap Minn) 20 (5 Peripheral Nervous System Disorders) : 1359-1372, 2014.
 
16) Okuda DT : Immunosuppressive treatments in multiple sclerosis. Handb Clin Neurol 122 : 503-511, 2014.
PubMed
17) Pittock SJ, et al : Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders : an open-label pilot study. Lancet Neurol 12 : 554-562, 2013.
PubMed
18) Sieb JP : Myasthenia gravis : an update for the clinician. Clin Exp Immunol 175 : 408-418, 2014.
PubMed
19) Tanaka M, et al : Corticosteroid and tacrolimus treatment in neuromyelitis optica related disorders. Mult Scler 21 : 669, 2015.
PubMed
20) Younger DS : Headaches and vasculitis. Neurol Clin 32 : 321-362, 2014.
PubMed
21) 田中正美ほか : 多発性硬化症へのフィンゴリモド治療-どのように使用するか? 神経内科 76 : 390-397, 2012.
 
22) 田中正美ほか : 針治療後にタクロリムスの血中濃度が低下し, 再発した視神経脊髄炎. 神経内科 77 : 672, 2012.
 
P.219 掲載の参考文献
1) Polman CH, et al : A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354 : 899-910, 2006.
PubMed
2) Rudick RA, et al : Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354 : 911-923, 2006.
PubMed
3) Hutchinson M, et al : The efficacy of natalizumab in patients with relapsing multiple sclerosis : subgroup analyses of AFFIRM and SENTINEL. J Neurol 256 : 405-415, 2009.
PubMed
4) Miller DH, et al : MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 68 : 1390-1401, 2007.
 
5) Iaffaldano P, et al : Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis : a prospective, open-label, two years observational study. PLoS One 7 : e35843, 2012.
PubMed
6) Portaccio E, et al : Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis : a prospective, non-randomized pilot study. Eur J Neurol 20 : 986-990, 2013.
PubMed
7) Svenningsson A, et al : Natalizumab treatment reduces fatigue in multiple sclerosis : results from the TYNERGY trial : a study in the real life setting. PLoS One 8 : e58643, 2013.
 
8) Calabresi PA, et al : The incidence and significance of anti-natalizumab antibodies : results from AFFIRM and SENTINEL. Neurology 69 : 1391-1403, 2007.
PubMed
9) O'Connor P, et al : Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology 83 : 78-86, 2014.
PubMed
10) Bloomgren G, et al : Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366 : 1870-1880, 2012.
PubMed
11) Clerico M, et al : Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab : evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study). JAMA Neurol 71 : 954-960, 2014.
 
12) Salhofer-Polanyi S, et al : What to expect after natalizumab cessation in a real-life setting. Acta Neurol Scand 130 : 97-102, 2014.
 
13) Jokubaitis VG, et al : Fingolimod after natalizumab and the risk of short-term relapse. Neurology 82 : 1204-1211, 2014.
PubMed
14) Cohen M, et al : Switching from natalizumab to fingolimod in multiple sclerosis : a French prospective study. JAMA Neurol 71 : 436-441, 2014.
PubMed
P.227 掲載の参考文献
1) Johnson KP, et al : Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis : results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45 : 1268-1276, 1995.
 
2) Comi G, et al : European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49 : 290-297, 2001.
 
3) Comi G, et al : Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study) : a randomised, double-blind, placebo-controlled trial. Lancet 374 : 1503-1511, 2009.
PubMed
4) Khan O, et al : Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol 73 : 705-713, 2013.
PubMed
5) Calabresi PA, et al : Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE) : a randomised, phase 3, double-blind study. Lancet Neurol 13 : 657-665, 2014.
PubMed
6) O'Connor P, et al : Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365 : 1293-1303, 2011.
PubMed
7) Confavreux C, et al : Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 13 : 247-256, 2014.
 
8) Miller AE, et al : Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 13 : 977-986, 2014.
 
9) Gold R, et al : Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367 : 1098-1107, 2012.
PubMed
10) Fox RJ, et al : Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367 : 1087-1097, 2012.
PubMed
11) Coles AJ, et al : The window of therapeutic opportunity in multiple sclerosis : evidence from monoclonal antibody therapy. J Neurol 253 : 98-108, 2006.
PubMed
12) Cohen JA, et al : Alemtuzumab versus interferon beta la as first-line treatment for patients with relapsing-remitting multiple sclerosis : a randomised controlled phase 3 trial. Lancet 380 : 1819-1828, 2012.
 
13) Coles AJ, et al : Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy : a randomised controlled phase 3 trial. Lancet 380 : 1829-1839, 2012.
PubMed
14) Pfender N, Martin R : Daclizumab (anti-CD25) in multiple sclerosis. Exp Neurol 262 Pt A : 44-51, 2014.
 
15) Kappos L, et al : Primary results of DECIDE : a randomized, double-blind, double-dummy, active-controlled trial of daclizumab HYP vs interferon beta-1a in RRMS patients. Presented at : 2014 Joint ACTRIMS-ECTRIMS Meeting ; September 10-13 Boston, MA, Abstract FC 1.1, 2014.
 
16) Comi G, et al : Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 366 : 1000-1009, 2012.
PubMed
17) Vollmer TL, et al : A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol 261 : 773-783, 2014.
PubMed
P.233 掲載の参考文献
1) Hyman N, et al : Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis : a prospective, randomised, double blind, placebo controlled, dose ranging stUdy. J Neurol Neurosurg Psychiatry 68 : 707-712, 2000.
PubMed
2) Penn RD, et al : Intrathecal baclofen for severe spinal spasticity. N Engl J Med 320 : 1517-1521, 1989.
PubMed
3) Collin C, et al : A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 32 : 451-459, 2010.
 
4) Brafias P, et al : Treatments for fatigue in multiple sclerosis : a rapid and systematic review. Health Technol Assess 4 : 1-61, 2000.
 
5) Hosseini H, et al : Unilateral thalamic deep brain stimulation for disabling kinetic tremor in multiple sclerosis. Neurosurgery 70 : 66-69, 2012.
PubMed
6) Solaro C, et al : Pregabalin for treating paroxysmal painful symptoms in multiple sclerosis : a pilot study. J Neurol 256 : 1773-1774, 2009.
PubMed
7) Vollmer TL, et al : A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis. Pain Pract 14 : 732-744, 2014.
PubMed
8) Leandri M, et al : Therapy of trigeminal neuralgia secondary to multiple sclerosis. Expert Rev Neurother 3 : 661-671, 2003.
PubMed
9) Solaro C, et al : Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. Mult Scler 6 : 192-193, 2000.
PubMed
10) DMKG study group : Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis. J Neurol 250 : 542-545, 2003.
 
11) Mathieu D, et al : Comparative study of Gamma Knife surgery and percutaneous retrogasserian glycerol rhizotomy for trigeminal neuralgia in patients with multiple sclerosis. J Neurosurg 117 (Suppl) : 175-180, 2012.
 
12) Wolter T : Spinal cord stimulation for neuropathic pain : current perspectives. J Pain Res 7 : 651-663, 2014.
PubMed
13) Starck M, et al : Acquired pendular nystagmus in multiple sclerosis : an examiner-blind cross-over treatment study of memantine and gabapentin. J Neurol 257 : 322-327, 2010.
PubMed
14) Xiao Y, et al : Sildenafil citrate for erectile dysfunction in patients with multiple sclerosis. Cochrane Database Syst Rev 4 : CD009427, 2012.
PubMed
15) Goodman AD, et al : A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 68 : 494-502. 2010.
PubMed
P.240 掲載の参考文献
1) Nielsen NM, et al : Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives : anationwide cohort study in Denmark. Mult Scler 14 : 823-829, 2008.
 
2) Marrie RA, et al : A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Mult Scler 21 : 282 -293, 2015.
 
3) Wahren-Herlenius M, Dorner T : Immunopathogenic mechanisms of systemic autoimmunc disease. Lancet 382 : 819-831, 2013.
PubMed
4) Marrie RA et al : Association betWeen comorbidity and clinical characteristics of MS. Acta Neurol Scand 124 : 135-141, 2011.
PubMed
5) De Keyser J : Autoimmunity in multiple sclerosis. Neurology 38 : 371-374, 1988.
PubMed
6) 小副川学 : MRI画像所見からみた日本人MS病像の解析 2004年MS全国臨床疫学調査. 神経免疫学 14 : 151-155, 2006.
 
7) 吉良潤一 : 多発性硬化症 : 日本における最近の動向. 日本医事新報 No 4301 : 53-59, 2006.
 
8) 膠原病合併 (Sjogren症候群など). 多発性硬化症治療ガイドライン2010 (「多発性硬化症治療ガイドライン」作成委員会編), p110-125, 医学書院, 2010.
 
9) Mavragani CP, et al : Increased serum type I interferon activity in organ-specfic autoimmune disorders : clinical, imaging, and serological associations. Front Immunol 4 : 238, 2013.
PubMed
10) Rotondi M, et al : Interferon-β but not Glatiramer acetate stimulates CXCL10 secretion in primary cultures of thyrocytes : a clue for understanding the different risks of thyroid dysfunctions in patients with multiple sclerosis treated with either of the two drugs. J Neuroimmunol 234 : 161-164, 2011.
 
11) Polman CH, et al : Interferon beta-1b treatment does not induce autoantibodies. Neurology 64 : 996-1000, 2005.
 
12) Caraccio N, et al : Long-term follow-up of 106 multiple sclerosis patients undergoing interferonbeta 1a or 1b therapy : predictive factors of thyroid disease development and duration. J Chn Endocrinol Metab 90 : 4133-4137, 2005.
PubMed
13) Monzani F, et al : Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin Exp Med 3 : 199-210, 2004.
PubMed
14) Alexander EL, et al : Primary Sj6gren'ssyndrome with central nervous system disease mimicking multiple sclerosis. Ann Intern Med 104 : 323-330, 1986.
 
15) Annunziata P, et al : Clinical features of Sjogren's syndrome in patients with multiple sclerosis. Acta Neurol Scand 124 : 109-114, 2011.
PubMed
16) Fanouriakis A, et al : Coexistence of systemic Iupus erythematosus and multiple sclerosis : prevalence, clinical characteristics, and natural history. Semin Arthritis Rheum 43 : 751-758, 2014.
 
17) 視神経脊髄炎患者・抗アクアポリン4抗体陽性患者. 多発性硬化症治療ガイドライン2010 (「多発性硬化症治療ガイドライン」作成委員会編), p92-103, 医学書院, 2010.
 
18) Wingerchuk DM, et al : The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53 : 1107-1114, 1999.
PubMed
19) 吉良潤一ほか : 多発性硬化症 (MS) 2004年全国臨床疫学調査結果第3報 : 合併症からみた日本人MSの病像. 厚生労働科学研究費補助金 (難治性疾患克服研究事業) 免疫性神経疾患に関する調査研究 (主任研究者吉良潤一), 平成17年度総括・分担研究報告書, p151-152, 2005.
 
20) Ciccarelli O, et al : Antinuclear antibodies and response to IFNβ-1a therapy in relapsing-remitting multiple sclerosis. Mult Scler 6 : 137-139, 2000.
 
21) Signoriello E, et al : Fingolimod efficacy in multiple sclerosis associated with Sjogren syndrome. Acta Neurol Scand 131 : 140-143, 2015.
PubMed
P.245 掲載の参考文献
1) Chitnis T, et al : Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Mult Scler 15 : 627-631, 2009.
 
2) Renoux C, et al : Natural history of multiple sclerosis with childhood onset. N Engl J Med 356 : 2603-2613, 2007.
PubMed
3) Julian L, et al : Cognitive impairment occurs in children and adolescents with multiple sclerosis : results from a United States network. J Child Neurol 28 : 102-107, 2013.
PubMed
4) Amato MP, et al : Cognitive and psychosocial features of childhood and juvenile MS. Neurology 70 : 1891-1897, 2008.
PubMed
5) Krupp LB, et al : Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 68 : S7-12, 2007.
 
6) Sadaka Y, et al : 2010 McDonald criteria for diagnosing pediatric multiple sclerosis. Ann Neurol 72 : 211-223, 2012.
PubMed
7) Krupp LB, et al : International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders : revisions to the 2007 definitions. Mult Scler 19 : 1261-1267, 2013.
 
8) Mikaeloff Y, et al : Prognostic factors for early severity in a childhood multiple sclerosis cohort. Pediatrics 118 : 1133-1139, 2006.
 
9) Banwell B, et al : Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination : a prospective national cohort study. Lancet Neurol 10 : 436-445, 2011.
PubMed
10) Waubant E, et al : Common viruses associated with lower pediatric multiple sclerosis risk. Neurology 76 : 1989-1995, 2011.
PubMed
11) Mikaeloff Y, et al : Parental smoking at home and the risk of childhood-onset multiple sclerosis in children. Brain 130 : 2589-2595, 2007.
PubMed
12) Langer-Gould A, et al : Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology 80 : 548-552, 2013.
PubMed
13) Chabas D, et al : Vanishing MS T2-bright lesions before puberty : a distinct MRI phenotype? Neurology 71 : 1090-1093, 2008.
PubMed
14) Chabas D, et al : Younger children with MS have a distinct CSF inflammatory profile at disease onset. Neurology 74 : 399-405, 2010.
PubMed
15) Gorman MP, et al : Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 66 : 54-59, 2009.
PubMed
16) Mowry EM, et al : Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 67 : 618-624, 2010.
PubMed
17) Waldman AT, et al : Management of pediatric central nervous system demyelinating disorders : consensus of United States neurologists. J Child Neurol 26 : 675-682, 2011.
PubMed
18) Yeh EA, et al : Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol 68 : 437-444, 2011.
PubMed
19) Banwell B, et al : Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology 66 : 472-476, 2006.
PubMed
20) Tenembaum SN, et al : Subcutaneous interferon Beta-1a in pediatric multiple sclerosis : a retrospective study. J Child Neurol 28 : 849 -856, 2013.
 
21) Kornek B, et al : Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics 34 : 120-126, 2003.
PubMed
22) Chitnis T, et al : Consensus statement : evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler 18 : 116-127, 2012.
PubMed
23) Ghezzi A, et al : Natalizumab in pediatric multiple sclerosis : results of a cohort of 55 cases. Mult Scler 19 : 1106-1112, 2013.
 
24) Kornek B, et al : Natalizumab therapy for highly active pediatric multiple sclerosis. JAMA Neurol 70 : 469-475, 2013.
PubMed
25) Beres SJ, et al : Rituximab use in pediatric central demyelinating disease. Pediatr Neurol 51 : 114-118, 2014.
PubMed
26) Gorman MP, et al : Daclizumab use in patients with pediatric multiple sclerosis. Arch Neurol 69 : 78-81, 2012.
PubMed
27) Etemadifar M, et al : Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis. Eur J Paediatr Neurol 18 : 119-125, 2014.
PubMed
28) Makhani N, et al : Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology 72 : 2076-2082, 2009.
PubMed
P.252 掲載の参考文献
1) 菊地ひろみ : QOLとケア・生活指導の進め方. 最新アプローチ 多発性硬化症と視神経脊髄炎, p288-229, 中山書店, 2012.
 
2) Kikuchi H, et al : Structural equation modeling of factors contributing to quality of life in Japanese patients with multiple sclerosis. BMC Neurol 13 : 10, 2013.
PubMed
3) Kikuchi H, et al : Impact and characteristics of quality of life in Japanese patients with multiple sclerosis. Qual Life Res 20 : 119-131, 2011.
PubMed
4) Yamout B, et al : Predictors of quality of life among multiple sclerosis patients : a comprehensive analysis. Eur J Neurol 20 : 756-764, 2013.
PubMed
5) Chahin S, et al : Vision in a phase 3 trial of natalizumab for multiple sclerosis : relation to disability and quality of 1ife. J Neuroophthalmol 35 : 6-11, 2015.
 
6) Calabro RS, et al : Sexual dysfunction in male patients with multiple sclerosis : a need for counseling!. Int J Neurosci 124 : 547-557, 2014.
PubMed
7) Labiano-Fontcuberta A, et al : Cognitive impairment in patients with multiple sclerosis predicts worse caregiver's health-related quality of life. Mult Scler 20 : 1769-1779, 2014.
PubMed
8) Mitchell AJ, et al : Quality of life and its assessment in multiple sclerosis : integrating Physical and psychological components of wellbeing. Lancet Neurol 4 : 556-566, 2005.
PubMed
9) Penner IK, et al ; TYNERGY trial investigators : Improvement in Fatigue during Natalizumab Treatment is Linked to Improvement in Depression and Day-Time Sleepiness. Front Neurol 6 : 18, 2015.
PubMed
10) Montalban X, et al : Oral fingolimod (FTY720) in relapsing multiple sclerosis : impact on health-related quality of life in a phase II study. Mult Scler 17 : 1341-1350, 2011.
 
11) CalkWood J, et al : Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient-and physician-reported outcomes in relapsing multiple sclerosis : post hoc analyses of the EPOC trial. BMC Neurol 14 : 220, 2014.
PubMed
12) He A, et al ; for the MSBase Study Group : Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. JAMA Neurol 9 : 1-10, 2015.
 
13) Fernandez-Mufi oz JJ, et al : Disability, quality of life, personality, cognitive and psychological variables associated with fatigue in patients with multiple sclerosis. Acta Neurol Scand 132 : 118-124, 2015.
 
P.259 掲載の参考文献
1) Jarius S, Wildemann B : The history of neuromyelitis optica. J Neuroinflammation 10 : 8, 2013.
PubMed
2) Jarius S, Wildemann B : 'Spinal amaurosis' (1841). On the early contribution of Edward Hocken to the concept of neuromyelitis optica. J Neurol 261 (2) : 400-404, 2014.
 
3) 宮澤イザベルほか : Neuromyelitis optica (Devic病) と視神経脊髄型MS. 脳と神経53 : 901-910, 2001.
 
4) Mandler RN, et al : Devic's neuromyelitis optica : a clinicopathological study of 8 patients. Ann Neurol 34 (2) : 162-168, 1993.
PubMed
5) Wingerchuk DM, et al : The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53 (5) : 1107-1114, 1999.
PubMed
6) Misu T, et al : Pure optic-spinal form of multiple sclerosis in Japan. Brain 125 (Pt11) : 2460-2468, 2002.
 
7) Lucchinetti CF, et al : A role for humoral mechanisms in the pathogenesis of Devic'sneuromyelitis optica. Brain 125 (Pt 7) : 1450-1461, 2002.
 
8) Lennon VA, et al : A serum autoantibody marker of neuromyelitis optica : distinction from multiple sclerosis. Lancet 364 (9451) : 2106-2112, 2004.
PubMed
9) Lennon VA, et al : IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202 (4) : 473-477, 2005.
 
10) Pittock SJ, et al : Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 63 (7) : 964-968, 2006.
PubMed
11) Wingerchuk DM, et al : Revised diagnostic criteria for neuromyelitis optica. Neurology 66 (10) : 1485-1489, 2006.
PubMed
12) Miller DH, et al : Differential diagnosis of suspected multiple sclerosis : aconsensus approach. Mult Scler 14 : 1157-1174, 2008.
 
13) Wingerchuk DM, et al : The spectrum of neuromyelitis optica. Lancet Neurol 6 (9) : 805-815, 2007.
PubMed
14) Sato DK, et al : Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82 (6) : 474-481, 2014.
PubMed
15) Fujihara K : Neuromyelitis optica and astrocytic damage in its pathogenesis. J Neurol Sci 306 (1-2) : 183-187, 2011.
 
P.264 掲載の参考文献
1) 宮本勝一 : 多発性硬化症・視神経脊髄炎の疫学. 多発性硬化症と視神経脊髄炎-基礎・臨床研究の最新知見-. 日本臨牀 72 : 1903-1908, 2014.
 
2) Ascherio A, et al : The initiation and prevention of multiple sclerosis. Nat Rev Neurol 8 : 602-612, 2012.
PubMed
3) Graves J, et al : Protective environmental factors for neuromyelitis optica. Neurology 83 : 1923-1929, 2014.
PubMed
4) Multiple Sclerosis International Federation : Epidemiology of MS. MS Atlas 2013, p 8-11, 2013.
 
5) Kira J : Multiple sclerosis in the Japanese population. Lancet Neurol 2 : 117-127, 2003.
PubMed
6) Osoegawa M, et al ; Research Committee of Neuroimmunological Diseases : Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese : nationwide survey results over 30 years. Mult Scler 15 : 159-173, 2009.
PubMed
7) 坂田清美 : 多発性硬化症の全国疫学調査成績. 特定疾患の疫学に関する研究, 平成16年度総括・分担研究報告書, p 164-165, 2005.
 
8) Houzen H, et al : Increased prevalence, incidence, and female predominance of multiple sclerosis in northern Japan. J Neurol Sci 323 : 117-122, 2012.
PubMed
9) Wingerchuk DM, et al : Revised diagnostic criteria for neuromyelitis optica. Neurology 66 : 1485-1489, 2006.
PubMed
10) 玉腰暁子 : 全国疫学調査によるNMO患者の臨床像. 免疫性神経疾患に関する調査研究, 平成25年度総括・分担研究報告書, p80-89, 2014.
 
11) 原寿郎 : 我が国のNMO/NMO spectrum disorderについて. 免疫性神経疾患, に関する調査研究, 平成23年度総括・分担研究報告書, p40-42, 2012.
 
P.270 掲載の参考文献
1) Lennon VA, et al : A serum autoantibody marker of neuromyelitis optica : distinction from multiple sclerosis. Lancet 364 : 2106-2112, 2004.
PubMed
2) Lennon VA et al : IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202 : 473 -477, 2005.
 
3) Wingerchuk DM, et al : Revised diagnostic criteria for neuromyelitis optica. Neurology 66 : 1485-1489, 2006.
PubMed
4) Nagaishi A, et al : Clinical features of neuromyelitis optica in a large Japanese cohort : comparison between phenotypes. J Neurol Neurosurg Psychiatry 82 : 1360-1364, 2011.
 
5) Jung JS, et al : Molecular characterization of an aquaporin cDNA from brain : candidate osmoreceptor and regulator of water balance. Proc Natl Acad Sci USA 91 : 13052-13056, 1994.
PubMed
6) Nicchia GP, et al : Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. Glia 57 : 1363-1373, 2009.
PubMed
7) Hinson SR, et al : Molecular outcomes of neuromyelitis optica (NMO) -IgG binding to aquaporin-4 in astrocytes, Proc Natl Acad Sci USA 109 (4) : 1245-1250, 2012.
PubMed
8) Tanaka K, et al : Anti-aquaporin 4 antibody in Japanese multiple sclerosis with long spinal cord lesions. Mult Scler 13 : 850-855, 2007.
PubMed
9) Matsuoka T, et al : Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 130 : 1206-1223, 2007.
PubMed
10) Takahashi T, et al : Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO : a study on antibody titre. Brain 130 : 1235-1243, 2007.
 
11) Waters PJ, et al : Serological diagnosis of NMO : A multicenter comparison of aquaporin-4-IgG assays. Neurology 78 : 665-675, 2012.
PubMed
12) Misu T, et al : Loss of aquaporin 4 in lesions of neuromyelitis optica : distinction from multiple sclerosis. Brain 130 : 1224-1234, 2007.
PubMed
13) Hinson SR, et al : Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med 205 : 2473 -2481, 2008.
 
14) Kinoshita M, et al : Neuromyelitis optica : Passive transfer to rat by human immunoglobulin. Biochem Biophys Res Commun 386 : 623-627, 2009.
PubMed
15) Bradl M, et al : Neuromyelitis optica : pathogenicity of patient immunoglobulin in vivo. Ann Neurol 66 : 630-643, 2009.
PubMed
P.276 掲載の参考文献
1) 池本智ほか : 特異な掻痒を呈したneuromyelitis opticaの32歳男性例. 日内会誌 99 : 1650-1652, 2010.
 
2) 甲斐太ほか : 難治性吃逆・嘔吐で発症し, 意識障害, 呼吸障害, 眼球運動障害を呈し, 広汎な脳幹病変をみとめた抗アクアポリン4抗体関連疾患の1例. 臨床神経 51 : 255-260, 2011.
 
3) Takahashi T, et al : Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody : a herald of acute exacerbations. J Neurol Neurosurg Psychiatry 79 : 1075-1078, 2008.
PubMed
4) Shimizu Y : Clinical features of NMO according to brain MRI findings. Brain Nerve 62 : 933-943, 2010.
PubMed
5) Pittock SJ, et al : Brain abnormalities in neuromyelitis optica. Arch Neurol 63 : 390-396, 2006.
PubMed
6) 仲野達ほか : 初発症状として低体温, 記銘力障害を呈し, MRIで間脳のみに病変をみとめた抗アクアポリン抗体関連疾患の69歳女性例. 臨床神経学 54 : 653-656, 2014.
 
7) Kanbayashi T, et al : Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis : new neurochemical and immunological implications. Arch Neurol 66 : 1563-1566, 2009.
PubMed
8) Lotze TE, et al : Spectrum of pediatric neuromyelitis optica. Pediatrics 122 : e1039-1047, 2008.
PubMed
9) 中野健ほか : 経過中に抗利尿ホルモン不適合分泌症候群, 過眠を呈し, MRIで両側視床下部病変をみとめた視神経脊髄炎の1例. 臨床神経 51 : 599-602, 2011.
 
10) Yamasaki K, et al : Hyperprolactinemia in optico-spinal multiple sclerosis. Intern Med 39 : 296-299, 2000.
PubMed
11) Saji E, et al : Cognitive impairment and cortical degeneration in neuromyelitis optica. Ann Neurol 73 : 65-76, 2013.
PubMed
12) Magana SM, et al : Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 72 : 712-717, 2009.
PubMed
13) 嶋崎晴雄ほか : 経過中にposterior reversible encephalopathy syndrome (PRES) と甲状腺癌を合併した視神経脊髄炎の47歳女性例. 日内会誌 99 : 1913-1915, 2010.
 
P.282 掲載の参考文献
1) Devic E : Myelite subaigue compliquee de nevrite optique. Bull Med (Paris) 8 : 1033-1034, 1894.
 
2) Okinaka S, et al : Multiple sclerosis and allied diseases in Japan ; clinical characteristics. Neurology 8 (10) : 756-763, 1958.
PubMed
3) Wingerchuk DM, et al : The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53 (5) : 1107-1114, 1999.
PubMed
4) Misu T, et al : Pure optic-spinal form of multiple sclerosis in Japan. Brain 125 (Pt 11) : 2460-2468, 2002.
 
5) Kira J : Multiple sclerosis in the Japanese population. Lancet Neurol 2 (2) : 117-127, 2003.
PubMed
6) deSeze J, et al : IsDevic's neuromyehtis optica a separate disease? A comparative study with multiple sclerosis. Mult Scler 9 (5) : 521-525, 2003.
 
7) Flanagan EP, et al : Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol 72 (1) : 81-87, 2015.
PubMed
8) Misu T, et al : Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 65 (9) : 1479-1482, 2005.
PubMed
9) Takahashi T, et al : Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody : a herald of acute exacerbations. J Neurol Neurosurg Psychiatry 79 (9) : 1075-1078, 2008.
PubMed
10) Popescu BF, et al : Neuromyelitis optica unique area postrema lesions : nausea, vomiting, and pathogenic implications. Neurology 76 (14) : 1229-1237, 2011.
PubMed
11) Nakamura M, et al : Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. Mult Scler 15 (6) : 695-700, 2009.
PubMed
12) Ito S, et al : "Cloud-like enhancement" is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol 66 (3) : 425-428, 2009.
PubMed
13) Pittock SJ, et al : Brain abnormalities in neuromyelitis optica. Arch Neurol 63 (3) : 390-396, 2006.
PubMed
14) Storoni M, et al : Distinguishing optic neuritis in neuromyelitis optica spectrum disease from multiple sclerosis : a novel magnetic resonance imaging scoring system. J Neuroophthalmol 33 (2) : 123-127, 2013.
PubMed
15) Jarius S, et al : Cerebrospinal nuid findings in aquaporin-4 antibody positive neuromyelitis optica : results from 211 lumbar punctures. J Neurol Sci 306 (1-2) : 82-90, 2011.
 
16) Milano E, et al : Neuromyelitis optica : importance of cerebrospinal fluid examination during relapse. Neurol Sci 24 (3) : 130-133, 2003.
PubMed
17) Nakashima I, et al : Oligoclonal IgG bands in Japanese multiple sclerosis patients. J Neuroimmunol 101 (2) : 205-206, 1999.
PubMed
18) Nakashima I, et al : Absence of IgG1 response in the cerebrospinal fluid of relapsing neuromyelitis optica. Neurology 62 (1) : 144-146, 2004.
PubMed
19) Jarius S, et al : Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica : Results from 211 lumbar punctures. J Neurol Sci 306 (1-2) : 82-90, 2011.
 
20) Kim SM, et al : Cerebrospinal fluid/serum gradient of IgG is associated with disability at acute attacks of neuromyelitis optica. J Neurol 258 (12) : 2176-2180, 2011.
PubMed
21) Mandler RN, et al : Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic'sneuromyelitis optica. Brain 124 (3) : 493-498, 2001.
 
22) Hosokawa T, et al : Increased serum matrixmetalloproteinase-9 in neuromyelitis optica : implication of disruption of blood-brain barrier. J Neuroimmunol 236 (1-2) : 81-86, 2011.
 
23) Misu T, et al : Loss of aquaporin 4 in lesions of neuromyelitis optica : distinction from multiple sclerosis. Brain 130 (Pt5) : 1224-1234, 2007.
 
24) Takano R, et al : Astrocytic damage is far more severe than demyelination in NMO : a clinical CSF biomarker study. Neurology 75 (3) : 208-216, 2010.
PubMed
25) Petzold A, et al : Glial but not axonal protein biomarkers as a new supportive diagnostic criteria for Devic neuromyelitis optica? Preliminary results on 188 patients with different neurological diseases. J Neurol Neurosurg Psychiatry 82 (4) : 467-469, 2011.
 
P.287 掲載の参考文献
1) Wingerchuk DM, et al : Revised diagnostic criteria for neuromyelitis optica. Neurology 66 : 1485-1489, 2006.
PubMed
2) Wingerchuk DM, et al : The spectrum of neuromyelitis optica. Lancet Neurol 6 : 805-815, 2007.
PubMed
3) Sato DK, et al : Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology 80 : 2210-2216, 2013.
PubMed
4) Wingerchuk D, et al : Revised Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders (S63.001). Neurology April 8, 2014 vol. 82 no. 10 Supplement S63.001.
 
5) Trebst C, et al : Update on the diagnosis and treatment of neuromyelitis optica : Recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261 (1) : 1-16, 2014.
 
6) Wingerchuk DM, et al : The spectrum of neuromyelitis optica. Lancet Neurol 6 : 805-815, 2007.
PubMed
7) Nakamura M, et al : Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefes Arch Clin Exp Ophthalmol 248 : 1777-1785, 2010.
PubMed
8) Nakamura M, et al : Preferential spinal central gray matter involvement in neuromyelitis optica : an MRI study. J Neurol 255 : 163-170, 2008.
PubMed
9) Misu T, et al : Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 65 : 1479-1482, 2005.
PubMed
10) Takahashi T, et al : Intractable hiccup and nausea in neuromyelitis optica with anti -aquaporin -4 antibody : aherald of acute exacerbations. J Neurol Neurosurg Psychiatry 79 : 1075-1078, 2008.
PubMed
11) Baba T, et al : Narcolepsy as an initial manifestation of neuromyelitis optica with anti-aquaporin-4 antibody. J Neurol 256 : 287-288, 2009.
PubMed
12) Nakamura M, et al : Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. Mult Scler 15 : 695-700, 2009.
PubMed
13) Jarius S, et al : Antibodies to CV2/CRMP5 in neuromyelitis optica like disease : case report and review of the literature. Clin Neurol Neurosurg 114 : 331-335, 2012.
PubMed
14) Uygunoきlu U, et al : Recurrent longitudinal extensive transverse myelitis in a neuro-Behget syndrome treated with infliximab. J Spinal Cord Med 38 (1) : 111-114, 2015.
 
15) Sato T, et al : Coexistence of amyotrophic lateral sclerosis with neuro-Behget's disease presenting as a longitudinally extensive spinal cord lesion : clinicopathologic features of an autopsied patient. Neuropathology 34 (2) : 185-189, 2014.
 
16) 富沢雄二ほか : 内科疾患と脳神経疾患 : 診断と治療の進歩X. 膠原病と脳神経疾患. 日内会誌 101 : 2242-2248, 2012,
 
17) Kolfenbach JR, et al : Neuromyelitis optica spectrum disorder in patients with connective tissue disease and myelitis. Arthritis Care Res (Hoboken) 63 (8) : 1203-1208, 2011.
PubMed
18) Park JH, et al : Presence of anti-Ro/SSA antibody may be associated with anti-aquaporin-4 antibody positivity in neuromyelitis optica spectrum disorder. J Neurol Sci 348 (1-2) : 132-135, 2015.
 
19) Bradley DA, et al : Diagnosis and management of spinal cord sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 23 (1) : 58-65, 2006.
PubMed
20) Sawaya R Radwan W : Sarcoidosis associated with neuromyelitis optica. J Clin Neurosci 20 (8) : 1156-1158, 2013.
PubMed
21) Tsivgoulis G, et al : Teaching neuroimages : neuromyelitis optica misdiagnosed as spinal cord tumor. Neurology 82 (4) : e33, 2014.
PubMed
22) Habek M, et al : Spinal cord tumor versus transverse myelitis. Spine J 1 : 1143-1145, 2011.
PubMed
23) Sato DK et al : Distinction betWeen MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82 (6) : 474-481, 2014.
PubMed
24) Kitley J, et al : Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies : a comparative study. JAMA Neurol 71 (3) : 276-283, 2014.
PubMed
25) Ramanathan S, et al : Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm 1 (4) : e40, 2014.
PubMed
26) Nakajima H, et al : Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis. BMJ Open 5 : e007766, 2015.
PubMed
P.293 掲載の参考文献
1) Wingerchuk DM, et al : The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53 : 1107-1114, 1999.
PubMed
2) Lucchinetti CF, et al : A role for humoral mechanisms in the pathogenesis of Devic'sneuromyelitis optica. Brain 125 : 1450-1461, 2002.
PubMed
3) Lennon VA, et al : A serum autoantibody marker of neuromyelitis optica : distinction from multiple sclerosis. Lancet 364 : 2106-2112, 2004.
PubMed
4) Lennon VA, et al : IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202 : 473-477, 2005.
 
5) Wingerchuk DM, et al : Revised diagnostic criteria for neuromyelitis optica. Neurology 66 : 1485-1489, 2006.
PubMed
6) Miller DH, et al : Differential diagnosis of suspected multiple sclerosis : aconsensus approach. Mult Scler 14 : 1157-1174, 2008.
 
7) Polman CH, et al : Diagnostic criteria for multiple sclerosis : 2010 revisions to the McDonald criteria. Ann Neurol 69 : 292-302, 2011.
 
8) Wingerchuk DM, et al : The spectrum of neuromyelitis optica. Lancet Neurol 6 : 805-815, 2007.
PubMed
9) Yanagawa K, et al : Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology 73 : 1628-1637, 2009.
PubMed
10) Sellner J, et al : EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 17 : 1019-1032, 2010.
PubMed
11) Saji E, et al : Cognitive impairment and cortical degeneration in neuromyelitis optica Ann Neurol 73 : 65-76, 2013.
PubMed
12) Pittock SJ, et al : Brain abnormalities in neuromyelitis optica. Arch Neurol 63 : 390-396, 2006.
PubMed
13) Bernard-Valnet R, et al : Neuromyelitis optica : a positive appraisal of seronegative cases. Eur J Neurol, 2015.
PubMed
14) O'Connor KC, et al : Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 13 : 211-217, 2007.
PubMed
15) Kitley J, et al : Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79 : 1273-1277, 2012.
PubMed
P.301 掲載の参考文献
1) Sato D, et al : Treatment of neuromyelitis optica : an evidence based review. Arq Neuropsiquiatr 70 : 59-66, 2012.
PubMed
2) Weinshenker BG, et al : A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46 (6) : 878-886, 1999.
PubMed
3) Watanabe S, et al : Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 13 : 128-132, 2007.
PubMed
4) Keegan M, et al : Plasma exchange for severe attacks of CNS demyelination : predictors of response. Neurology 58 : 143-146, 2002.
PubMed
5) 高橋利幸ほか : NMOにおける単純血漿交換療法の検討. Neuroimmunology 17 : 73, 2009.
 
6) 野村恭一, 王子聡 : MS/NMOに対する血液浄化療法. 厚生労働省科学研究費援助金難治性疾患克服研究事業 (免疫性神経疾患に関する調査研究), H23年度報告, p 11-15, 2011.
 
7) Wang KC, et al : The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci 18 : 43-46, 2011.
PubMed
8) Magraner MJ, et al : The effect of intravenous immunoglobulin on neuromyelitis optica. Neurologia 28 : 65-72, 2013.
PubMed
9) Watanabe S, et al : Low-dose corticosteroids reduce relapse in neuromyelitis optica : a retrospective analysis. Mult Scler 13 : 968-974. 2007.
PubMed
10) Mandler RN, et al : Devic's neuromyelitis optica : a prospective study of seven patients treated with prednisone and azathioprine. Neurology 51 : 1219-1220, 1998.
PubMed
11) 宮本勝一ほか : 経口ステロイド薬とcyclospolineの併用による視神経脊髄炎の再発予防効果. 神経治療 29 : 347-350, 2012.
 
12) Jacob A, et al : Treatment of neuromyelitis optica with mycophenolate mofetil : retrospective analysis of 24 patients. Arch Neurol 66 : 1128-1133, 2009.
PubMed
13) Kim SH, et al : Efficacy and safty of mitxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol 68 : 473-479, 2011.
 
14) Bedi GS, et al : Inpact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 17 : 1225-1230, 2011.
 
15) Kim SH, et al : Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relaspsing neuromyelitis optica over 2 years. Arch Neurol 68 : 1412-1420, 2011.
PubMed
16) Uzawa A, et al : Cytokines and chemokines in neuromyelitis optica : pathogenetic and therapeutic implications. Brain Pathol 24 : 67-73, 2014.
PubMed
17) Chihara N, et al : Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 108 : 3701-3706, 2011.
PubMed
18) Araki M, et al : Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 23 : 827, 2013.
 
19) 山村隆, 荒木学 : IL-6受容体 : トシリズマブ 視神経脊髄炎への応用. BRAIN and NERVE 66 (10) : 1159-1165, 2014.
 
20) Pittock SJ, et al : Eculizumab in AQP4-IgG-positive relapsing neuromyelitis otpica spectrum disorders : an open-label pilot study. Lancet Neurol 12 : 554-562, 2013.
PubMed
P.307 掲載の参考文献
1) Wingerchuk DM, Weinshenker BG : Neuromyelitis optica (Devic's syndrome). Handb Clin Neurol 122 : 581-599, 2014.
PubMed
2) Papadopoulos MC, et al : Treatment of neuromyelitis optica : state-of-the-art and emerging therapies. Lancet Neurol 10 : 493-506, 2014.
 
3) Elsone L, et al : Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica : experience in 10 patients. Mult Scler 20 : 501-504, 2014.
PubMed
4) Jacob A, et al : Detrimental role of granulocyte-colony stimulating factor in neuromyelitis optica clinical case and histological evidence, Mult Scler 18 : 1801-1803, 2012.
PubMed
5) Shimizu F, et al : Sera from neuromyelitis optica patients disrupt the blood-brain barrier. J Neurol Neurosurg Psychiatry 83 : 288-297, 2012.
PubMed
6) Levy M, et al : Immunopathogenesis of neuromyelitis optica. Adv Immunol 121 : 213-242, 2014.
PubMed
7) Uzawa A, et al : Cytokine and chemokine profiles in neuromyelitis optica : significance of interleukin-6. Mult Scler 16 : 1443-1452, 2010.
PubMed
8) Chihara N, et al : Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 108 : 3701-3706, 2011.
PubMed
9) Araki M, et al : Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica : a pilot study. Neurology 82 : 1302-1306, 2014.
PubMed
10) Kim SH, et al : A5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 70 : 1110-1117, 2013.
PubMed
11) Trebst C, et al : Update on the diagnosis and treatment of neuromyelitis optica : Recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261 : 1-16, 2014.
 
12) Pittock SJ, et al : Eculizumab in AQP4 IgG positive relapsing neuromyelitis optica spectrum disorders an open-label pilot study. Lancet Neurol 12 : 554-562, 2013.
PubMed
13) Verkman AS, et al : Biology of AQP4 and anti-AQP4 antibody : therapeutic implications for NMO. Brain Pathol 23 : 684-695, 2013.
PubMed
14) Tradtrantip L, et al : Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody. Ann Neurol 73 : 77-85, 2013.
PubMed
15) Tradtrantip L, et al : Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica. FASEB J 26 : 2197-2208, 2012.
PubMed
P.314 掲載の参考文献
1) Lotze TE, Chadwick DJ : Acute disseminated encephalomyelitis in children : Pathogenesis, clinical features, and diagnosis. UpToDate, 2015.
 
2) Torisu H, et al : Clinical study of childhood acute disseminated encephalomyelitis, multiple sclerosis, and acute transverse myelitis in Fukuoka Prefecture, Japan. Brain Dev 32 : 454-462, 2010.
PubMed
3) Matsumoto N, et al : Acute disseminated encephalomyelitis in an infant with incontinentia pigmenti. Brain Dev 31 : 625-628, 2009.
 
4) Young NP, et al : Perivenous demyelination : association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. Brain 133 : 333-348, 2010.
PubMed
5) Robinson CA, et al : Early and widespread injury of astrocytes in the absence of demyelination in acute haemorrhagic leukoencephalitis. Acta Neuropathol Commun 2 : 52, 2014.
PubMed
6) Krupp LB, et al : Intemational Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders : revisions to the 2007 definitions. Mult Scler 19 : 1261-1267, 2013.
 
7) Krupp LB, et al : Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 68 : S7-S12, 2007.
 
8) Chabas D, et al : Vanishing MS T2-bright lesions before puberty : a distinct MRI phenotype? Neurology 71 : 1090-1093, 2008.
PubMed
9) Callen DJ, et al : Role of MRI in the differentiation of ADEM from MS in children. Neurology 72 : 968-973, 2009.
PubMed
10) Verhey LH, et al : MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination : a prospective national cohort study. Lancet Neurol 10 : 1065-1073, 2011.
PubMed
11) Lotze TE : Differential diagnosis of acute central nervous system demyehnation in children. UpToDate, 2013.
 
12) Lotze TE, Chadwick DJ : Acute disseminated encephalomyelitis in children : Treatment and Prognosis, UpToDate, 2015.
 
13) Pohl D, Tenembaum S : Treatment of acute disseminated encephalomyelitis. Curr Treat Options Neurol 14 : 264-275, 2012.
PubMed
14) Mikaeloff Y, et al : Acute disseminated encephalomyelitis cohort study : Prognostic factors for relapse. Eur J Paediatr Neurol 11 : 90-95, 2007.
PubMed
P.318 掲載の参考文献
1) Snider LA, Swedo SE : Post-streptococcal autoimmune disorders of the central nervous system. Curr Opin Neurol 16 : 359-365, 2003.
PubMed
2) Dale RC : Post-streptococcal autoimmune disorders of the central nervous system. Dev Med Child Neurol 47 : 785-791, 2005.
PubMed
3) Cardoso F : Sydenham's chorea. Handb Clin Neurol 100 : 221-229, 2011.
PubMed
4) Swedo SE, et al : Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections : clinical description of the first 50 cases. Am J psychiatry 155 : 264-271, 1998.
PubMed
5) Williams KA, Swedo SE : Post-infectious autoimmune disorders : Sydenham's chorea, PANDAS and beyond. Brain Res 1617 : 144-154, 2015.
PubMed
6) Dale RC, et al : Poststreptococcal acute disseminated encephalomyelitis with basal ganglia involvement and auto-reactive antibasal ganglia antibodies. Ann Neurol 50 : 588-595, 2001.
PubMed
7) Church AJ, et al : Anti-basal ganglia antibodies in acute and persistent Sydenham's chorea. Neurology 59 : 227-231, 2002.
PubMed
8) Church AJ, et al : Tourette's syndrome : a cross sectional study to examine the PANDAS hypothesis. J Neurol Neurosurg Psychiatry 74 : 602-607, 2003.
PubMed
9) Dale RC, et al : Neuronal surface glycolytic enzymes are autoantigen targets in post-streptococcal autoimmune CNS disease. J Neuroimmunol 172 : 187-197, 2006.
PubMed
10) Kirvan CA, et al : Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med 9 : 914-920, 2003.
PubMed
11) Irani SR, et al : Cell-surface central nervous system autoantibodies : clinical relevance and emerging paradigms. Ann Neurol 76 : 168-184, 2014.
PubMed
12) Dale RC, et al : Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain 135 : 3453-3468, 2012.
PubMed
13) Cox CJ, et al : Brain human monoclonal autoantibody from sydenham chorea targets dopaminergic neurons in transgenic mice and signals dopamine D2 receptor : implications in human disease. J Immunol 191 : 5524-5541, 2013.
 
14) Dale RC, Brilot F : Autoimmune basal ganglia disorders. J Child Neurol 27 : 1470-1481, 2012.
PubMed
15) Murphy TK, et al : Pediatric acute-onset neuropsychiatric syndrome. Psychiatr Clin North Am 37 : 353-374, 2014.
PubMed
P.325 掲載の参考文献
1) Balo J : Encephalitis periaxialis concentrica. Arch Neurol Psychiatr 19 : 242-264, 1928.
 
2) Marburg O : Die sogenannte 'akute multiple Sklerose' (Encephalomyelitis periaxialis scleroticans). Jb Neurol Psychiatr 27 : 211-312, 1906.
 
3) Wang C, et al : Balo's disease showing benign clinical course and co-existence with multiple sclerosis-like lesions in Chinese. Mult Scler 14 : 418-424, 2008.
 
4) Wengert O, Siebert E : Images in clinical medicine. Balo's concentric sclerosis. N Engl J Med 365 : 742, 2011.
PubMed
5) Graber JJ, et al : Neuromyelitis optica and concentric rings of Balo in the brainstem. Arch Neurol 66 : 274-275, 2009.
PubMed
6) Matsuoka T, et al : Reappraisal of aquaporin-4 astrocytopathy in Asian neuromyelitis optica and multiple sclerosis patients. Brain Pathol 21 : 516-532, 2011.
PubMed
7) Kira J : Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis : astrocytopathy as acommon denominator in demyelinating disorders. J Neurol Sci 311 : 69-77, 2011.
 
8) Hardy TA, et al : Balo's concentric sclerosis and tumefactive demyelination : a shared immunopathogenesis? J Neurol Sci 348 : 279-281, 2015.
PubMed
9) Hallervorden J, Spatz H : Uber die konzentrische Sklerose und die physikalisch-chemischen Faktoren bei der Ausbreitung von Entmarkungsprozessen. Arch Psychiatr Nervenkr 98 : 641-701, 1933.
 
10) Stadelmann C, et al : Tissue preconditioning may explain concentric lesions in Balo's type of multiple sclerosis. Brain 128 : 979-987, 2005.
 
11) Chitnis T, et al : CADASIL mutation and Balo concentric sclerosis : a link between demyelination and ischemia? Neurology 78 : 221-223, 2012.
PubMed
12) Chen CJ, et al : Serial magnetic resonance imaging in patients with Balo's concentric sclerosis : natural history of lesion development. Ann Neurol 46 : 651-656, 1999.
PubMed
13) Kastrup O, et al : Balo's concentric sclerosis. Evolution of active demyelination demonstrated by serial contrast-enhanced MRI. J Neurol 249 : 811-814, 2002.
PubMed
14) 田平武 : 同心円硬化症 (Balo). 別冊日本臨牀 神経症候群II, p 423-426, 日本臨牀社, 1999.
 
15) Wiendl H, et al : Diffusion abnormality in Baio's concentric sclerosis : clues for the pathogenesis. Eur Neurol 53 : 42-44, 2005.
 
16) Kavanagh EC, et al : Diffusion-weighted imaging findings in Balo concentric sclerosis. Br J Radiol 79 : e28-e31, 2006.
PubMed
17) Chen CJ : Serial proton magnetic resonance spectroscopy in lesions of Balo concentric sclerosis. J Comput Assist Tomogr 25 : 713-718, 2001.
PubMed
18) Berghoff M, et al : 7 Tesla MRI demonstrates vascular pathology in Balo's concentric sclerosis. Mult Scler 19 : 120-122, 2013.
 
19) Matsuoka T, et al : Aquaporin-4 astrocytopathy in Balo's disease. Acta Neuropathol 120 : 651-660, 2010.
PubMed
20) Kira J : Astrocytopathy in Balo's disease. Mult Scler 17 : 771-779, 2011.
PubMed
21) Masaki K, et al : Extensive loss of connexins in Balo's disease : evidence for an auto-antibody-independent astrocytopathy via impaired astrocyte-oligodendrocyte/myelin interaction. Acta Neuropathol 123 : 887-900, 2012.
PubMed
22) Lucchinetti C, et al : Heterogeneity of multiple sclerosis lesions : implications for the pathogenesis of demyelination. Ann Neurol 47 : 707-717, 2000.
PubMed
23) Long L, et al : Levamisole-induced leukoencephalopathy mimicking Balo disease. Neurology 84 : 328, 2015.
PubMed
P.332 掲載の参考文献
1) Kira J, et al : Acute myelitis associated with hyperIgEemia and atopic dermatitis. J Neurol Sci 148 : 199-203, 1997.
PubMed
2) Isobe N, et al : First diagnostic criteria for atopic myelitis with special reference to discrimination from myelitis-onset multiple sclerosis. J Neurol Sci 316 : 30-35, 2012.
PubMed
3) Osoegawa M, et al : Myelitis with atopic diathesis : a nationwide survey of 79 cases in Japan. J Neurol Sci 209 : 5-11, 2003.
PubMed
4) Isobe N, et al : Neural damage associated with atopic diathesis : anationwide survey in Japan. Neurology 73 : 790-797, 2009.
 
5) Osoegawa M, et al : Eosinophilic myelitis associated with atopic diathesis : a combined neuroimaging and histopathological study. Acta Neuropathol 105 : 289-295, 2003.
PubMed
6) Sato S, et al : HIA-DPB1*0201 is associated with susceptibility to atopic myelitis in Japanese. J Neuroimmunol 251 : 110-113, 2012.
 
7) 山崎亮, 吉良潤一 : アトピー性脊髄炎. 別冊日本臨臨牀 神経症候群 (第2版) II, p 822-826, 日本臨牀社, 2014.
 
8) Barkhof F, et al : Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120 (Pt 11) : 2059-2069, 1997.
 
9) Murai H, et al : Effect of immunotherapy in myelitis with atopic diathesis. J Neurol Sci 227 : 39-47, 2004.
PubMed
P.337 掲載の参考文献
1) Transverse Myelitis Consortium Wbrking Group : Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 59 : 499-505, 2002.
PubMed
2) Frohman EM, Wingerchunk DM : Transverse myelitis. N Engl J Med 363 : 564-572, 2010.
 
3) Krishnan C, et al : Transverse myelitis. UpToDate, 2015.
 
4) Borchers AT, Gershwin ME : Transverse myelitis. Autoimmun Rev 11 : 231-248, 2013.
 
5) Deiva K, et al : Acute idiopathic transverse myelitis in children. Neurology 84 : 341-349, 2015.
PubMed
6) Bourre B, et al : Long-term follow-up of acute partial transverse myelitis. Arch Neurol 69 : 357-362, 2012.
PubMed

III 中枢・末梢連合脱髄症

P.344 掲載の参考文献
1) Baumann N, Pham-Dinh D : Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev 81 : 871-927, 2001.
PubMed
2) Stathopoulos P, et al : Autoimmune antigenic targets at the node of Ranvier in demyelnating disorders. Nat Rev Neurol 11 : 143-156, 2015.
 
3) Zee PC, et al : Peripheral nervous system involvement in multiple sclerosis. Neurology 41 : 457-460, 1991.
PubMed
4) Bouchard C, et al : Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 52 : 498-503, 1999.
PubMed
5) Adamovic T, et al : Acute combined central and peripheral nervous system demyelination in children. Pediatr Neurol 39 : 307-316, 2008.
PubMed
6) Thomas PK, et al : Chronic demyelinating peripheral neuropathy associated with multifocal central nervous system demyelination. Brain 110 (Pt 1) : 53-76, 1987.
 
7) Quan D, et al : Spinal and cranial hypertrophic neuropathy in multiple sclerosis. Muscle Nerve 31 : 772-779, 2005.
PubMed
8) Falcone M, et al : Spreading of autoimmunity from central to peripheral myelin : two cases of clinical association between multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. Neurol Sci 27 : 58-62, 2006.
PubMed
9) Zephir H, et al : Relapsing demyelinating disease affecting both the central and peripheral nervous systems. J Neurol Neurosurg Psychiatry 79 : 1032 -1039, 2008.
 
10) Ogata H, et al : A nationwide survey of combined central and peripheral demyelination in Japan. J Neurol Neurosurg Psychiatry, 2015, [Epub ahead of print]
 
11) Kawamura N, et al : Anti-neurofascin antibody in patients with combined central and peripheral demyelination. Neurology 81 : 714-722, 2013.
PubMed
12) Ng JKM, et al : Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology 79 : 2241-2248, 2012.
PubMed
13) Querol L, et al : Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology 82 : 879-886, 2014.
PubMed
P.351 掲載の参考文献
1) Kamm C, Zettl UK : Autoimmune disorders affecting both the central and peripheral nervous system. Autoimmun Rev 11 : 196-202, 2012.
PubMed
2) Marchioni E, et al : Postinfectious inflammatory disorders : subgroups based on prospective follow-up. Neurology 65 : 1057-1065, 2005.
PubMed
3) Zephir H, et al : Relapsing demyelinating disease affecting both the central and peripheral nervous systems. J Neurol Neurosurg Psychiatry 79 : 1032-1039, 2008.
PubMed
4) Kawamura N, et al : Anti-neurofascin antibody in patients with combined central and peripheral demyelination. Neurology 81 : 714-722, 2013.
PubMed
5) Mathey EK et al : Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 204 : 2363-2372, 2007.
PubMed
6) Ng JK, et al : Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology 79 : 2241-2248, 2012.
PubMed
7) Querol L, et al : Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to Mg. Neurology 82 : 879-886, 2014.
PubMed
8) Devaux JJ, et al : Nodal proteins are target antigens in Guillain-Barre syndrome. J peripher Nerv Syst 17 : 62-71, 2012.
PubMed
9) Querol L, et al : Antibodies to contactin-1 in chronic innammatory demyelinating polyneuropathy. Ann Neurol 73 : 370-380, 2013.
 
10) Howell OW, et al : Disruption of neurofascin localization reveals early changes preceding demyelination and remyelination in multiple sclerosis. Brain 129 : 3173-3185, 2006.
PubMed
P.356 掲載の参考文献
1) Zee PC, et al : Peripheral nervous system involvement in multiple sclerosis. Neurology 41 : 457-460, 1991.
PubMed
2) Bouchard C, et al : Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 52 : 498-503, 1999.
PubMed
3) Adamovic T, et al : Acute combined central and peripheral nervous system demyelination in children. Pediatr Neurol 39 : 307-316, 2008.
PubMed
4) Kamm C, et al : Autoimmune disorders affecting both the central and peripheral nervous system. Autoimmun Rev 11 : 196-202, 2012.
PubMed
5) Kawamura N, et al : Anti-neurofascin antibody in patients with combined central and peripheral demyelination. Neurology 81 : 714-722, 2013.
PubMed
6) Zephir H, et al : Relapsing demyelinating disease affecting both the central and peripheral nervous systems. J Neurol Neurosurg Psychiatry 79 : 1032 -1039, 2008.
 
7) Ogata H, et al : A nationwide survey of combined central and peripheral demyelination in Japan. J Neurol Neurosurg Psychiatry, 2015 Feb 11. pii : jnnp-2014-309831. doi : 10.1136/jnnp-2014-309831. [Epub ahead of print]
 
8) Ng JK, et al : Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology 79 : 2241-2248, 2012.
PubMed
9) Querol L, et al : Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to rVIg. Neurology 82 : 879-886, 2014.
 

IV 免疫性末梢神経疾患

P.366 掲載の参考文献
1) Ilyas AA, et al : IgM in a human neuropathy related to paraproteinemia binds to a carbohydrate determinant in the myelin-associated glycoprotein and to a ganglioside. Proc Natl Acad Sci USA 81 : 1225-1229, 1984.
 
2) Ilyas AA, et al : Serum antibodies to gangliosides in Guillain-Barre syndrome. Ann Neurol 23 : 440-447, 1988.
 
3) Lopez PHH, Schnaar RL : Gangliosides in cell recognition and membrane protein regulation. Curr Opin Struct Biol 19 : 1-9, 2009.
 
4) Kaida K, Kusunoki S : Antibodies to gangliosides and ganglioside complexes in Guillain-Barre syndrome and Fisher syndrome : mini-review. J Neuroimmunol 223 : 5-12, 2010.
PubMed
5) Hafer-Macko C, et al : Acute motor axonal neuropathy : An antibody-mediated attack on axolemma. Ann Neurol 40 : 635-644, 1996.
PubMed
6) Susuki K et al : Anti-GMI antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 27 : 3956-3967, 2007.
 
7) Lopez PH, et al : Structural requirements of anti-GD1a antibodies determine their target specificity. Brain 131 : 1926-1939, 2008,
PubMed
8) Rojas-Garcia R, et al : Clinical and serological features of acute sensory ataxic neuropathy with antiganglioside antibodies. J Peripher Nerv Syst 17 : 158-168, 2012.
PubMed
9) Kusunoki S, et al : Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurol 39 : 424-431, 1996.
PubMed
10) Susuki K, et al : Dysfunction of nodes of Ranvier : a mechanism for anti-ganglioside antibody-mediated neuropathies. Exp Neurol 233 : 534-542, 2012.
PubMed
11) Kaida K, et al : Ganglioside complexes as new target antigens in Guillain-Barre syndrome. Ann Neurol 56 : 567-571, 2004.
PubMed
12) Ogawa G, et al : An antibody to the GM1/GalNAc-GD1a complex correlates with development of pure motor Guillain-Barre syndrome with reversible conduction failure. J Neuroimmunol 254 : 141-145, 2013.
 
13) Kuwahara M, et al : Antibodies to LM1 and LM1-containing ganglioside complexes in Guillain-Barre syndrome and chronic inflammatory demyelinating Polyneuropathy. J Neuroimmunol 239 : 87-90, 2011.
PubMed
14) Kanzaki M, et al : Ganglioside complexes containing GQ1b as targets in Miller Fisher and Guillain-Barre syndromes. J Neurol Neurosurg Psychiatry 79 : 1148-1152, 2008.
 
15) Zitman FM, et al : Neuropathophysiological potential of Guillain-Barre syndrome anti-ganglioside complex antibodies at mouse motor nerve terminals. Clin Exp Neuroimmunol 2 : 59-67. 2011.
 
P.373 掲載の参考文献
1) Kaida K, et al : Ganglioside complexes as new target antigens in Guillain-Barre syndrome. Ann Neurol 56 : 567-571. 2004.
PubMed
2) Feasby TE, et al : An acute axonal form of Guillain-Barre polyneuropathy. Brain 109 : 1115-1126, 1986.
PubMed
3) ギラン・バレー症候群, フィッシャー症候群診療ガイドライン2013 (ギラン・バレー症候群, フィッシャー症候群診療ガイドライン作成委員会編), 南江堂, 2013.
 
4) Sejvar JJ, et al : Population incidence of Guillain-Barre syndrome : asystematic review and meta-analysis. Neuroepidemiology 36 : 123-133, 2011.
 
5) Bianca van den Berg, et al : Guillain-Barre syndrome : pathogenesis diagnosis, treatment and diagnosis. Nat Rev Neurol 10 : 469-482, 2014.
PubMed
6) Hadden RD, et al : Electrophysiological classification of Guillain-Barre syndrome : clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Ann Neurol 44 : 780-788, 1998.
PubMed
7) Mitsui Y, et al : A multicentre prospective study of Guillain-Barre syndrome in Japan : a focus on the incidence of subtypes. J Neurol Neurosurg Psychiatry 86 : 110-114, 2015.
PubMed
8) Ho TW, et al : Guillain-Barre syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies, Brain 118 (Pt 3) : 597-605, 1995.
 
9) Ropper AH, et al : Guillain-Barre Syndrome, p 57, EA Davis, Philadelphia, 1991.
 
10) 三澤園子, 桑原聡 : 軸索型Guillain-Barre症候群. 神経内科 78 : 25-30, 2013.
 
11) 荻野美恵子ほか. Guillain-Barre症候群の全国調査-第3次調査を含めた最終報告-. 厚生労働省特定疾患対策研究・事業免疫性神経疾患に関する調査研究班平成12年度研究報告書, p99-101, 2001.
 
12) 楠進 : Guillain-Barre症候群 (GBS) とFisher症候群. 免疫性神経疾患ハンドブック (楠進編), p 127-145, 南江堂, 2013.
 
13) Kaida K, et al : GalNAc-GD1a in human peripheral nerve : target sites of anti-ganglioside antibody. Neurology 61 : 465-470, 2003.
PubMed
14) Kaida K, et al : GM1/GalNAc-GD1a complex : a target for pure motor Guillain-Barre syndrome. Neurology 71 : 1683-1690, 2008.
PubMed
15) 岡崎真央ほか : Gumain-Barre症候群の亜型 "acute oropharyngeal palsy". 神経内科 78 : 39-44, 2013.
 
16) Kuwahara M, et al : Antibodies to LM1 and LM1-containing ganglioside complexes in Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 239 : 87-90, 2011.
PubMed
17) Samukawa M, et al : Clinical features in Guillain-Barre syndrome with anti-Gal-C antibody. J Neurol Sci 337 : 55-60, 2014.
 
P.379 掲載の参考文献
1) Asbury AK, Cornblath DR : Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 27 : S21-S24, 1990.
PubMed
2) Kuwabara S, et al : Hyperreflexia in axonal Guillain-Barre syndrome subsequent to Compylobacter jejuni enteritis. J Neurol Sci 199 : 89-92, 2002.
 
3) Ho TW, et al : Guillain-Barre syndrome in northern China. Relationship to Camppylobacter jejuni infection and anti-glycolipid antibodies. Brain 118 : 597-605, 1995.
PubMed
4) Kawakami S, et al : A-waves in Guillain-Barre syndrome : correlation with electrophysiological subtypes and antiganglioside antibodies. Clin Neurophysiol 123 : 1234-1241, 2012.
PubMed
5) Kadoya A, et al : The correlation between the change of distal motor latency of the median nerve and the abundant A-waves in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 2015 Apr 9. pii : jnnp-2014-309945. doi : 10.1136/jnnp-2014-309945. [Epub ahead of print]
 
6) Saifudheen K, et al : Guillain-Barre syndrome and SIADH. Neurology 76 : 701-704, 2011.
PubMed
7) Ropper AH, Shahani BT : Pain in Guillain-Barre syndrome. Arch Neurol 41. 511-514, 1984.
PubMed
8) Ropper AH, et al : Guillain-Barre Syndrome (Contemporary Neurology Series 34), p 184, FA Davis, Philadelphia, 1991.
 
9) Gorson KC, et al : Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barre syndrome. Neurology 47 : 813-817, 1996.
PubMed
10) Coskun A, et al : Childhood Guillain-Barre syndrome. MR imaging in diagnosis and follow-up. Acta Radiol 44 : 230-235, 2003.
PubMed
11) Hughes RA, et al : Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 7 : CD002063, 2012.
PubMed
12) Ruts L, et al : Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome : a prospective study. Neurology 74 : 1680-1686, 2010.
PubMed
13) van den Berg B, et al : Guillain-Barre syndrome : pathogenesis. diagnosis, treatment and prognosis. Nat Rev Neurol 10 : 469-482, 2014.
PubMed
P.386 掲載の参考文献
1) Willison HJ : The immunobiology of. Guillain-Barre syndrome. J Peripher Nerv Syst 10 : 94-112, 2005,
PubMed
2) Ruts L, et al ; Dutch GBS Study Group : Distinguishing acute-onset CIDP from fiuctuating Guillan Barre syndrome : a prospective study. Neurology 74 : 1680-1686, 2010.
 
3) ギランバレー症候群, フィッシャー症候群診療ガイドライン2013 (日本神経学会監), 南江堂, 2013.
 
4) Plasmapheresis and acute Guillain-Barre syndrome. The Guillain-Barre syndrome Study Group. Neurology 35 (8) : 1096-1104, 1985.
 
5) Efficiency of plasma exchange in Guillain-Barre syndrome : role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome. Ann Neurol 22 : 753-761, 1987.
 
6) Raphael JC, et al : Plasma exchange for Guillain-Barre syndrome (Review), Cochrane Database Syst Rev (2) : CD001798, 2002.
PubMed
7) Kleyweg RP, et al : Treatment of Guillain-Barre syndrome with high dose gammaglobulin. Neurology 38 : 1639-1641, 1988.
PubMed
8) van der Meche FGA, Schmitz PIM ; Dutch Guillian-Barre Study Group : A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med 326 : 1123-1129, 1992.
 
9) Bril V, et al : Pilot trial of immunogolobulin versus plasma exchange in patients with Guillain-Barre syndrome. Neurology 46 : 100-103, 1996.
 
10) Randomised trial of plasma exchange, intravenous immunoglobulin, and combined tretments in Guillain-Barre syndrome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Lancet 349 : 225-230, 1997.
 
11) 野村恭一ほか : Guillain-Barre症候群に対する免疫グロブリン療法と血漿交換療法とのランダム割り付け比較試験. 神経治療 18 (1) : 69-81, 2001.
 
12) Hughes RA, et al : Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev (6) : CD002063, 2010.
PubMed
13) Hughes RA, et al : Corticosteroids for GuiUain-Barre syndrome. Cochrane Database Syst Rev (2) : CD001446, 2010.
PubMed
14) Winer JB, et al : A prospective study of acute idiopathic nuropathy : I. clinical features and their prognostic value. J Neurol Neurosurg Psychiatry 51 : 605-612, 1988.
PubMed
15) Rees JH, et al : Epidemiological study of Guillain-Barre syndrome in south east England. J Neurol Neurosurg Psychiatry 64 : 74-77, 1998.
 
16) Rajabally YA, Uncini A : Outcome and its predictors in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 83 : 711-718, 2012.
PubMed
17) The prognosis and main prognostic indicators of Guillain-Barre syndrome. A multicentre prospective study of 297 patients. The Italian Guillain-Barre Study Group. Brain 119 : 2053-2061, 1996.
 
18) Kuwabara S, et al : Two patterns of clinical recoverly in Guillain-Barre syndrome with IgG anti-GM1 antibody. Neurology 51 : 1656-1660, 1998.
PubMed
19) Visser LH, et al : Prognostic factors of Guillain-Barre syndrome after intravenous immunoglobilin or plasma exchange. Dutch Guillain-Barre study Group. Neurology 53 : 589-604, 1999.
 
20) Van Konigsveldk, et al : A clinical prognostic scoring system for Guillain-Barre syndrome. Lanset Neurol 6 : 589-594, 2007.
 
21) Walgaard C, et al : Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology 76 : 968-975, 2011.
PubMed
22) Kuitwaard K, et al : Pharmacokinetics of intravenous immunoglobuline and outcome in Guillain-Barre syndrome. Ann Neurol 66 : 597-603, 2009.
PubMed
23) Kaida K, Kusunoki S : Antibidies to gangliosides and gangliosde complaexs in Guillain-Barre syndrome and Fisher syndrome : mini-review. J Neuroimmunol 223 : 5-12, 2010.
 
24) Walgaard C, et al : Prediction of respiratory insufficiency in Guillain-Barre syndrome, Ann Neurol 67 : 781-787, 2010.
PubMed
P.393 掲載の参考文献
1) Fisher M : An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 255 (2) : 57-65, 1956.
PubMed
2) Chiba A, et al : Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 31 (6) : 677-679, 1992.
PubMed
3) Chiba A, et al : Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome : clinical and immunohistochemical studies. Neurology 3 (10) : 1911-1917, 1993.
 
4) Mori M, et al : Fisher syndrome : clinical features, immunopathogenesis and management. Expert Rev Neurother 12 (1) : 39-51, 2012.
PubMed
5) Mori M, et al : Clinical features and prognosis of Miller Fisher syndrome. Neurology 56 : 1104-1106, 2001.
PubMed
6) Bogliun G, Beghi E ; Italian GBS Registry Study Group : Incidence and clinical features of acute inflammatory polyradiculoneuropathy in Lombardy, Italy, 1996. Acta Neurol Scand 110 : 100-106, 2004.
 
7) Yuan CL, et al : Miller fisher syndrome : a hospital-based retrospective study. Eur Neurol 44 : 79-85, 2000.
PubMed
8) Mori M, et al : Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology 68 : 1144-1146, 2007.
PubMed
9) Berlit P, Rakicky J : The Fisher syndrome. Review of the literature. J Clin Neuroopthalmol 12 : 57-63, 1992.
 
10) Liu JX, et al : Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles. Invest Ophthalmol Vis Sci 50 : 3226-3232, 2009.
PubMed
11) Kusunoki S, et al : Anti-GQ1b IgG antibody is associated with ataxia as well as ophthalmoplegia. Muscle Nerve 22 : 1071-1074, 1999.
PubMed
12) Kuwabara S, et al : Special sensory ataxia in Miller Fisher syndrome detected by postural body sway analysis, Ann Neurol 45 : 533-536, 1999.
PubMed
13) Ito M, et al : Bickerstaff's brainstem encephalitis and Fisher syndrome form a continuous spectrum : clinical analysis of 581 cases. J Neurol 255 : 674-682, 2008.
 
14) Koga M, et al : Miller Fisher syndrome and Haemophilus influenzae infection. Neurology 57 : 686-691, 2001.
PubMed
15) Yuki N, et al : Molecularmimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann Neurol 36 : 791-793, 1994.
 
16) Funakoshi K, et al : Clinical predictors of mechanical ventilation in Fisher/Guillain-Barre overlap syndrome. J Neurol Neurosurg Psychiatry 80 : 60-64, 2009.
PubMed
17) Odaka M, et al : Bickerstaff s brainstem encephalitis : clinical features of 62 cases and a subgroup associated with Guillain-Barre syndrome. Brain 126 : 2279-2290, 2003.
 
18) Saito K, et al : Blood-brain barrier destruction determines Fisher/Bickerstaff clinical phenotypes : an in vitro study. J Neurol Neurosurg Psychiatry 84 : 756-765, 2013.
 
P.399 掲載の参考文献
1) 日本神経治療学会・日本神経免疫学会合同神経免疫疾患治療ガイドライン委員会 : 神経免疫疾患治療ガイドライン ギラン・バレー症候群 (GBS) /慢性炎症性脱髄性多発ニューロパチー (CIDP) 治療ガイドライン. 神経治療 20 : 193-210, 2003.
 
2) Criteria for diagnosis of Guillain-Barre syndrome. Ann Neurol 3 : 565-566, 1978.
PubMed
3) Asbury AK, Cornblath DR : Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 27 (Suppl) : S21-S24, 1990.
 
4) Ad Hoc Committee WHO-AIREN : Acute onset flaccid paralysis, Division of Mental Health, World Health Organization, Geneva, 1993.
 
5) Van der Meche FG, et al : Diagnostic and classification criteria for the Guillain-Barre syndrome. Eur Neurol 45 : 133-139, 2001.
PubMed
6) Hughes RA, et al : Practice parameter : immunotherapy for Guillain-Barre syndrome : report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 61 : 736-740, 2003.
 
7) 斎藤豊和ほか : ギラン・バレー症候群全国疫学調査 : 第二次アンケート調査の結果報告. 厚生省免疫性神経疾患に関する調査研究班平成11年度研究報告, p83-84, 2000.
 
8) 荻野美恵子ほか : Guillain-Barre症候群の全国調査 : 第3次調査結果を含めた最終報告. 厚生省免疫性神経疾患に関する調査研究班平成12年度研究報告書, p99-101, 2001.
 
9) van Koningsveld R, et al : A clinical prognostic scoring system for Guillain-Barre syndrome. Lancet Neurol 6 : 589-594, 2007.
PubMed
10) Ho TW, et al : Guillain-Barr syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 118 : 597-605, 1995.
 
11) Walgaard C, et al : Prediction of respiratory insufficiency in Guillain-Barre syndrome. Ann Neurol 67 : 781-787, 2010.
PubMed
12) Mitsui Y, et al : A multicentre prospective study of Guillain-Barre Syndrome in Japan : a focus on the incidence of subtypes. J Neurol Neurosurg Psychiatry 86 : 110-114, 2015.
PubMed
P.406 掲載の参考文献
1) Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 41 : 617-618, 1991.
 
2) Van den Bergh PY, et al : European Federation of Neurological Societies ; Peripheral Nerve Society : European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy : report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. Eur J Neurol 17 : 356-363, 2010.
PubMed
3) Breiner A Brannagan TH 3rd : Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy, Muscle Nerve 50 : 40-46, 2014.
PubMed
4) Iijima M, et al ; Refractory Peripheral Neuropathy Study Group of Japan : Prevalence and incidence rates of chronic inflammatory demyelinating Polyneuropathy in the Japanese population. J Neurol Neurosurg Psychiatry 79 : 1040-1043, 2008.
 
5) Rajabally YA, et al : Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria : study of a UK population. Muscle Nerve 39 : 432-438, 2009.
PubMed
6) Kaku DA et al : Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain 117 : 941-947, 1994.
PubMed
7) Cocito D, et al : Terminal latency index in polyneuropathy with IgM paraproteinemia and anti-MAG antibody. Muscle Nerve 24 : 1278-1282, 2001.
PubMed
8) Dyck PI, et al : Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 325 : 1482-1486, 1991.
 
9) Sinnreich M, et al : Chronic immune sensory polyradiculopathy : a possibly treatable sensory ataxia. Neurology 63 : 1662-1669, 2004.
PubMed
10) Ruts L, et al : Distinguishing acute-onset CIDP from Guillain-Barre syndrome with treatment related fluctuations. Neurology 65 : 138-140, 2005.
PubMed
11) Willison HJ, et al : The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 124 : 1968-1977, 2001.
PubMed
12) Goebel A, et al : Pain intensity and distribution in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 46 : 294-295, 2012.
PubMed
13) Figueroa JJ, et al : Autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 78 (10) : 702-708, 2012.
PubMed
14) Saifee TA, et al : Tremor in inflammatory neuropathies. J Neurol Neurosurg Psychiatry 84 : 1282-1287, 2013.
PubMed
15) Straver DCG, et al : Symptoms of activity-induced weakness in peripheral nervous system disorders. J Peripheral Nerv Syst 16 : 108-112, 2011.
PubMed
P.412 掲載の参考文献
1) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuroaphty : Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society, J peripher Nerv Syst 10 : 220-228, 2005.
 
2) Joint Task Force of the EFNS and the PNS : European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy : Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision. J Peripher Nerv Syst 15 : 1-9, 2010.
 
3) Aramideh M, et al : Somatosensory evoked potentials, sensory nerve potentials and sensory nerve conduction in hereditary motor and sensory neuropathy type I. J Neurol 239 : 277-283, 1992.
PubMed
4) 小川雅也ほか : CIDPの感覚伝導異常. 神経内科 50 : 223-230, 1999.
 
5) Mathey EK, et al : Chronic lnflammatory demyelinating polyradiculoneuropathy : from pathology to phenotype. J Neurol Neurosurg Psychiatry, 2015. [Epub ahead of print]
 
6) Bosboom WMJ, et al : Diagnostic value of sural nerve demyelination in chronic inflammatory demyelinating polyneuropathy. Brain 124 : 2427-2438, 2001.
 
7) Hahn AF, et al : Chronic Inflammatory Demyelinating polyradiculoneuropathy. In : Peripheral Neuropathy, Fourth Edition (ed by Dyck PJ, Thomas PK), p 2221-2253, Elsevier Saunders, Philadelphia, 2005.
 
8) Duggins AJ, et al : Spinal root and plexus hypertrophy in chronic infiammatory demyelinating polyneuropathy. Brain 122 : 1383-1390, 1999.
 
9) Taniguchi N, et al : Sonographic detection of diffuse peripheral nerve hypertrophy in chronic inflammatory demyelinating polyradicurlneuropathy. J Clin Ultrasound 28 : 488-491, 2000.
PubMed
10) 慢性炎症性脱髄性多発根ニューロパチー, 多巣性運動ニューロパチー診療ガイドライン2013 (日本神経学会慢性炎症性脱髄性多発根ニューロパチー多巣性運動ニューロパチー診療ガイドライン作成委員会編), 南江堂, 2013.
 
11) Simmons Z, et al : Longterm follow-up of patients with chronic inflammatory demyelinationg polyradiculoneuropathy, without and with mononclonal gammopathy. Brain 118 : 359-368, 1995.
 
12) Miki Y, et al : A family with IVIg-responsive Charcot-Marie-Tooth disease. J Neurol 260 : 1147-1151, 2013.
PubMed
13) Koike H, et al : Type I (transthyretin Met 30) familial amyloid polyneuropathy in Japan : early vs late-onset form. Arch Neurol 59 : 1771-1776, 2002.
 
14) Suzuki C, et al : Reversible multifocal conduction block in sarcoid neuropathy. J Peripher Nerv Syst 11 : 93-95, 2006.
PubMed
P.417 掲載の参考文献
1) 慢性炎症性脱髄性多発根ニューロパチー, 多巣性運動ニューロパチー診療ガイドライン2013 (慢性炎症性脱髄性多発根ニューロパチー, 多巣性運動ニューロパチー診療ガイドライン作成委員会, 日本神経学会), 南江堂, 2013.
 
2) Dyck PJ, et al : Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 11 : 136-141, 1982.
PubMed
3) van Schaik IN, et al : Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study) : a double-blind, randomised, controlled trial. Lancet Neurol 9 : 245-253, 2010.
PubMed
4) Hahn AF, et al : Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 119 (Pt 4) : 1067-1077, 1996.
 
5) Hughes RA, et al : Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study) : a randomised placebo-controlled trial. Lancet Neurol 7 : 136-144, 2008.
PubMed
6) Mendell JR, et al : Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56 : 445-449, 2001.
PubMed
7) Thompson N, et al : A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 243 : 280-285, 1996.
 
8) Vermeulen M, et al : Intravenous immunoglobulin treatment in patients with chronic innammatory demyelinating polyneuropathy : a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 56 : 36 -39, 1993.
 
9) Dyck PJ, et al : Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 314 : 461-465, 1986.
PubMed
10) Hahn AF, et al : Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 119 (Pt 4) : 1055-1066, 1996.
 
11) Dyck PJ, et al : A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36 : 838-845, 1994.
PubMed
12) Hughes R, et al : Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50 : 195-201, 2001.
PubMed
13) Green H, et al : Prophylaxis for Pneumocystis pneumonia (PCP) in non-HrV immunocompromised patients. Cochrane Database Syst Rev (3) : CD005590, 2007.
PubMed
14) Suzuki Y, et al : Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research : 2014 update. J Bone Miner Metab 32 : 337-350, 2014.
PubMed
15) Cocito D, et al : The efficacy of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating Polyneuropathy responders to intravenous immunoglobulin. J peripher Nerv Syst 16 : 150-152, 2011.
PubMed
16) Markvardsen LH, et al : Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 20 : 836-842, 2013.
PubMed
17) Gladstone DE, et al : High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 10 : 11-16, 2005.
PubMed
18) Good JL, et al : Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 51 : 1735-1738, 1998.
PubMed
19) Barnett MH, et al : Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 21 : 454-460, 1998.
PubMed
20) Hodgkinson SJ, et al : Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 53 : 327-330, 1990.
PubMed
21) Mahattanakul W, et al : Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A J Neurol Neurosurg Psychiatry 60 : 185-187, 1996.
PubMed
22) Matsuda M, et al : Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Sci 224 : 29-35, 2004.
PubMed
23) Odaka M, et al : Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin. J Neurol Neurosurg Psychiatry 76 : 1115-1120, 2005.
PubMed
24) Dyck PJ, et al : Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology 35 : 1173-1176, 1985.
PubMed
25) Kuwabara S, et al : Long term prognosis of chronic inflammatory demyelinating polyneuropathy : a five year follow up of 38 cases. J Neurol Neurosurg Psychiatry 77 : 66-70, 2006.
 
26) Iijima M, et al : Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP. Neurology 64 : 1471-1475, 2005.
PubMed
27) Mygland A, et al : Onset and course of chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 31 : 589-593, 2005.
PubMed
28) Sghirlanzoni A, et al : Chronic inflammatory demyelinating polyradiculoneuropathy : long-term course and treatment of 60 patients. Neurol Sci 21 : 31-37, 2000.
PubMed
29) Van den Bergh PY, et al : European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy : report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. Eur J Neurol 17 : 356-363, 2010.
PubMed
30) Iijima M, et al : Single nucleotide polymorphism of TAG-1 influences Mg responsiveness of Japanese patients with CIDP. Neurology 73 : 1348-1352, 2009.
PubMed
P.421 掲載の参考文献
1) Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 41 : 617-618, 1991.
 
2) Joint Task Force of the EFNS and the PNS : European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy : Report of a joint task force of the European Federation of Neurological Societies and Peripheral Nerve Society-first revision. J Peripher Nerv Syst 15 : 75-92, 2010.
 
3) Van den Bergh PY, et al ; European Federation of Neurological Societies ; Peripheral Nerve Society : European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy : report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. Eur J Neurol 17 : 356-363, 2010.
PubMed
4) Joint Task Force of the EFNS and the PNS : European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and Peripheral Nerve Society-first revision. J Peripher Nerv Syst 15 : 295-301, 2010.
PubMed
P.424 掲載の参考文献
1) Mlyashiro A, et al : Are multifocal motor neuropathy patients underdiagnosed? An epidemiological survey in Japan. Muscle Nerve 49 : 357-361, 2014.
PubMed
2) Nobile-Orazio E : Multifocal motor neuropathy. J Neuroimmunol 115 : 4-18, 2001.
PubMed
3) Cats EA, et al : Correlations of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology 75 : 818-825, 2010.
PubMed
4) Parry GJ, Clarke S : Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve 11 : 103-107, 1988.
PubMed
5) Kaji R, et al : Multifocal demyelinating motor neuropathy : cranial nerve involvement and immunoglobulin therapy. Neurology 42 : 506-509, 1992.
PubMed
6) Kaji R, et al : Pathological findings at the site of conduction block in multifocal motor neuropathy. Ann Neurol 33 : 152-158, 1993.
PubMed
7) Taylor BV, et al : Multifocal motor neuropathy : pathologic alterations at the site of conduction block. J Neuropathol Exp Neurol 63 : 129-137, 2004.
PubMed
8) Cats EA, et al : Multifocal motor neuropathy : Association of anti-GM1 IgM antibodies with clinical features. Neurology 75 : 1961-1967, 2010.
PubMed
9) Slee M, et al : Multifocal motor neuropathy. The diagnostic spectrum and response to treatment. Neurology 69 : 1680-1687, 2007.
PubMed
10) Kaji R, et al : Anti-GM1 antibodies and impaired blood-nerve barrier may interfere with remyelination in multifocal motor neuropathy. Muscle Nerve 17 : 108-110, 1994.
PubMed
11) Chaudhry V, et al : Worsening of multifocal motor neuropathy during pregnancy. Neurology 59 : 139-141, 2002.
PubMed
12) 神田隆 : 血液神経関門updateニューロパチー. BRAIN and NERVE 63 : 557-569, 2011.
 
13) Shimizu F, et al : Sera from patients with multifocal motor neuropathy disrupt the blood-nerve barrier. J Neurol Neurosurg Psychiatry 85 : 526-537, 2014.
PubMed
14) Furukawa T, et al : Increased proinflammatory cytokines in sera of patients with multifocal motor neuropathy. J Neurol Sci 346 : 75-79, 2014.
PubMed
P.432 掲載の参考文献
1) Lawson VH, Arnold WD : Multifocal motor neuropathy : a review of pathogenesis, diagnosis, and treatment. Neuropsychiatr Dis Treat 10 : 567-576, 2014.
PubMed
2) Olney RK, et al : Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve 27 : 117-121, 2003.
PubMed
3) European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. J Peripher Nerv Syst 15 : 295-301, 2010.
PubMed
4) Van Asseldonk JTH, et al : Criteria for conduction block based on computer simulation studies of nerve conduction with human data obtained in the forearm segment of the median nerve. Brain 129 : 2447-2460, 2006.
PubMed
5) Muley SA, Parry GJ : Multifocal motor neuropathy. J Clin Neurosci 19 (9) : 1201-1209, 2012.
 
6) Taylor BV, et al : Multifocal motor neuropathy : pathologic alterations at the site of conduction block. J Neuropathol Exp Neurol 63 : 129-137, 2004.
PubMed
7) Nobile-Orazio E : Multifocal motor neuropathy. J Neuroimmunol 115 : 4-18. 2001.
PubMed
8) van Es HW, et al : Magnetic resonance imaging of the brachial plexus in patients with multifocal motor neuropathy. Neurology 48 : 1218-1224, 1997.
PubMed
9) Grimm A, et al : Nerve ultrasound for differentiation betWeen amyotrophic lateral sclerosis and multifocal motor neuropathy. J Neurol 262 : 870-880, 2015.
PubMed
10) Cats EA, et al : Multifocal motor neuropathy : association of anti-GMI IgM antibodies with clinical features. Neurology 75 : 1961-1967, 2010.
 
11) Nobile-Orazio E, et al : How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies? J Neurol Sci 266 : 156-163, 2008.
PubMed
12) Park SB, et al : Activity-dependent conduction failure : molecular insights. J Peripher Nerv Syst 16 (3) : 159-168, 2011.
PubMed
13) Gondim FA, et al : Peripheral neuropathy in patients with inflammatory bowel disease. Brain 128 : 867-879, 2005.
PubMed
14) Noguchi M, et al : Multifocal motor neuropathy caused by a B-cell lymphoma producing a monoclonal IgM autoantibody against peripheral nerve myelin glycolipids GM1 and GD1b. Br J Haematol 123 : 600-605, 2003.
 
15) Cats EA. et al : Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology 75 : 818-825, 2010.
PubMed
P.438 掲載の参考文献
1) Azulay JP, et al : Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies : a double-blind, placebo-controlled study. Neurology 44 : 429-432, 1994.
PubMed
2) Van den Berg LH, et al : Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins : a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 59 : 248-252, 1995.
PubMed
3) Federico P, et al : Multifocal motor neuropathy improved by IVIg : randomized, double-blind, placebo-controlled study. Neurology 55 : 1256-1262, 2000.
PubMed
4) Leger JM, et al : Intravenous immunoglobulin therapy in multifocal motor neuropathy : a double-blind, placebo-controlled study. Brain 124 : 145-153, 2001.
PubMed
5) van Schaik IN, et al : Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev (2) : CDOO4429, 2005.
 
6) Hahn AF, et al : A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. J Peripher Nerv Syst 18 : 321-330, 2013.
PubMed
7) 日本神経学会 (監) : 慢性炎症性脱髄性多発根ニューロパチー, 多巣性運動ニューロパチー診療ガイドライン2013. 南江堂, 2013.
 
8) Joint Task Force of the EFNS and the PNS : European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. J Peripher Nerv Syst 15 : 295-301, 2010.
PubMed
9) Van den Berg-Vos RM, et al : Multifocal motor neuropathy : long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 125 : 1875-1886, 2002.
PubMed
10) Van den Berg-Vos RM, et al : Multifocal motor neuropathy : diagnostic criteria that predict the response to immunoglobulin treatment. Ann Neurol 48 : 919-926, 2000.
PubMed
11) Piepers S, et al : IVIg inhibits classical pathway activity and anti-GMI IgM-mediated complement deposition in MMN. J Neuroimmunol 229 : 256-262, 2010.
 
12) Harbo T, et al : Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy : a randomized, single-blinded cross-over trial. Eur J Neurol 16 : 631-638, 2009.
PubMed
13) Umapathi T, et al : Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev 4 : CD003217, 2012.
PubMed
14) White CM, et al : Exercise for people with peripheral neuropathy. Cochrane Database Syst Rev (4) : CD003904, 2004.
PubMed
15) Akaza M, et al : Motor nerve conduction study in cauda equina with high-voltage electrical stimulation in multifocal motor neuropathy and amyotrophic lateral sclerosis. Muscle Nerve 43 : 274-282, 2011.
PubMed
P.444 掲載の参考文献
1) Kelly JJ Jr, et al : Prevalence of monoclonal protein in peripheral neuropathy. Neurology 31 : 1480-1483, 1981.
PubMed
2) Nobile-Orazio E, et al : How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies ? J Neurol Sci 266 : 156-163, 2008.
PubMed
3) Nobile-Orazio E, et al : Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 123 : 710-717, 2000.
PubMed
4) Hellqvist E, et al : Myelin protein zero is naturally processed in the B cells of monoclonal gammopathy of undetermined significance of immunoglobulin M isotype : aberrant triggering of a patient's T cells. Haematologica 95 : 627-636, 2010.
 
5) Stalder AK, et al : Immunoglobulin M deposition in cutaneous nerves of anti-myelin-associated glycoprotein polyneuropathy patients correlates with axonal degeneration. J Neuropathol Exp Neurol 68 : 148-158, 2009.
PubMed
6) Kawagashira Y, et al : Morphological progression of myelin abnormalities in IgM-monoclonal gammopathy of undetermined significance anti-myelin-associated glycoprotein neuropathy. J Neuropathol Exp Neurol 69 : 1143-1157, 2010.
PubMed
7) Ilyas AA, et al : Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG. J Neuroimmunol 193 : 87-93, 2008.
PubMed
8) Ellie E, et al : Neuropathy associated with "benign" anti-myelin-associated glycoprotein IgM gammopathy : clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases. J Neurol 243 : 34-43, 1996.
 
9) Kawagashira Y, et al : IgM MGUS anti-MAG neuropathy with predominant muscle weakness and extensive muscle atrophy. Muscle Nerve 42 : 433-435, 2010.
PubMed
10) Luigetti M, et al : Clinical and pathological heterogeneity in a series of 31 patients with IgM-related neuropathy. J Neurol Sci 319 : 75-80, 2012.
 
11) Kuijf ML, et al : Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy. Neurology 73 : 688-695, 2009.
PubMed
12) Kaku DA, et al : Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain 117 : 941-947, 1994.
PubMed
13) Dalakas MC, et al : Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 65 : 286-293, 2009.
PubMed
14) Leger JM, et al : Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology 80 : 2217-2225, 2013.
PubMed
15) Hospital MA, et al : Immunotherapy-based regimen in anti-MAG neuropathy : results in 45 patients. Haematologica 98 : e155-157, 2013.
PubMed
P.450 掲載の参考文献
1) Kuwabara S, et al : Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. Cochrane Database Systematic Review (4) : CD006828, 2008.
PubMed
2) Nakanishi T, et al : The Crow-Fukase syndrome : a study of 102 cases in Japan. Neurology 34 : 712-720, 1984.
PubMed
3) 納光弘ほか : Crow-Fukase症候群の全国疫学調査2004. 厚生労働省免疫性神経に関する調査研究班平成16年度報告書. p 141-144, 2004.
 
4) Watanabe O, et al : Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet 347 : 702, 1996.
PubMed
5) Abe D, et al : Restrictive usage of monoclonal immunoglobulin lambda light chain germline in POEMS syndrome. Blood 112 : 836-839, 2008.
PubMed
6) Kuwabara S, et al : Long term melphalan-prednisolone chemotherapy for POEMS syndrome. Neurol Neurosurg Psychiatry 63 : 385-387, 1997.
PubMed
7) 桑原聡, 三澤園子 : Crow-Fukase症候群の新規治療展望. Annual Review神経2007, 中外医学社, p214-220, 2007.
 
8) Wong VA, Wade NK : POEMS syndrome : an unusual cause of bilateral optic disk swelling. Am J Ophthalmol 126 : 452-454, 1998.
PubMed
9) Jaccard A, et al : High-dose therapy and autologous blood stem cell transplantation in POEMS syndrome. Blood 99 : 3057-3059, 2002.
PubMed
10) Dispenzieri A, et al : Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood 104 : 3400-3407, 2004.
 
11) Kuwabara S, et al : Autologous peripheral blood stem cell transplantation for POEMS syndrome. Neurology 66 : 105-107, 2006.
PubMed
12) Kuwabara S, et al : Neurologic improvement after peripheral blood stem cell transplantation in POEMS syndrome. Neurology 71 : 1691-1695, 2008.
PubMed
13) Kuwabara S, et al : Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome. J Neurol Neurosurg Psychiatry 79 : 1255-1257, 2008.
PubMed
14) Dispenzieri A, et al : Lenalidomide therapy in a patient with POEMS syndrome. Blood 110 : 1075-1076, 2007.
 
15) Kanai K, et al : Failure of treatment with anti-VEGF monoclonal antibody for long-standing POEMS syndrome. Intern Med 46 : 311-313, 2007.
PubMed
P.456 掲載の参考文献
1) Koike H, et al : The spectrum of immune-mediated autonomic neuropathies : insights from the clinicopathological features. J Neurol Neurosurg Psychiatry 84 : 98-106, 2013.
PubMed
2) Vernino S, et al : Invited Article : Autonomic ganglia : target and novel therapeutic tool. Neurology 70 : 1926-1932, 2008.
PubMed
3) Koike H, et al : Clinicopathological features of acute autonomic and sensory neuropathy, Brain 133 : 2881-2896, 2010.
PubMed
4) Ohyama K, et al : Differential recovery in cardiac and vasomotor sympathetic functional markers in acute autonomic sensory and motor neuropathy : a case report. Intern Med 52 : 497-502, 2013.
PubMed
5) Colan RV, et al : Acute autonomic and sensory neuropathy. Ann Neurol 8 : 441-444, 1980.
PubMed
6) Fagius J, et al : Acute pandysautonomia and severe sensory deficit with poor recovery. A clinical, neurophysiological and pathological case study. J Neurol Neurosurg Psychiatry 46 : 725-733, 1983.
PubMed
7) Tohgi H, et al : Acute autonomic and sensory neuropathy : report of an autopsy case. Acta Neuropathol 77 : 659-663, 1989.
PubMed
8) Kanda F, et al : Acute autonomic and sensory neuropathy : a case report. J Neurol 237 : 42-44, 1990.
PubMed
9) Pavesi G, et al : Acute sensory and autonomic neuropathy : possible association with coxsackie B virus infection. J Neurol Neurosurg Psychiatry 55 : 613-615, 1992.
PubMed
10) Bennett JL, et al : Epstein-Barr virus-associated acute autonomic neuropathy. Ann Neurol 40 : 453-455, 1996.
PubMed
11) Kurokawa K, et al : A case of pandysautonomia with associated sensory ganglionopathy. J Neurol Neurosurg Psychiatry 65 : 278-279, 1998.
PubMed
12) Irioka T, et al : Acute autonomic and sensory neuropathy after interferon alpha-2b therapy for chronic hepatitis C. J Neurol Neurosurg Psychiatry 70 : 408-410, 2001.
PubMed
13) Koike H, Sobue G : The wide range of clinicopathological features in immune-mediated autonomic neuropathies. Clin Exp Neuroimmunol 4 : 46-59, 2013.
 
14) Mori K, et al : The wide spectrum of clinical manifestations in Sjogren's syndrome-associated neuropathy. Brain 128 : 2518-2534, 2005.
PubMed
15) Koike H, et al : The spectrum of clinicopathological features in pure autonomic neuropathy. J Neurol 259 : 2067-2075, 2012.
PubMed
P.462 掲載の参考文献
1) 古賀道明 : 急性汎自律神経異常症とニコチン作動性アセチルコリン受容体抗体. 脳神経 65 : 425-432, 2013.
 
2) 小池春樹, 祖父江元 : 抗アセチルコリン受容体抗体陽性の自律神経傷害性ニューロパチー. Annual Review 神経2010 (鈴木則宏ほか編), p 223-228, 中外医学社, 2010.
 
3) Vernino S, et al : Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes. Neurology 50 : 1806-1813, 1998.
PubMed
4) Vernino S, et al : Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 343 : 847-855, 2000.
PubMed
5) Vernino S, et al : Characterization of ganglionic acetylcholine receptors autoantibodies. J Neuroimmunol 197 : 63-69, 2007.
 
6) Lennon VA, et al : Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease. J Clin Invest 111 : 907-913, 2003,
PubMed
7) Vernino S, et al : Experimental autoimmune autonomic neuropathy. J Neurophysiol 90 : 2053-2059, 2003.
PubMed
8) Vernino S, et al : Passive transfer of autoimmune autonomic neuropathy to mice. J Neurosci 24 : 7037-7042, 2004.
PubMed
9) Wang Z, et al : Antibody-mediated impairment and homeostatic plasticity of autonomic ganglionic synaptic transmission. Exp Neurol 222 : 114-119, 2010.
PubMed
10) Klein CM, et al : The spectrum of autoimmune autonomic neuropathies. Ann Neurol 53 : 752-758, 2003.
PubMed
11) Sandroni P, et al : Idiopathic autonomic neuropathy : comparison of cases seropositive and seronegative for ganglionic acetylcholine receptor antibody. Arch Neurol 61 : 44-48, 2004.
PubMed
12) Gibbons C, et al : Combined immunomodulatory therapy in autoimmune autonomic ganglionopathy. Arch Neurol 65 : 213-217, 2008.
PubMed
13) Baker SK, et al : Transient neonatal autoimmune autonomic ganglionopathy. Neurol Neuroimmunol Neuroinflamm 1 : e35, 2014.
PubMed
14) Kondo T, et al : Autoimmune autonomic ganglionopathy with Sjogren's syndrome : significance of ganglionic acetylcholine receptor antibody and therapeutic approach. Auton Neurosci 146 : 33-35, 2009.
PubMed
15) Balestra B, et al : Antibodies against neuronal nicotinic receptor subtypes in neurological disorders. J Neuroimmunol 102 : 89-97, 2000.
PubMed
16) Dhamija R, et al : Serologic profiles aiding the diagnosis of autoimmune gastrointestinal dysmotility. Clin Gastroenterol Hepatol 6 : 988-992, 2008.
PubMed
17) Sandroni P, Low PA : Other autonomic neuropathies associated with ganglionic antibody. Auton Neurosci 146 : 13-17, 2009.
PubMed
18) Koike H, et al : The spectrum of clinicopathological features in pure autonomic neuropathy. J Neurol 259 : 2067-2075, 2012.
PubMed
19) Li Y, et al : Clinical experience of seropositive ganglionic acetylcholine receptor antibody in a tertiary neurology referral center. Muscle Nerve, 2014. [Epub ahead of print]
 
20) Koike H, et al : Clinicopathological features of acute autonomic and sensory neuropathy. Brain 133 : 2881-2896, 2010.
PubMed
21) 古賀道明 : 自律神経ニューロパチーの治療. 神経治療 30 : 11-15, 2013.
Medical*Online
22) Iodice V, et al : Immunotherapy for autoimmune ganglionopathy. Auton Neurosci 146 : 22-25, 2009.
PubMed
23) Nishihara H, et al : Combined immunomodulatory therapies resulted in stepwise recovery in autoimmune autonomic ganglionopathy. Clin Exp Neuroimmunol. (in press)
 

V 免疫性筋疾患

P.470 掲載の参考文献
1) Vincent A, et al : Myasthenia gravis seronegative for acetylcholine receptor antibodies. Ann NY Acad Sci 1132 : 84-92, 2008.
PubMed
2) Higuchi O, et al : Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69 (2) : 418-422, 2011.
PubMed
3) 本村政勝ほか : 新知見Overview : MuSKとDok-7. 日本臨牀 66 (6) : 1140-1148, 2008.
Medical*Online
4) Weiss JM, et al : The thymus in autoimmune Myasthenia Gravis : Paradigm for a tertiary lymphoid organ. Rev Neurol (Paris) 169 (8-9) : 640-649, 2013.
 
5) Scarpino S, et al : Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin Exp Immunol 149 (3) : 504-512, 2007.
 
6) Shiraishi H, et al : Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 57 (2) : 289-293, 2005.
PubMed
7) Tzartos SJ, et al : Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol Rev 163 : 89-120, 1998.
PubMed
8) Vincent A, et al : Response to human acetylcholine receptor alpha 138-199 : determinant spreading initiates autoimmunity to self-antigen in rabbits. Immunol Lett 39 (3) : 269-275, 1994.
PubMed
9) Huijbers MG, et al : Pathogenic immune mechanisms at the neuromuscular synapse : the role of specific antibody-binding epitopes in myasthenia gravis. J Intern Med 275 (1) : 12-26, 2014.
PubMed
10) Kawakami Y, et al : Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology 77 (20) : 1819-1826, 2011.
PubMed
11) Weatherbee SD, et al : LDL-receptor-related protein 4 is crucial for formation of the neuromuscular junction. Development 133 (24) : 4993-5000, 2006.
PubMed
12) Shen C, et al : Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest 123 (12) : 5190-5202, 2013.
PubMed
13) Yumoto N, et al : Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses. Nature 489 (7416) : 438-442, 2012.
PubMed
14) Suzuki N : Cardiac involvements in myasthenia gravis associated with anti-Kv1. 4 antibodies. Eur J Neurol 21 (2) : 223-230, 2014.
PubMed
15) Zhang B, et al : Autoantibodies to agrin in myasthenia gravis patients. PLoS One 9 (3) : e91816, 2014.
PubMed
16) Gallardo E, et al : Cortactin autoantibodies in myasthenia gravis. Autoimmun Rev 13 (10) : 1003-1007, 2014.
PubMed
P.476 掲載の参考文献
1) Murai H, et al : Characteristics of myasthenia gravis according to onset-age : Japanese nationwide survey. J Neurol Sci 305 : 97-102, 2011.
PubMed
2) Grob D, et al : Lifetime course of myasthenia gravis. Muscle Nerve 37 : 141-149, 2008.
PubMed
3) 平山宗広ほか : 重症筋無力症の疫学的研究. 昭和48年度厚生省特定疾患重症筋無力症調査研究班報告書, p50-66, 1974.
 
4) 高守正治, 井形昭弘 : 重症筋無力症疫学調査報告. 厚生省特定疾患免疫性神経疾患調査研究班昭和62年度研究報告書, p227-245, 1988.
 
5) Jaretzki A, et al : Myasthenia gravis : recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America (MGFA). Neurology 55 : 16-23, 2000.
 
6) Wolfe GI, et al : Myasthenia gravis activities of daily living profile. Neurology 52 : 1487-1489, 1999.
PubMed
7) Matsuda M, et al : Increase in incidence of elderly-onset patients with myasthenia gravis in Nagano Prefecture, Japan. Intern Med 44 : 572-577, 2005.
PubMed
8) Matsui N, et al : Increasing incidence of elderly onset patients with myasthenia gravis in a local area of Japan. J Neurol Neurosurg Psychiatry 80 : 1168-1171, 2009.
 
9) Murai H, et al : Clinical features and treatment status of adult myasthenia gravis in Japan. Clin Exp Neuroimmunol 5 : 84-91, 2014.
 
10) Strobel P, et al : The ageing and myasthenic thymus : a morphometric study validating a standard procedure in the histological workup of thymic specimens. J Neuroimmunol 201-202 : 64-73, 2008.
 
11) Akaishi T, et al : Insights into the classification of myasthenia gravis. PLoS One 9 : e106757, 2014.
PubMed
12) Imai T, et al : Oral corticosteroid therapy and present disease status in myasthenia gravis. Muscle Nerve 2014 Aug 25. doi : 10.1002/mus. 24438. [Epub ahead of print]
 
13) Carr AS, et al : A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol 10 : 46, 2010.
PubMed
14) Evoli A, et al : Thymoma in patients with MG : characteristics and long-term outcome. Neurology 59 : 1844-1850, 2002.
PubMed
P.481 掲載の参考文献
1) 渡辺源也ほか : 重症筋無力症における確定診断までに要する期間に関する検討, 第55回日本神経学会学術大会, 2014.
 
2) Grob D, et al : Lifetime course of myasthenia gravis. Muscle Nerve 37 (2) : 141, 2008.
PubMed
3) Murai H, et al : Characteristics of myasthenia gravis according to onset-age : Japanese nationwide survey. J Neurol Sci 305 (1-2) : 97-102, 2011.
 
4) Grob D, et al : The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci 505 : 472, 1987.
PubMed
5) 重症筋無力症診療ガイドライン2014 (日本神経学会監, 「重症筋無力症診療ガイドライン」作成委員会編), 南江堂, 2014.
 
6) Mantegazza R, et al : A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy. J Neurol 237 (6) : 339-344, 1990.
PubMed
7) 標準的神経治療 : 高齢発症重症筋無力症 (日本神経治療学会治療指針作成委員会編). 神経治療 27 : 241-254, 2010.
 
8) Ybarra MI, et al : Psychiatric disorders in myasthenia gravis. Arq Neuropsiquiatr 69 (2A) : 176-179, 2011.
PubMed
9) Magni G, et al : Psychiatric disturbances associated with myasthenia gravis. Acta Psychiatr Scand 77 (4) : 443-445, 1988.
PubMed
10) Suzuki Y, et al : Factors associated with depressive state in patients with myasthenia gravis : a multicentre cross-sectional study. BMJ Open 1 (2) : e000313, 2011.
 
11) Martinez-Lapiscina EH, et al : Myasthenia gravis : sleep quality, quality of life, and disease severity. Muscle Nerve 46 (2) : 174-180, 2012.
PubMed
12) 鈴木重明 : 胸腺腫関連重症筋無力症にみられる多様な抗体とその意義. 脳と神経 63 : 705-712, 2011.
 
13) 渡辺源也ほか : 重症筋無力症における自己免疫性甲状腺疾患合併例の臨床的特徴の検討. 第24回日本神経免疫学会学術集会, 2012.
 
P.487 掲載の参考文献
1) 重症筋無力症診療ガイドライン2014 (日本神経学会監, 「重症筋無力症診療ガイドライン」作成委員会編), p10-17, 南江堂, 2014.
 
2) Mittal MK, et al : Ocular myasthenia gravis in an academic neuro-ophthalmology clinic : clinical features and therapeutic response. J Clin Neuromuscul Dis 13 : 46-52, 2011.
 
3) Osserman KE, Kaplan LI : Rapid diagnostic test for myasthenia gravis. Increased muscle strength, without fasciculations, after intravenous administration of edrophonium (Tensilon(R)) chloride. JAMA 150 : 265-268, 1952.
 
4) Beekman R, et al : Myasthenia gravis : diagnosis and follow-up of 100 consecutive patients. J Neurol 244 : 112-118, 1997.
PubMed
5) Scherer K, et al : Does this patient have myasthenia gravis? JAMA 293 : 1906-1914, 2005.
PubMed
6) Oh SJ, et al : Diagnostic sensitivity of the laboratory tests in myasthenia gravis. Muscle Nerve 15 : 720-724, 1992.
PubMed
7) Sanders DB : Clinical impact of single-fiber electromyography. Muscle Nerve 11 : S15-S20, 2002.
PubMed
8) Kokubun N, et al : Reference values for voluntary and stimulated single-fibre EMG using concentric needle electrodes : a multicentre prospective study. Clin Neurophysiol 123 : 613-620, 2012.
PubMed
9) Jaretzki A 3rd, et al : Myasthenia gravis : recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America (MGEA). Neurology 55 : 16-23, 2000.
 
10) Wolfe GI, et al : Myasthenia gravis activities of daily living profile. Neurology 52 : 1487-1489, 1999.
PubMed
11) Mullins LL, et al : Disease-specific measure of quality of life for myasthenia gravis. Muscle Nerve 38 : 947-956, 2008.
PubMed
12) Muppidi S, et al : MG-ADL : still a relevant outcome measure, Muscle Nerve 44 : 727-731, 2011.
 
13) Burns TM : The MG composite : an outcome measure for myasthenia gravis for use in clinical trials and everyday practice. Ann N Y Acad Sci 1274 : 99-106, 2012.
PubMed
14) Masuda M, et al : The MG-QOL15 Japanese version : validation and associations with clinical factors. Muscle Nerve 46 : 166-173, 2012.
PubMed
15) Mulder DW, et al : Myasthenic syndrome in patients with amyotrophic lateral sclerosis. Neurology 9 : 627-631, 1959.
PubMed
P.493 掲載の参考文献
1) Gilhus NE : Autoimmune myasthenia gravis. Expert Rev Neurother 9 : 351-358, 2009.
PubMed
2) Grob D, et al : Lifetime course of myasthenia gravis. Muscle Nerve 37 : 141-149, 2008.
PubMed
3) Burns TM : History of outcome measures for myasthenia gravis. Muscle Nerve 42 : 5-13, 2010.
PubMed
4) Jaretzki A 3rd, et al ; for the Task Force of the Medical Scientific Advisory Board of Myasthenia Gravis Foundation of America : Myasthenia gravis : recommendations for clinical research standers. Neurology 55 : 16-23, 2000.
 
5) Masuda M, et al : The MG-QOL15 Japanese version : validation and associations with clinical factors. Muscle Nerve 46 : 166-173, 2012.
PubMed
6) Utsugisawa K, et al : Health-related quality of life and treatment targets in myasthenia gravis. Muscle Nerve 50 : 493-500, 2014.
PubMed
7) Suzuki Y, et al : Factors associated with depressive state in patients with myasthenia gravis : a multicentre cross-sectional study. BMJ Open 1 : e000313, 2011.
 
8) Twork S, et al : Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes 8 : 129-138, 2010.
PubMed
9) 重症筋無力症診療ガイドライン2014 (日本神経学会監, 「重症筋無力症診療ガイドライン」作成委員会編), 南光堂, 2014.
 
10) Murai H : Japanese clinical guidelines for myasthenia gravis : Putting into practice. Clin Exp Neuroimmunol 6 : 21-31, 2015.
 
11) Nagane Y, et al : Early aggressive treatment strategy against myasthenia gravis. Eur Neurol 65 : 16-22, 2011.
PubMed
12) Imai T, et al : Oral corticosteroid therapy and present disease status in myasthenia gravis. Muscle Nerve 51 : 692-696, 2015.
PubMed
13) Murai H, et al : Clinical features and treatment status of adult myasthenia gravis in Japan. Clin Exp Neuroimmunol 5 : 84-91, 2014.
 
14) Sanders DB, Evoli A : Immunosuppressive therapies in myasthenia gravis. Autoimmunity 43 : 428-435, 2010.
PubMed
15) Truhan AP, Ahmed AR : Corticosteroids : a review with emphasis on complications of prolonged systemic therapy. Ann Allergy 62 : 375-391, 1989.
PubMed
16) Brown ES, Suppes T : Mood symptoms during corticosteroid therapy : a review. Harvard Rev Psychiatry 5 : 239 -246, 1998.
 
17) Aarli JA : Myasthenia gravis in the elderly : is it different? Ann N Y Acad Sci 1132 : 238-243, 2008.
PubMed
18) Murai H, et al : Characteristics of myasthenia gravis according to onset-age : Japanese nationwide survey. J Neurol Sci 305 : 97-102, 2011.
PubMed
19) Nagane Y, et al : Factors associated with response to calcineurin inhibitors in myasthenia gravis. Muscle Nerve 41 : 212-218, 2010.
PubMed
20) Utsugisawa K, et al : Treatment of myasthenia gravis patients with calcineurin inhibitors in Japan : Aretrospective analysis of outcomes. Clin Exp Neuroimmunol 2015. (in press)
 
21) 槍沢公明, 長根百合子 : 胸腺異常と重症筋無力症. Brain Nerve 63 : 685-694, 2011.
 
22) Strobel P, et al : The ageing and myasthenic thymus : a morphometric study validating a standard procedure in the histological workup of thymic specimens. J Neuroimmunol 201-202 : 64-73, 2008.
 
23) Marx A, et al : Pathogenesis of myasthenia gravis. Virchows Arch 430 : 355-364, 1997.
PubMed
24) Akaishi T, et al : Insights into the classification of myasthenia gravis. PLoS One 9 : e106757, 2014.
PubMed
P.499 掲載の参考文献
1) Murai H, et al : Characteristics of myasthenia gravis according to onset-age : Japanese nationwide survey. J Neurol Sci 305 : 97-102, 2011.
PubMed
2) 重症筋無力症診療ガイドライン2014 (日本神経学会監, 「重症筋無力症診療ガイドライン」作成委員会編), 南江堂, 2014.
 
3) Evoli A et al : Clinical characteristics and prognosis of myasthenia gravis in older people. J Am Geriatr 48 : 1442-1448, 2000.
 
4) 高守正治, 井形昭弘 : 重症筋無力症疫学調査報告. 厚生省特定疾患免疫性神経疾患調査研究班昭和62年度研究報告書, p227-245, 1988.
 
5) Vincent A et al : Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 74 : 1105-1108, 2003.
 
6) Somnier FE : Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis. Neurology 65 : 928-930, 2005.
PubMed
7) 標準的神経治療 : 高齢発症重症筋無力症 (日本神経治療学会監修), 医学書院, 2012.
 
8) Suzuki S, et al : Clinical and immunological differences between early and late-onset myasthenia gravis in Japan. J Neuroimmunol 230 : 148-152, 2011.
PubMed
9) Marx Al, et al : The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 12 : 875-884, 2013.
 
10) Sugawara M, et al : Long-term follow up of thymus in patients with myasthenia gravis. J Neuroimmunol 221 : 121-124, 2010.
PubMed
11) Kawaguchi N, et al : Effects of thymectomy on late-onset myasthenia gravis without thymoma. Clin Neurol Neurosurg 109 : 858-861, 2007.
PubMed
12) Gronseth GS, Barohn RJ : Practice parameter : Thymectomy for autoimmune myasthenia gravis (an evidence-based review) -Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55 : 7-15, 2000.
 
13) Nagane Y, et al : Factors associated with response to calcineurin inhibitors in myasthenia gravis. Muscle Nerve 41 : 212-218, 2010.
PubMed
14) Palace J, et al : A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 50 : 1778-1783, 1998.
 
15) Zinman L, et al : IV immunoglobulin in patients with myasthenia gravis : a randomized controlled trial. Neurology 68 : 837-841, 2007.
PubMed
16) Yeh JH, Chiu HC : Optimal volume of processed plasma and total number of selective plasmapheresis sessions in the treatment of patients with severe generalized myasthenia gravis. J Clin Apher 14 : 177-180, 1999.
PubMed
P.505 掲載の参考文献
1) Walker MB : Treatment of myasthenia gravis with physostigmine. Lanset 1 : 1200-1201, 1934.
 
2) Maggi L, Mantegazza R : Treatment of myasthenia gravis : focus on pyridostigmine. Clin Drug Investig 31 : 691-701, 2011.
PubMed
3) Shin HY, et al : Clinical and Electrophysiologic Responses to Acetylcholinesterase Inhibitors in MuSK-Antibody-Positive Myasthenia Gravis : Evidence for Cholinergic Neuromuscular Hyperactivity. J Clin Neurol 10 : 119-124, 2014.
PubMed
4) Mehndiratta MM, et al : Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev 10 : CD006986, 2014.
PubMed
5) Nagane Y, et al : Topical naphazoline in the treatment of myasthenic blepharoptosis. Muscle Nerve 44 : 41-44, 2011.
PubMed
6) Morsch M, et al : Pyridostigmine but not 3, 4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody. J Physiol 591 : 2747-2762, 2013.
 
7) Meshorer E, Soreq H : Virtues and woes of AChE alternative splicing in stress-related neuropathologies. Trends Neurosci 29 : 216-224, 2006.
PubMed
8) Kaufer D, Soreq H : Tracking cholinergic pathways from psychological and chemical stressors to variable neurodeterioration paradigms. Curr Opin Neurol 12 : 739-743, 1999.
PubMed
9) Brenner T, et al : The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. FASEB J 17 : 214-222, 2003.
PubMed
10) Angelini C, et al : New treatments for myasthenia : a focus on antisense oligonucleotides. Drug Des Devel Ther 7 : 13-17, 2013.
PubMed
11) Argov Z, et al : Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase. Neurology 69 : 699-700, 2007.
PubMed
12) Grisaru D, et al : ARP, a peptide derived from the stress-associated acetylcholinesterase variant, has hematopoietic growth promoting activities. Mol Med 7 : 93-105, 2001.
 
P.510 掲載の参考文献
1) Schneider-Gold C, et al : Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev (2) : CD002828, 2005.
PubMed
2) Gilhus NE : Autoimmune myasthenia gravis. Expert Rev Neurother 9 : 351-358, 2009.
PubMed
3) Grob D, et al : Lifetime course of myasthenia gravis. Muscle Nerve 37 : 141-149, 2008.
PubMed
4) Tindall RSA, et al : Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 316 : 719-724, 1987.
 
5) Yoshikawa H, et al : Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry 82 : 970-977, 2011.
PubMed
6) Nagane Y, et al : Factors associated with response to calcineurin inhibitors in myasthenia gravis. Muscle Nerve 41 : 212-218, 2010.
PubMed
7) Utsugisawa K, et al : Monitoring treatment with cyclosporine microemulsion in myasthenia gravis. Eur J Neurol 15 : 598-604, 2008.
PubMed
8) Masuda M, et al : The MG-QOL15 Japanese version : validation and associations with clinical factors. Muscle Nerve 46 : 166-173, 2012.
PubMed
9) Suzuki Y, et al : Factors associated with depressive state in patients with myasthenia gravis : a multicentre cross-sectional study. BMJ Open 1 : e000313, 2011.
 
10) Warmolts JR, et al : Alternate-day prednisone in a patient with myasthenia gravis. Lancet 2 : 1198-1199, 1970.
 
11) Kawaguchi N, et al : Treatment and outcome of myasthenia gravis : retrospective multi-center analysis of 470 Japanese patients, 1999-2000. J Neurol Sci 224 : 43-47, 2004.
PubMed
12) Takamori M, et al : Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis. Neurology 62 : 1894-1896, 2004.
PubMed
13) Palace J, et al : A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 50 : 1778-1783, 1998.
 
14) Sanders DB, et al : An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 71 : 400-406, 2008.
PubMed
15) Hehir MK, et al : Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis : outcomes in 102 patients. Muscle Nerve 41 : 593-598, 2010.
PubMed
P.513 掲載の参考文献
1) 重症筋無力症診療ガイドライン2014 (日本神経学会監, 「重症筋無力症診療ガイドライン」作成委員会編), p64-66, 南江堂, 2014.
 
2) Murai H, et al : Characteristics of myasthenia gravis according to onset-age : Japanese nationwide survey. J Neurol Sci 305 : 97-102, 2011.
PubMed
3) Dalakas MC : Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291 : 2367-2375, 2004.
PubMed
4) Samuelsson A, et al : Anti-inflammatory activity of MG mediated through inhibition of Fc receptor. Science 291 : 484 -486, 2001.
 
5) Zinman L et al : IV immunoglobulin in patients with myasthenia gravis : a randomized controlled trial. Neurology 68 : 837-841, 2007.
PubMed
6) Barth D, et al : Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 76 : 2017-2023, 2011.
PubMed
7) Vlam L, et al : Pharmacokinetics of intravenous immunoglobulin in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 85 : 1145-1148, 2014.
PubMed
8) Patwa HS, et al : Evidence-based guideline : intravenous immunoglobulin in the treatment of neuromuscular disorders : report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 78 : 1009-1015, 2012.
 
9) Dalakas MC : The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases : evidence-based indications and safety profile. Pharmacol Ther 102 : 177-193, 2004.
PubMed
10) 高守正治 : 重症筋無力症疫学調査報告 : 厚生省特定疾患免疫性神経疾患調査研究班. 昭和62年度報告書, p227-245, 1988.
 
11) Kawaguchi N, et al : Treatment and outcome of myasthenia gravis : Retrospective multi-center analysis of 470 Japanese patients, 1999-2000. J Neurol Sci 224 : 43-47, 2004.
PubMed
12) Gilhus NE : Neuromuscular disease : acute treatment for myasthenia gravis. Nat Rev Neurol 7 : 132-134, 2011.
PubMed
13) Miller RG, et al : Expanding the evidence base for therapeutics in myasthenia gravis. Ann Neurol 68 : 776-777, 2010.
PubMed
14) Mandawat A, et al : Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol 68 : 797-805, 2010.
PubMed
15) Sorgun MH, et al : Intravenous immunoglobulin for prophylaxis of acute exacerbation in Myasthenia Gravis. Neurol Sci 35 : 891-896, 2014.
PubMed
P.519 掲載の参考文献
1) Lewis RA et al : Myasthenia gravis : immunological mechanisms and immnotherapy. Ann Neurol 37 : S51-62, 1995.
 
2) Bergstrom K, et al : The effect of thoracic duct lymph drainage on myasthenia gravis. Eur Neurol 9 : 157-167, 1973.
PubMed
3) Pinching AJ, et al : Remission of myasthenia gravis following plasma exchange. Lancet 2 : 1373-1376, 1976.
PubMed
4) Dau PC, et al : Plasmapheresis and immunosupressive drug therapy in myasthenia gravis. N Engl J Med 297 : 1134-1140, 1977.
 
5) Newsom-Davis J, et al : Function of circulating antibody to acetylcholine receptor in myasthenia gravis : investigation by plasma exchange. Neurology 28 : 266-272, 1978.
PubMed
6) Gajods P, et al : Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev 4 : CD002275, 2002.
 
7) Lindstrom J : Autoimmune response to acetylcholine receptors in myasthenia gravis and its animal model. Adv Immunol 27 : 1-50, 1979.
PubMed
8) Bufler J, et al : Purified IgG from seropositive and seronegative patients with myasthenia gravis reversibly blocks currents through nicotinic acetylcholine receptor channels. Ann Neurol 43 : 458-464, 1998.
PubMed
9) Szczepiorkowski ZM, et al : Guidelines on the use of therapeutic apheresis in clinical practice : evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 22 : 106-175, 2007.
PubMed
10) Stricker RB, et al : Myasthenic crisis : response to plasmapheresis followiong failure of intravenous gamma-globulin. Arch Neurol 50 : 837-840, 1993.
PubMed
11) Gajdos P, et al : Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 41 : 789-796, 1997.
PubMed
12) Antrozzi C, et al : A short plasma exchange protocol is effective in severe myasthnia gravis. J Neurol 238 : 103-107, 1991.
 
13) Ide Y, et al : Treatment of myasthenia gravis with a specific immunoadsorbent bound to acetylcholine receptor peptide α 183-200. In : Therapeutic Plasmapheresis (IX) (ed by Koga N, et al), p 147-152, ICAOT Press, Cleveland, 1991.
 
14) Tzartos SJ, et al : Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera. Ann N Y Acad Sci 1132 : 291-299, 2008.
PubMed
15) Skriapa L, et al : Expression of extracellular domains of muscle specific kinase (MuSK) and use as immunoadsorbents for the development of an antigen-specific therapy. J Neuroimmunol 276 : 150-158, 2014.
PubMed
P.526 掲載の参考文献
1) Patrick J, Lindstrom J : Autoimmune response to acetylcholine receptor. Science 180 : 871-872, 1973.
PubMed
2) Schumacher CH, Roth P : Thymektomie bei einem Fall von Morbus Basedowi mit Myasthenie. Mitt Grenzgeb Med Chir 25 : 746-765, 1913.
 
3) Blalock A, et al : Myasthenia gravis and tumors of the thymic region : report of a case in which the tumor was removed. Ann Surg 110 : 544-561, 1939.
PubMed
4) Lanska DJ : Indications for thymectomy in myasthenia gravis. Neurology 40 : 1828-1829, 1990.
PubMed
5) Gronseth GS, Barohn RJ : Practice parameter : thymectomy for autoimmune myasthenia gravis (an evidence-based review) : report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55 : 7-15, 2000.
 
6) Cea G, et al : Thymectomy for non-thymomatous myasthenia gravis. Cochrane Database Syst Rev 10 : Cd008111, 2013.
PubMed
7) Ettinger DS, et al : Thymomas and thymic carcinomas : Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 11 : 562-576, 2013.
PubMed
8) Pennathur A, et al : Comparison of surgical techniques for early-stage thymoma : feasibility of minimally invasive thymectomy and comparison with open resection. J Thorac Cardiovasc Surg 141 : 694-701, 2011.
PubMed
9) Newsom-Davis J, et al : Status of the thymectomy trial for nonthymomatous myasthenia gravis patients receiving prednisone. Ann N Y Acad Sci 1132 : 344-347, 2008.
PubMed
10) Jaretzki A 3rd, et al : Myasthenia gravis : recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55 : 16-23, 2000.
PubMed
11) Matsui N, et al : Increasing incidence of elderly onset patients with myasthenia gravis in a local area of Japan. J Neurol Neurosurg Psychiatry 80 : 1168-1171, 2009.
 
12) Carr AS, et al : A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol 10 : 46, 2010.
PubMed
13) Alshekhlee A, et al : Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 72 : 1548-1554, 2009.
PubMed
14) Shiono H, et al : National survey of endoscopic thymectomy : survey report from the Japanese Association for Research on the Thymus. Gen Thorac Cardiovasc Surg 57 : 22-27, 2009.
PubMed
15) Sonett JR, Jaretzki A 3rd : Thymectomy for nonthymomatous myasthenia gravis : a critical analysis. Ann NY Acad Sci 1132 : 315-328, 2008.
PubMed
P.532 掲載の参考文献
1) Cavalcante P, et al : The thymus in myasthenia gravis : Site of "innate autoimmunity"? Muscle Nerve 44 : 467-484, 2011.
PubMed
2) Scarpino S, et al : Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin Exp Immunol 149 : 504-512, 2007.
 
3) Sahashi K, et al : Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis. J Neuropathol Exp Neurol 37 : 212-223, 1978.
PubMed
4) Drachman DB, et al : Mechanisms of acetylcholine receptor loss in myasthenia gravis. J Neurol Neurosurg Psychiatry 43 : 601-610, 1980.
PubMed
5) Burges J, et al : A myasthenia gravis plasma immunoglobulin reduces miniature endplate potentials at human endplates in vitro. Muscle Nerve 13 : 407-413, 1990.
 
6) Hoorn EJ, et al : Pathogenesis of calcineurin inhibitor-induced hypertension. J Nephrol 25 : 269-275, 2012.
PubMed
7) Zaja F, et al : Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 55 : 1062-1063, 2000.
PubMed
8) Stein B, Bird SJ : Rituximab in the treatment of MuSK antibody-positive myasthenia gravis. J Clin Neuromuscul Dis 12 : 163-164, 2011.
PubMed
9) Lindberg C, Bokarewa M : Rituximab for severe myasthenia gravis-experience from five patients. Acta Neurol Scand 122 : 225-228, 2010.
PubMed
10) 重症筋無力症ガイドライン2014 (日本神経学会監, 「重症筋無力症診療ガイドライン」作成. 委員会編), p26-27, 南江堂, 2014.
 
11) Dalakas MC : Bcells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 4 : 557-567, 2008.
PubMed
12) Winkler U, et al : Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94 : 2217-2224, 1999.
PubMed
13) Howard JF Jr, et al : A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve 48 : 76-84, 2013.
PubMed
14) Ragheb S, et al : A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis. Arch Neurol 65 : 1358-1362, 2008.
 
15) Rowin J, et al : Granulocyte macrophage colony-stimulating factor treatment of a patient in myastheniccrisis : effects on regulatory T cells. Muscle Nerve 46 : 449-453, 2012.
 
P.538 掲載の参考文献
1) Murai H, et al : Characteristics of myasthenia gravis according to onset-age : Japanese nationwide survey. J Neurol Sci 305 : 97-102, 2011.
PubMed
2) 野村芳子 : 小児重症筋無力症. Clinical Neuroscience 26 : 986-989, 2008.
 
3) 瀬川昌也 : 小児重症筋無力症-潜在性全身型-. 内科 31 : 1222-1226, 1973.
 
4) Gronseth GS, Barohn RJ : Practice parameter : thymectomy for autoimmune myasthenia gravis (an evidence-based review) : report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55 : 7-15, 2000.
 
5) Andrews PI, et al : Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis. Neurology 44 : 1208-1214, 1994.
PubMed
6) Andrew PI : Atreatment algorithm for autoimmune myasthenia gravis in childhood. Ann NY Acad Sci 841 : 789-802, 1998.
 
7) Olanow CW, et al : Thymectomy as primary therapy in myasthenia gravis. Ann NY Acad Sci 505 : 595-606, 1987.
PubMed
8) Sathasivam S : Steroids and immunosuppressant drugs in myasthenia gravis. Nat Clin Pract Neurol 4 : 317-327, 2008.
PubMed
9) Schneider-Gold C, et al : Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev (2) : CD002828, 2005.
PubMed
10) Finnis MF, Jayawant S : Juvenile myasthenia gravis : a paediatric perspective. Autoimmune Dis 2011 : 404101, 2011.
PubMed
11) Hart IK, et al : Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev (4) : CD005224, 2007.
PubMed
12) Yoshikawa H, et al : Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry 82 : 970-977, 2011.
PubMed
13) Hehir MK, et al : Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis : outcomes in 102 patients. Muscle Nerve 41 : 593-598, 2010.
PubMed
14) Gajdos P, et al : Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev (1) : CD002277, 2008.
PubMed
15) Gajdos P, et al : Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev (4) : CD002275, 2002.
PubMed
P.544 掲載の参考文献
1) Gilhus NE : Autoimmune myasthenia gravis. Expert Rev Neurother 9 : 351-358, 2009.
PubMed
2) Sanders DB, Evoli A : Immunosuppressive therapies in myasthenia gravis. Autoimmunity 43 : 428-435, 2010.
PubMed
3) Grob D, et al : Lifetime course of myasthenia gravis. Muscle Nerve 37 : 141-149, 2008.
PubMed
4) Nagane Y, et al : Early aggressive treatment strategy against myasthenia gravis. Eur Neurol 65 : 16-22, 2010.
PubMed
5) Pascuzzi RM, et al : Long-term corticosteroid treatment of myasthenia gravis : report of 116 patients. Ann Neurol 15 : 291-298, 1984.
PubMed
6) Muscle Study Group : A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 71 : 394-399, 2008.
 
7) Richman DP, Agius MA : Treatment of autoimmune myasthenia gravis. Neurology 61 : 1652-1661, 2003.
PubMed
8) Truhan AP, Ahmed AR : Corticosteroids : a review with emphasis on complications of prolonged systemic therapy. Ann Allergy 62 : 375-391, 1989.
PubMed
9) Twork S, et al : Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes 8 : 129, 2010.
PubMed
10) 重症筋無力症診療ガイドライン2014 (「重症筋無力症診療ガイドライン」作成委員会編), p26-29, 南山堂, 2014.
 
11) Burns TM : History of outcome measures for myasthenia gravis. Muscle Nerve 42 : 5-13, 2010.
PubMed
12) Jaretzki A 3rd, et al : Myasthenia gravis : recommendation for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55 : 16-23, 2000.
PubMed
13) Vincent KA, et al : Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL). Neurology 68 : 1051-1057, 2007.
PubMed
14) Sadjadi R, et al : Validation of the individualised neuromuscular quality of life for the USA with comparison of the impact of muscle disease on those living in USA versus UK. Health Qual Life Outcomes 9 : 114, 2011.
PubMed
15) Padua L, et al : Myasthenia gravis outcome measure : development and validation of a disease-specific self-administered questionnaire. Neurol Sci 23 : 59-68, 2002.
PubMed
16) Mullins LL, et al : Disease-specific measure of quality of life for myasthenia gravis. Muscle Nerve 38 : 947-956, 2008.
PubMed
17) Burns TM, et al : Less is more, or almost as much : a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve 38 : 957-963, 2008.
 
18) Burns TM, et al ; MG Composite and MG-QOL15 Study Group : The MG Composite : Avalid and reliable outcome measure for myasthenia gravis. Neurology 74 : 1434-1440, 2010.
 
19) Burns TM, et al : The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis. Muscle Nerve 43 : 14-18, 2011.
PubMed
20) Barnett C, et al : Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis. J Neurol Neurosurg Psychiatry 84 : 94-97, 2013.
PubMed
21) Masuda M, et al : The MG-QOL15 Japanese version : validation and associations with clinical factors. Muscle Nerve 46 : 166-173, 2012.
PubMed
22) Mourao AM, et al : Brazilian cross-cultural translation and adaptation of the "Questionnaire of Life Quality Specific for Myasthenia Gravis-15 items". Arq Neuropsiquiatr 71 : 955-958, 2013.
PubMed
23) Utsugisawa K, et al : Health-related quality-of-life and treatment targets in myasthenia gravis. Muscle Nerve 50 : 493-500, 2014.
PubMed
24) Suzuki S, et al : Quality of life in purely ocular myasthenia in Japan. BMC Neurol 14 : 142, 2014.
PubMed
25) Keesey JC : Does myasthenia gravis affect the brain? JNeurol Sci 170 : 77-89, 1999.
PubMed
26) Kulaksizoglu IB : Mood and anxiety disorders in patients with myasthenia gravis : aetiology, diagnosis and treatment. CNS Drugs 21 : 473-481, 2007.
PubMed
27) Suzuki Y, et al : Factors associated with depressive state in patients with myasthenia gravis : a multicentre cross-sectional study. BMJ Open 1 : e000313, 2011.
 
28) Brown ES, Suppes T : Mood symptoms during corticosteroid therapy : a review. Harvard Rev Psychiatry 5 : 239-246, 1998,
 
29) Amino A, et al : Sleep apnoea in well-controlled myasthenia gravis and the effect of thymectomy. J Neurol 245 : 77-80, 1998.
PubMed
30) Nicolle MW, et al : Sleep apnea in patients with myasthenia gravis. Neurology 67 : 140-142, 2006.
PubMed
31) Martinez-Lapiscina EH, et al : Myasthenia gravis : sleep quality, quality of life, and disease severity. Muscle Nerve 46 : 174-180, 2012.
PubMed
32) Lacomis D : Myasthenic crisis. Neurocrit Care 3 : 189-194, 2005.
PubMed
33) Batocchi AP, et al : Course and treatment of myasthenia gravis during pregnancy. Neurology 52 : 447-452, 1999.
PubMed
34) Ferrero S, et al : Myasthenia gravis : management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol 121 : 129-138, 2005.
PubMed
35) Norwood F, et al : Myasthenia in pregnancy : best practice guidelines from a U. K. multispecialty working group. J Neurol Neurosurg Psychiatry 85 : 538-543, 2014.
 
36) Tellez-Zenteno JF, et al : Myasthenia gravis and pregnancy : clinical imphcations and neonatal outcome. BMC Musculoskelet Disord 5 : 42, 2004.
PubMed
37) Hoff JM, et al : Myasthenia gravis : consequences for pregnancy, delivery, and the newborn. Neurology 61 : 1362-1366, 2003.
PubMed
38) Barrons RW : Drug-induced neuromuscular blockade and myasthenia gravis. Pharmacotherapy 17 : 1220-1232, 1997.
PubMed
39) Feldman S, Karalliedde L : Drug interactions with neuromuscular blockers. Drug Saf 15 : 261-273, 1996.
PubMed
40) Auriel E, et al : Safety of influenza and H1N1 vaccinations in patients with myasthenia gravis, and patient compliance. Muscle Nerve 43 : 893-894, 2011.
PubMed
P.552 掲載の参考文献
1) Kaplan JE, et al : The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J Acquir Immune Defic Syndr 3 (11) : 1096-1101, 1990.
PubMed
2) Izumo S, et al : HTLV-1-associated myelopathy. Neuropathology 20 : S65-S68, 2000.
PubMed
3) Matsuoka E, et al : Perivascular T cells are infected with HTLV-I in the spinal cord lesions with HTLV-I-associated myelopathy/tropical spastic paraparesis : double staining of immunohistochemistry and polymerase chain reaction in situ hybridization. Acta Neuropathol 96 (4) : 340-346, 1998.
PubMed
4) Nagai M, et al : Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers : High proviral load strongly predisposes to HAM/TSP. J Neurovirol 4 (6) : 586-593, 1998,
PubMed
5) Jacobson S : Immunopathogenesis of human T cell lymphotropic virus type I-associated neurologic disease. J Infect Dis 186 : S187-192, 2002.
 
6) Zhou X, et al : Instability of the transcription factor Foxp31eads to the generation of pathogenic memory T cells in vivo. Nat Immunol 10 : 1000-1007, 2009.
 
7) Araya N, et al : HTLV-1 induces a Th1-like state in CD4+ CCR4+ T cells. J Clin Invest 124 (8) : 3431-3442, 2014.
 
8) Yamamoto-Taguchi N, et al : HTLV-1 bZIP factor induces inflammation through labile Foxp3 expression. PLoS Pathog 9 : e1003630, 2013.
PubMed
9) Sato T, et al : CSF CXCL10, CXCL9, and neopterin as candidate prognostic biomarkers for HTLV-1-associated myelopathy/tropical spastic paraparesis. PLoS Negl Trop Dis 7 (10) : e2479, 2013.
PubMed
10) Ando H, et al : Positive feedback loop via astrocytes causes chronic inflammation in virus-associated myelopathy. Brain 136 (9) : 2876-2887, 2013.
 
11) Buyse M, et al : Biomarkers and surrogate end points-the challenge of statistical validation. Nat Rev Clin Oncol 7 : 309-317, 2010.
PubMed
12) Taylor GP, et al : Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-1-associated myelopathy : a randomised trial. Retrovirology 3 : 63, 2006.
 
13) Cavrois M, et al : Persistent oligoclonal expansion of human T-cell leukemia virus type 1-infected circulating cells in patients with Tropical spastic paraparesis/HTLV-1 associated myelopathy. Oncogene 17 : 77-82, 1998.
PubMed
14) Yamano Y, et al : Abnormally high levels of virus-infected IFN-γ+ CCR4+ CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory disorder. PLoS One 4 : e6517, 2009.
 
15) Yamauchi J, et al : Mogamulizumab, an anti-CCR4 antibody, targets human T-lymphotropic virus type 1-infected CD8+ and CD4+ T cells to treat associated myelopathy. J Infect Dis 211 : 238-248, 2015.
PubMed
P.560 掲載の参考文献
1) Nakashima R, Mimori T : Clinical and pathophysiological significance of myositis-specific and myositis-associated autoantibodies. Int J Clin Rheumatol 5 : 523-536, 2010.
 
2) Nakashima R, et al : The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS One 9 (1) : e85062, 2014.
PubMed
3) Howard OM, et al : Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells, J Exp Med 196 : 781-791, 2002.
 
4) Hengstman GJ, et al : Anti-signal recognition particle autoantibodies : marker of a necrotising myopathy. Ann Rheum Dis 65 : 1635-1638, 2006.
PubMed
5) Seelig HP, et al : Two forms of the major antigenic protein of the dermatomyositis-specific Mi-2 autoantigen. Arthritis Rheum 39 : 1769-1771, 1996.
PubMed
6) Sato S, et al : Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52 : 1571-1576, 2005.
PubMed
7) Gono T, et al : Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 49 : 1713-1719, 2010.
PubMed
8) Sato S, et al : RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis : Association with rapidly progressive interstitial lung disease. Arthritis Rheum 60 : 2193-2200, 2009.
 
9) Nakashima R. et al : The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 49 : 433-440, 2010.
PubMed
10) Targoff IN, et al : A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 54 : 3682-3689, 2006.
PubMed
11) Kaji K, et al : Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis : an association with malignancy. Rheumatology (Oxford) 46 : 25-28, 2007.
PubMed
12) Fujimoto M, et al : Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 64 : 513-522, 2012.
PubMed
13) Gunawardena H, et al : Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 60 : 1807-1814, 2009.
PubMed
14) Espada G, et al : Clinical and serologic characterization of an Argentine pediatric myositis cohort : identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol 36 : 2547-2551, 2009.
 
15) Ichimura Y, et al : Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myo-pathies : possible association with malignancy. Ann Rheum Dis 71 : 710-713, 2012.
 
16) Betteridge ZE. et al : Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis 68 : 1621-1625, 2009.
PubMed
17) Christopher-Stine L, et al : A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 62 : 2757-2766, 2010.
PubMed
18) Mammen AL, et al : Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 63 : 713-721, 2011.
PubMed
19) Salajegheh M, et al : Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS One 6 (5) : e20266, 2011.
PubMed
20) Larman HB, et al : Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 73 : 408-418, 2013.
PubMed
P.565 掲載の参考文献
1) Morgan OS. et al : HTLV-I and polymyositis in Jamaica. Lancet ii : 1184-1187, 1989,
 
2) Higuchi I, et al : Detection of HTLV-I provirus by in situ polymerase chain reaction in mononuclear inflammatory cells in skeletal muscle of viral carriers with polymyositis. Muscle Nerve 18 : 854-858, 1995.
PubMed
3) Inose M, et al : Pathological changes in skeketal muscle in HTLV-I-associated myelopathy. J Neurol Sci 110 : 73-78, 1992.
 
4) Engel AG, Arahata K : Monoclonal antibody analysis of mononuclear cells in myopathies : II, phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 16 : 209-215, 1984.
PubMed
5) Nagaraju K, et al : Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci USA 97 : 9209-9214, 2000.
PubMed
6) Goebels N, et al : Differential expression of perforin in muscle-infiltrating T cell in polymyositis and dermatomyositis. J Clin Invest 97 : 2905-2910, 1996.
PubMed
7) Nishio J, et al : Clonal biases of peripheral CD8 T cell repertoire directly reflect local inflammation in polymyositis. J Immunol 167 : 4051-4058, 2001.
PubMed
8) Zong M, et al : TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis. Ann Rheum Dis 72 : 1390-1399, 2013.
PubMed
9) Cappelletti C, et al : Autophagy, inflammation and innate immunity in inflammatory myopathies. PLoS One 9 : e111490, 2014.
PubMed
10) Yamazaki H, et al : A wide spectrum of collagen vascular and autoimmune diseases in transgenic rats carrying the env-pX gene of human T lymphocyte virus type I. Int Immunol 9 : 339-346, 1997.
 
11) Hazem M, et al : Histopathological differences between human T-lymphotropic virus type 1-positive and human T-lymphotropic virus type 1-negative polymyositis. Neuroimmunology 2 : 12-24, 2011.
 
12) Higuchi I, et al : Detection of HTLV-I provirus by in situ polymerase chain reaction in mononuclear innammatory cells in skeletal muscle of viral carriers with polymyositis. Muscle Nerve 18 : 854-858, 1995.
 
13) Saito M, et al : Molecular analysis of T cell clonotypes in muscle-infiltrating lymphocytes from patients with human T lymphotropic virus type 1 polymyositis. J Infect Dis 186 : 1231-1241, 2002.
PubMed
14) Higuchi I, et al : In situ polymerase chain reaction detection of HTLV-I provirus and expression of the p53 tumor suppressor gene in infiltrating cells in skeletal muscle from a patient with adult T cell leukemia. Acta Neuropathol 90 : 323-327, 1995.
PubMed
15) Kawano N, et al : Adult T-cell leukemia development from a human T-cell leukemia virus type I carrier after a living-donor liver transplantation. Transplantation 82 : 840-843, 2006.
PubMed
P.572 掲載の参考文献
1) 藤本学 : 皮膚筋炎の診断と病型分類. J Visual Dermatol 11 : 794-800, 2012.
 
2) Bohan A, Peter JB : Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292 : 344-347, 1975.
PubMed
3) Bohan A, Peter JB : Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292 : 403-407, 1975.
PubMed
4) Tanimoto K et al : Classification criteria for polymyositis and dermatomyositis. J Rheumatol 22 : 668-674, 1995.
PubMed
5) Sontheimer RD, et al : Dermatomyositis. In : Cutaneous manifestations of rheumatic diseases (ed by Sontheimer RD, Provost TT), p 65-103, Lippincott Williams & Wilkins, Philadelphia, 2004.
 
6) Ito E, et al : Hydroxyurea-induced amyopathic dermatomyositis presenting with heliotrope erythema. Dermatol Online J 20 : pii : 13030/qt2r11f768, 2014.
 
7) 室慶直 : 皮膚筋炎の皮疹の見方-その多彩な皮膚症状. 医学のあゆみ 243 : 883-888, 2012.
Medical*Online
8) Mun JH, et al : Multicentric reticulohistiocytosis masquerading as dermatomyositis : similar and different features. J Dermatol 39 : 104-107, 2012.
PubMed
9) 工藤英郎ほか : 皮膚筋炎との鑑別を要したサルコイドーシス. J Visual Dermatol 11 : 861-863, 2012.
 
10) 室慶直 : 皮膚筋炎の皮膚症状, 皮膚病理組織所見. 皮膚科臨床アセット7 皮膚科膠原病診療のすべて (佐藤伸一編), p218-222, 中山書店, 2011.
 
11) Quain Rd, Werth VP : Management of cutaneous dermatomyositis : current therapeutic options. Am J Clin dermatol 7 : 341-751, 2006.
PubMed
12) Lam C, Vleugels RA : Management of cutaneous dermatomyositis. Dermatol Ther 25 : 112-134, 2012.
PubMed
13) 藤本学ほか : 日本皮膚科学会ガイドライン 創傷・熱傷ガイドライン委員会報告 : 膠原病・血管炎にともなう皮膚潰瘍診療ガイドライン. 日皮会誌 121 : 2187-2223, 2011.
 
14) Arshanapalli A, et al : The role of type I interferons and other cytokines in dermatomyositis. Cytokine 73 : 319-325, 2015.
PubMed
P.582 掲載の参考文献
1) Amato AA, Barohn RI : Inclusion body myositis : old and new concepts. J Neurol Neurosurg Psychiatry 80 : 1186-1193, 2009.
 
2) Suzuki N, et al : Increase in number of sporadic inclusion body myositis (sIBM) in Japan. J Neurol 259 : 554-556, 2012.
PubMed
3) Needham M, Mastaglia FL : Sporadic inclusion body myositis : a continuing puzzle. Neuromuscul Disord 18 : 6-16, 2008.
PubMed
4) Murata KY, et al : A dysphagia study in patients with sporadic inclusion body myositis (s-IBM). Neurol Sci 33 : 765-770, 2012.
PubMed
5) Amato AA, et al : Inclusion body myositis : clinical and pathological boundaries. Ann Neurol 40 : 581-586, 1996.
PubMed
6) Koffman BM, et al : Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 21 : 115-117, 1998.
PubMed
7) Dabby R, et al : Inclusion body myositis mimicking motor neuron disease. Arch Neurol 58 : 1253-1256, 2001.
PubMed
8) Chou SM : Myxovirus-like structures in a case of human chronic polymyositis. Science 158 : 1453-1455, 1967.
 
9) Calabrese LH, et al : Inclusion body myositis presenting as treatment-resistant polymyositis. Arthritis Rheum 30 : 397-403, 1987.
PubMed
10) Lotz BP, et al : Inclusion body myositis. Observations in 40 patients. Brain 112 (Pt 3) : 727-747, 1989.
 
11) Rose MR : 188th ENMC International Workshop : Inclusion Body Myositis, 2-4 December 2011. Naarden, The Netherlands. Neuromuscul Disord 23 : 1044-1055, 2013,
PubMed
12) Suzuki N, Aoki M : Inclusion body myositis. Brain Nerve 63 : 1205-1215, 2011.
PubMed
13) Goebels N, et al : Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest 97 : 2905-2910, 1996.
PubMed
14) Murata K, Dalakas MC : Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol 155 : 453-460, 1999.
PubMed
15) Dalakas MC : Review : An update on inflammatory and autoimmune myopathies. Neuropathol Appl Neurobiol 37 : 226-242, 2011.
PubMed
16) Figarella-Branger D, et al : Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve 28 : 659-682, 2003.
PubMed
17) Dalakas MC, et al : Inclusion body myositis with human immunodeficiency virus infection : four cases with clonal expansion of viral-specific T cells. Ann Neurol 61 : 466-475, 2007.
PubMed
18) Matsuura E, et al : Inclusion body myositis associated with human T-lymphotropic virus-type I infection : eleven patients from an endemic area in Japan. J Neuropathol Exp Neurol 67 : 41-49, 2008.
PubMed
19) Amemiya K, et al : Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies. Brain 123 (Pt 10) : 2030-2039, 2000.
 
20) Askallas V, Engel WK : Inclusion-body myositis : a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology 66 : S39-48, 2006.
 
21) Sarkozi E, et al : beta-Amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. Neuroreport 4 : 815-818, 1993.
PubMed
22) Vattemi G, et al : Presence of BACE1 and BACE2 in muscle fibres of patients with sporadic inclusion-body myositis. Lancet 358 : 1962-1964, 2001.
PubMed
23) Nogalska A, et al : Increased BACE1 mRNA and noncoding BACE1-antisense transcript in sporadic inclusion-body myositis muscle fibers-possibly caused by endoplasmic reticulum stress. Neurosci Lett 474 : 140-143, 2010.
PubMed
24) Sugarman MC, et al : Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci USA 99 : 6334-6339, 2002.
PubMed
25) Schmidt J, et al : Interrelation of inflammation and APP in sIBM : IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 131 : 1228-1240, 2008.
 
26) Cacciottolo M, et al : Dysferlin is a newly identified binding partner of AbetaPP and it co-aggregates with amyloid-beta42 within sporadic inclusion-body myositis (s-IBM) muscle fibers. Acta Neuropathol 126 : 781-783, 2013.
PubMed
27) Salajegheh M, et al : Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 40 : 19-31, 2009.
 
28) Olive M, et al : TAR DNA-Binding protein 43 accumulation in protein aggregate myopathies. J Neuropathol Exp Neurol 68 : 262-273, 2009.
PubMed
29) Ayala YM, et al : TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression. Proc Natl Acad Sci USA 105 : 3785-3789, 2008.
PubMed
30) Kusters B, et al : TDP-43 accumulation is common in myopathies with rimmed vacuoles. Acta Neuropathol 117 : 209 -211, 2009.
 
31) Weihl CC, et al : TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry 79 : 1186-1189, 2008.
PubMed
32) Nogalska A, et al : p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis. Acta Neuropathol 118 : 407-413, 2009.
PubMed
33) D'Agostino C, et al : In sporadic inclusion body myositis muscle fibres TDP-43-positive inclusions are less frequent and robust than p62 inclusions, and are not associated with paired helical filaments, Neuropathol Appl Neurobiol 37 : 315-320, 2011.
 
34) Delaunay A, et al : The ER-bound RING finger protein 5 (RNF5/RMA1) causes degenerative myopathy in transgenic mice and is deregulated in inclusion body myositis. PLoS One 3 : e1609, 2008.
PubMed
35) Ferrer I, et al : Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J Neuropathol Exp Neurol 63 : 484-498, 2004.
PubMed
36) Fratta P, et al : Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers. Am J pathol 167 : 517-526, 2005.
PubMed
37) Bjorkoy G, et al : p62/SQSTM1 : a missing link between protein aggregates and the autophagy machinery. Autophagy 2 : 138-139, 2006.
PubMed
38) Hiniker A, et al : Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies. Acta Neuropathol Commun 1 : 29, 2013.
PubMed
39) D'Agostino C, et al : Abnormalities of NBR1, a novel autophagy-associated protein, in muscle fibers of sporadic inclusion-body myositis. Acta Neuropathol 122 : 627-636, 2011.
PubMed
40) Yamashita S, et al : Optineurin is potentially associated with TDP-43 and involved in the pathogenesis of inclusion body myositis. Neuropathol Appl Neurobiol 39 : 406-416, 2013.
PubMed
41) Lunemann JD, et al : Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis. Ann Neurol 61 : 476-483, 2007.
PubMed
42) Nogalska A, et al : Impaired autophagy in sporadic inclusion-body myositis and in endoplasmic reticulum stress-provoked cultured human muscle fibers. Am J Pathol 177 : 1377-1387, 2010.
PubMed
43) Kitazawa M, et al : Innammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol 64 : 15-24, 2008.
 
44) Goyal NA, et al : Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement. J Neurol Neurosurg Psychiatry 2015 Apr 9. pii : jnnp-2014-310008. doi : 10.1136/jnnp-2014-310008. [Epub ahead of print]
 
45) Herbert MK et al : Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis 2015 Feb 24. pii : annrheumdis-2014-206691. doi : 10.1136/annrheumdis-2014-206691. [Epub ahead of print]
 
46) Larman HB, et al : Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 73 : 408-418, 2013.
PubMed
P.591 掲載の参考文献
1) Liang C, Needham M : Necrotizing autoimmune myopathy. Curr Opin Rheumatol 23 : 612-619, 2011.
PubMed
2) Bohan A, Peter JB : Polymyositis and dermatomyositis. N Engl J Med 292 : 403-407, 1975.
PubMed
3) Hoogendijk JE, et al : 119th ENMC international workshop : trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis 10-12 October, 2003, Naarden, The Netherlands. Neuromuscul Disord 14 : 337-345, 2004.
PubMed
4) Suzuki S, et al : Clinical and histological findings associated with autoantibodies detected by RNA immunoprecipitation in inflammatory myopathies. J Neuroimmunol 274 : 202-208, 2014.
PubMed
5) Reeves WH, et al : Human autoantibodies reactive with the signal-recognition particle. Proc Natl Acad Sci USA 83 : 9507-9511, 1986.
PubMed
6) Suzuki S, et al : Myopathy associated with antibodies to signal recognition particle : disease progression and neurological outcome. Arch Neurol 69 : 728-732, 2012.
PubMed
7) Benveniste O, et al : Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 63 : 1961-1971, 2011.
PubMed
8) Suzuki S, et al : Clinical utility of anti-signal recognition particle antibody in the differential diagnosis of myopathies. Rheumatology (Oxford) 47 : 1539-1542 2008.
PubMed
9) Mohassel P, Mammen AL : The spectrum of statin myopathy. Curr Opin Rheumatol 25 : 747-752, 2013.
PubMed
10) Mammen AL, et al : Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 63 : 713-721, 2011.
PubMed
11) Watanabe Y, et al : Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies : an observational study in Japan. Medicine (Baltimore) 94 : e416, 2015.
PubMed
12) Hill CL, et al : Frequency of specific cancer types in dermatomyositis and polymyositis : a population-based study. Lancet 357 (9250) : 96-100, 2001.
PubMed

VI その他の免疫性神経疾患

P.601 掲載の参考文献
1) Leypoldt F, et al : Autoimmune encephalopathies. Ann N Y Acad Sci 1338 : 94-114, 2015.
PubMed
2) 田中恵子 : 傍腫瘍性神経症候群の診断と治療. 神経治療 31 (2) : 153-155, 2014.
 
3) Dalmau J, et al : Anti-NMDA-receptor encephalitis : case series and analysis of the effects of antibodies. Lancet Neurol 7 : 1091-1098, 2008.
PubMed
4) Lai M, et al : Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels : a case series. Lancet Neurol 9 : 776-785, 2010.
PubMed
5) Irani SR, et al : Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 69 : 892-900, 2011.
PubMed
6) Ramanathan S, et al : Autoimmune encephalitis : recent updates and emerging challenges. J Clin Neurosci 21 : 722-730, 2014,
PubMed
7) Titulae MJ, et al : Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis : an observational cohort study. Lancet Neurol 12 : 157-165, 2013.
 
8) Bataller L, et al : Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor. Neurology 74 : 265-267, 2010.
 
9) Lancaster E, et al : Antibodies to the GABA (B) receptor in Hmbic encephaUtis with seizures : case series and characterization of the antigen. Lancet Neurol 9 : 67-76, 2010.
 
10) Hutchinson M, et al : Progressive encephalomyelitis, rigidity, and myoclonus : a novel glycine receptor antibody. Neurology 71 : 1291-1292, 2008.
PubMed
11) Tanaka M, et al : Cytotoxic T cells against a peptide of Yo protein in patients with paraneoplastic cerebellar degeneration and anti-Yo antibody. J Neurol Sci 168 : 28-31, 1999.
PubMed
12) Tanaka K, et al : Passive transfer and active immunization with the recombinant leucine-zipper (Yo) protein as an attempt to establish an animal model of paraneoplastic cerebellar degeneration. J Neurol Sci 127 : 153-158, 1994.
PubMed
13) Albert ML, et al : Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 47 : 9-17, 2000.
PubMed
14) Zhang Q, et al : Suppression of synaptic plasticity by cerebrospinal fluid from anti-NMDA receptor encephalitis patients. Neurobiol Dis 45 : 610-615, 2012.
PubMed
15) Witebsky E, et al : Chronic thyroiditis and autoimmunization. J Am Med Assoc 164 : 1439-1447, 1957.
PubMed
P.605 掲載の参考文献
1) Brain I, et al : Hashimoto's disease and encephalopathy. Lancet ii : 512-514, 1966.
 
2) Shaw PJ, et al : Hashimoto's encephalopathy : asteroid-responsive disorder associated with anti-thyroid antibody titers-report of 5 cases. Neurology 41 : 228-233, 1991.
 
3) 米田誠 : 橋本脳症と抗体. Brain & Nerve 65 : 365-376, 2013.
 
4) Ferracci F, et al : Hashimoto's encephalopathy : epidemiologic data and pathogenetic considerations. J Neurol Sci 217 : 165-182, 2004.
PubMed
5) Peschen-Rosin R, et al : Manifestation of Hashimoto's encephalopathy years before onset of thyroid disease. Eur Neurol 41 : 79-84, 1999.
PubMed
6) Fujii A, et al : Autoantibodies against the amino terminal of α-enolase are a useful diagnostic marker of Hashimoto's encephalopathy. J Neuroimmunol 162 : 130-136, 2005.
 
7) Yoneda M, et al : High prevalence of serum autoantibodies against the amino terminal of α-enolase in Hashimoto's encephalopathy. J Neuroimmunol 185 : 195-200, 2007.
 
8) Mitoma H, et al : Presynaptic dysfunction caused by CSF from a patient with ataxic form of Hashimoto's encephalopathy. Neurol Clin Neurosci 2 : 104-108, 2014.
 
9) Helene V, et al : Hashimoto encephalopathy and antibodies against dimethylargininase-1 : a rare cause of cognitive decline in a pediatric Down's syndrome patient. Clin Neurol Neurosurg 113 : 678-679, 2011.
 
10) Gini B, et al : Novel autoantigens recognized by CSF IgG from Hashimoto's encephalitis revealed by a proteomic approach. J Neuroimmunol 196 : 153-158, 2008.
PubMed
11) Nolte KW, et al : Hashimoto encephalopathy : a brainstem vasculitis? Neurology 54 : 769-770, 2000.
PubMed
12) Muramatsu T, et al : Pathophysiological decrease in the regional cerebral bloodflow in Hashimoto's encephalopathy : a multiple-case SPECT study. Eur Neurol 72 : 13-19, 2014.
 
13) Ishitobi M, et al : Hashimoto's encephalopathy with hippocampus involvement detected by continuous arterial spin labeling : A case report. Psychiatr Clin Neurosci 67 : 128-128, 2013.
 
14) Matsunaga A, et al : Hashimoto's encephalopathy as a treatable adult-onset cerebellar ataxia mimicking spinocerebellar degeneration. Eur Neurol 69 : 14-20, 2012.
PubMed
15) Cossu G, et al : Creutzfeldt-Jakob disease associated with high titer of antithyroid autoantibodies : case report and literature review. Neurol Sci 24 : 138-140, 2003.
PubMed
16) Marshall GA, Doyle JJ : Long-term treatment of Hashimoto's encephalopathy. J Neuropsychiatry Clin Neurosci 18 : 14-20, 2006.
PubMed
17) Drulovie J, et al : Hashimoto's encephalopathy : a long-lasting remission induced by intravenous immunoglobulins. Vojnosanit Pregl 68 : 452-454, 2011.
 
P.612 掲載の参考文献
1) Dalmau J, et al : Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 61 : 25-36, 2007.
PubMed
2) Dalmau J, et al : Anti-NMDA-receptor encephalitis : case series and analysis of the effects of antibodies. Lancet Neurol 7 : 1091-1098, 2008.
PubMed
3) Dalmau J, et al : Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 10 : 63-74, 2011.
PubMed
4) Titulaer MJ, et al : Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis : an observational cohort study. Lancet Neurol 12 : 157-165, 2013.
PubMed
5) Leypoldt F, et al : Autoimmune encephalopathies. Ann N Y Acad Sci 1338 : 94-114, 2015.
PubMed
6) Rosenfeld MR, et al : Paraneoplastic syndromes and autoimmune encephalitis : Five new things. Neurol Clin Pract 2 : 215-223, 2012.
PubMed
7) Niehusmann P, et al : Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy. Arch Neurol 66 : 458-464, 2009.
 
8) Zandi MS, et al : Disease-relevant autoantibodies in first episode schizophrenia. J Neurol 258 : 686-688, 2011.
PubMed
9) Titulaer MJ, et al : Prevalence and treatment of anti-NMDA receptor encephalitis-Authors' reply. Lancet Neurol l2 : 425-426, 2013.
 
10) Kayser MS, et al : Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol 70 : 1133-1139, 2013.
PubMed
11) Kruer, et al : NMDA receptor encephalitis mimicking seronegative neuromyelitis optica. Neurology 74 : 1473-1475, 2010.
PubMed
12) Outteryck, et al : Extensive myelitis associated with anti-NMDA receptor antibodies. BMC Neurol 13 : 211, 2013.
PubMed
13) Zoccarato M, et al : Aquaporin-4 antibody neuromyelitis optica following anti-NMDA receptor encephalitis. Neurology 260 : 3185-3187, 2013.
PubMed
14) Titulaer MJ, et al : Overlapping demyelinating syndromes and anti-NMDA receptor encephalitis. Ann Neurol 75 : 411-428, 2014.
PubMed
15) Waschbisch A, et al : Demyelinating disease and anti-N-methyl-D-aspartate receptor immunoglobulin G antibodies : a case report. BMC Res Notes 7 : 948, 2014.
 
16) Mackay G, et al : NMDA receptor autoantibodies in sporadic Creutzfeldt-Jakob disease. J Neurol 259 : 1979-1981, 2012.
PubMed
17) Grau-Rivera O, et al : Determination of neuronal antibodies in suspected and definite creutzfeldtjakob disease. JAMA Neurol 71 : 74-78, 2014.
PubMed
18) Armangue T, et al : Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol 75 : 317-323, 2014.
PubMed
19) Prifss H, et al : A case of inflammatory peripheral nerve destruction antedating anti-NMDA receptor encephalitis. Neurol Neuroimmunol Neuroinflamm 1 (2) : e14, 2014.
 
20) Planaguma J, et al : Human N -methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain 138 : 94-109, 2015.
 
21) Gresa-Arribas N, et al : Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis : a retrospective study. Lancet Neurol 13 : 167-177, 2014.
PubMed
P.617 掲載の参考文献
1) Buckley C, et al : Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 50 : 73-78, 2001.
PubMed
2) Vincent A, et al : Potassium channel antibody-associated encephalopathy : a potentially immunotherapy-responsive form of limbic encephalitis. Brain 127 : 701-712, 2004.
PubMed
3) Thieben MJ, et al : Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 62 : 1177-1182, 2004.
PubMed
4) Lai M, et al : Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels : a case series. Lancet Neurol 9 : 776-785, 2010.
PubMed
5) Irani SR et al : Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactived lprotein and contactin-associated protein-2 in limbic encephalitis, Morvan'ssyndrome and acquired neuromyotonia. Brain 133 : 2734-2748, 2010.
 
6) Lancaster E, et al : Encephalitis and antibodies to synaptic and neuronal cell surface protein. Neurology 77 : 179-189, 2011.
PubMed
7) Irani SR, et al : Morvan syndrome : Clinical and serological observations in 29 cases. Ann Neurol 72 (2) : 241-255, 2012.
PubMed
8) Vincent A, et al : Autoantibodies associated with diseases of the CNS : new developments and future challenges. Lancet Neurol 10 : 759-772, 2011.
PubMed
9) Irani SR, et al : Cell-surface central nervous system antibodies : clinical relevance and emerging paradigms. Ann Neurol 76 : 168-184, 2014.
PubMed
10) Ohkawa T, et al : Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Nuerosci 33 (46) : 18161-18174, 2013.
PubMed
11) Ohkawa T, et al : Identification and characterization of GABAA receptor autoantibodies in autoimmune encephalitis. J Neurosci 34 (24) : 8151-8163, 2014.
PubMed
12) Irani SR, et al : Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 69 : 892--900, 2011.
 
13) Butler CR et al : Persistent anterograde amnesia folloWing limbic encephalitis associated with antibodies to the voltage-gated potassium channel complex. J Neurol Neurosurg Psychiatry 85 (4) : 387-391, 2014.
 
P.625 掲載の参考文献
1) Rasmussen T, et al : Focal seizures due to chronic encephalitis : Neurology 8 : 435-445, 1958.
PubMed
2) Rogers SW, et al : Autoantibodies to Glutamate receptor GluR3 in Rasmussen's encephalitis. Science 265 : 648-651, 1994.
 
3) Bien CG, et al : Destruction of neurons by cytotoxic T cells : a new pathogenic mechanism in Rasmussen's syndrome. Ann Neurol 51 : 311-318, 2002.
PubMed
4) Bien CG, et al : Pathogenesis, diagnosis and treatment of Rasmussen encephalitis : A European consensus statement. Brain 128 : 454-471, 2005.
PubMed
5) 高橋幸利ほか : Rasmussen症候群. 小児内科 45 (2) : 416-421, 2013.
Medical*Online
6) 高橋幸利ほか : 小児の慢性進行性持続性部分てんかん・非進行性持続性部分てんかん : Rasmussen症候群を主体に. 別冊日本臨牀 神経症候群 (第2版), p41-46, 日本臨牀社, 2014.
 
7) Yamazaki E, et al : Temporal changes in brain MRI findings in Rasmussen syndrome. Epileptic Disord 13 : 229-239, 2011.
PubMed
8) Takahashi Y, et al : Immunomodulatory therapy versus surgery for Rasmussen syndrome in early childhood. Brain Dev 35 : 778-785, 2013.
PubMed
9) Takahashi Y, et al : A substantial number of Rasmussen syndrome patients have increased IgG, CD4+ T cells TNFα, and granzyme B in CSF. Epilepsia 50 : 1419-1431, 2009.
 
10) Takahashi Y, et al : Autoantibodies to NMDA receptor in patients with chronic forms of epilepsia partialis continua. Neurology 61 (7) : 891-896, 2003.
PubMed
11) Fukuyama T, et al : Semi-quantitative analyses of antibodies to N-methyl-D-asparate type glutamate receptor subunits (GluN2B & GluN1) in the clinical course of Rasmussen syndrome. Epilepsy Res 113 : 34-43, 2015.
 
12) Hughes EG, et al : Cellular and Synaptic Mechanisms of Anti-NMDA Receptor. J Neurosci 30 : 5866-5875, 2010.
PubMed
13) 高橋幸利ほか : 神経疾患, とNMDA型グルタミン酸受容体抗体. 日小児会誌 118 (12) : 1695-1707, 2014.
 
14) Takahashi Y, et al : Genetic variations of immunoregulatory genes associated with Rasmussen syndrome. Epilepsy Res 107 : 238-243, 2013.
PubMed
P.629 掲載の参考文献
1) Granerod J, et al : Causes of encephalitis and differences in their clinical presentations in England : a multicentre, population-based prospective study. Lancet Infect Dis 10 : 835-844, 2010.
 
2) Traynelis SE et al : Glutamate receptor ion channels : structure, regulation, and function. Pharmacol Rev 62 : 405-496, 2010.
 
3) Palmer CL, et al : The molecular pharmacology and cell biology of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Pharmacol Rev 57 : 253-277, 2005.
PubMed
4) Rogers SW, et al : Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 265 : 648-651, 1994.
 
5) Lai M, et al : AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 65 : 424-434, 2009.
PubMed
6) Gleichman AJ, et al : Antigenic and mechanistic characterization of anti-AMPA receptor encephalitis. Ann Clin Transl Neurol 1 : 180-189, 2014.
PubMed
7) Peng X et al : Cellular plasticity induced by anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor encephalitis antibodies. Ann Neurol 77 : 381-398, 2015.
 
8) Bataller L, et al : Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor. Neurology 74 : 265-267, 2010.
 
9) Dogan Onugoren M, et al : Limbic encephalitis due to GABAB and AMPA receptor antibodies : a case series. J Neurol Neurosurg Psychiatry, 2014. [Epub ahead of print]
 
10) Spatola M, et al : Serial brain 18FDG-PET in anti-AMPA receptor hmbic encephahtis. J Neuroimmunol 271 : 53-55, 2014.
 
11) Wei YC, et al : Rapid progression and brain atrophy in anti-AMPA receptor encephalitis. J Neuroimmunol 261 : 129-133, 2013.
PubMed
12) Graus F, et al : Antibodies and neuronal autoimmune disorders of the CNS. J Neurol 257 : 509-517, 2010.
PubMed
13) Vincent A, et al : Autoantibodies associated with diseases of the CNS : new developments and future challenges. Lancet Neurol 10 : 759-772, 2011.
PubMed
P.637 掲載の参考文献
1) Nanri K, et al : Low-titer anti-GAD-antibody-positive cerebellar ataxia. Cerebellum 12 : 171-175, 2013.
PubMed
2) Takino T, et al : A case of subacute cerebellar ataxia with anti-GAD antibodies in cerebrospinal fluid but not in serum. Neurol Clin Neurosci (in print)
 
3) McFarland NR, et al : Improvement with corticosteroids and azathioprine in GAD65-associated cerebellar ataxia. Neurology 67 : 1308-1309, 2006.
PubMed
4) Kuchling J, et al : GAD antibody-associated late-onset cerebellar ataxia in two female siblings. Case Rep Neurol 6 : 264-270, 2014.
PubMed
5) Hernandez-Lahoz C, et al : Familial gluten ataxia. Mov Disord 29 : 308-310, 2014.
PubMed
6) Hadjivassiliou M, et al : Dietary treatment of gluten ataxia. J Neurol Neurosurg Psychiatry 74 : 1221-1224, 2003.
PubMed
7) Burk K, et al : Effectiveness of intravenous immunoglobin therapy in cerebellar ataxia associated with gluten sensitivity. Ann Neurol 50 : 827-828, 2001.
PubMed
8) Sander HW, et al : Cerebellar ataxia and coeliac disease. Lancet 362 : 1548, 2003.
PubMed
9) Souayah N, et al : Effect of intravenous immunoglobulin on cerebellar ataxia and neuropathic pain associated with celiac disease. Eur J Neurol 15 : 1300-1303, 2008.
PubMed
10) Ihara M, et al : Gluten sensitivity in Japanese patients with adult-onset cerebellar ataxia. Intern Med 45 : 135-140, 2006.
PubMed
11) Nanri K, et al : Gluten ataxia in Japan. Cerebellum 13 : 623-627, 2014.
PubMed
12) Yoneda M, et al : High prevalence of serum autoantibodies against the amino terminal of α-enolase in Hashimoto's encephalopathy. J Neuroimmunol 185 : 195-200, 2007.
 
13) 米田誠 : 橋本脳症-小脳失調型を中心に-. 臨床神経 52 : 1369-1371, 2012.
 
P.642 掲載の参考文献
1) Bickerstaff ER, Cloake PC : Mesencephalitis and rhombencephalitis. Br Med J 2 : 77-81, 1951.
PubMed
2) Bickerstaff ER : Brain-stem encephalitis : Further observations on a grave syndrome with benign prognosis. Br Med J 1 : 1384-1387, 1957.
PubMed
3) Yuki N, et al : An immunologic abnormality common to Bickerstaff's brain stem encephalitis and Fisher's syndrome. J Neurol Sci 118 : 83-87, 1993.
 
4) Odaka M, et al : Bickerstaff's brainstem encephalitis : clinical features of 62 cases and a subgroup associated with Guillain-Barre syndrome. Brain 126 : 2279-2290, 2003.
 
5) Koga M, et al : Nationwide survey of patients in Japan with Bickerstaff brainstem encephalitis : epidemiological and clinical characteristics. J Neurol Neurosurg Psychiatry 83 : 1210-1215, 2012.
PubMed
6) Yuki N : Fisher syndrome and Bickerstaff brainstem encephalitis (Fisher-Bickerstaff syndrome). J Neuroimmunol 215 : 1-9, 2009.
PubMed
7) Ito M, et al : Bickerstaff's brainstem encephalitis and Fisher syndrome form a continuous spectrum : clinical analysis of 581 cases. J Neurol 255 : 674-682, 2008.
 
8) Saito K et al : Blood-brain barrier destruction determines Fisher/Bickerstaff clinical phenotypes : an in vitro study. J Neurol Neurosurg Psychiatry 84 : 756-765, 2013.
 
9) 小鷹昌明, 結城伸泰 : Bickerstaff型脳幹脳炎の診断と病因. 神経研究の進歩 43 : 114-127, 1999.
 
10) Koga M, et al : Antecedent infections in Fisher syndrome : a common pathogenesis of molecular mimicry. Neurology 64 : 1605-1611, 2005.
PubMed
11) Nagashima T, et al : Constinuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barre syndrome. Arch Neurol 64 : 1519-1523, 2007.
PubMed
12) Yuki N, Hurtung HP : Guillain-Barre syndrome. N Engl J Med 366 : 2294-2304, 2012.
 
13) Koga M, et al : Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barre syndrome. Neurology 65 : 1376-1381, 2005.
PubMed
14) Koga M, et al : Comprehensive analysis of bacterial risk factors for the development of Guillain-Barre syndrome after Campylobacter jejuni enteritis. J Infect Dis 193 : 547-555, 2006.
PubMed
15) Kimoto K, et al : Relationship of bacterial strains to clinical syndromes of Campylobacter-associated neuropathies. Neurology 67 : 1837-1843, 2006.
PubMed
16) Mori M, et al : Bickerstaffs brainstem encephalitis after an outbreak of Campylobacter jejuni enteritis. J Neuroimmunol 196 : 143-146, 2008.
 
17) Wakerley BR, et al : Atypical Bickerstaff brainstem encephalitis : ataxic hypersomnolence without ophthalmoplegia. J Neurol Neurosurg Psychiatry 84 : 1206-1207, 2013.
PubMed
P.648 掲載の参考文献
1) Jeltsch-David H, Muller S : Neuropsychiatric systemic lupus erythematosus : pathogenesis and biomarkers. Nat Rev Neurol 10 : 579-596, 2014.
PubMed
2) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42 : 599-608, 1999.
PubMed
3) Bertsias GK, et al : EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations : report of a task force of EULAR standing committee for clinical affairs. Ann Rheum Dis 69 : 2074-2082, 2010.
PubMed
4) Hanly JG, et al : Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis 70 : 1726-1732, 2011.
PubMed
5) Hanly JG : Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol 10 : 338-347, 2014.
PubMed
6) Fragoso-Loyo H, et al : Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus. Implications for diagnosis and pathogenesis. PLoS One 3 : e3347, 2008.
PubMed
7) Katzav A, et al : Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheum 56 : 938-948, 2007.
PubMed
8) Karassa FB, et al : Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus : an international meta-analysis. Arthritis Rheum 54 : 312-324, 2006.
PubMed
9) DeGiorgio LA, et al : Asubset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 7 : 1189-1193, 2001.
 
10) Lapteva L, et al : Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 54 : 2505-2514, 2006.
 
11) Yoshio T, et al : Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 54 : 675-678, 2006.
PubMed
12) Sato T, et al : Anti-U1 RNP antibodies in cerebrospinal fluid are associated with central neuropsychiatric manifestations in systemic lupus erythematosus and mixed connective tissue disease. Arthritis Rheum 62 : 3730-3740, 2010.
PubMed
13) Katsumata Y, et al : Serum antibodies against the 70k polypeptides of the U1 ribonucleoprotein complex are associated with psychiatric syndromes in systemic lupus erythematosus : a retrospective study. Mod Rheumatol 23 : 71-80, 2013.
PubMed
14) Yokoyama T, et al : Association between anti-U1 ribonucleoprotein antibodies and inflammatory mediators in cerebrospinal fluid of patients with neuropsychiatric systemic lupus erythematosus. Lupus 23 : 635-642, 2014.
PubMed
15) Fragoso-Loyo H, et al : Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus eryhtematosus. Arthritis Rheum 56 : 1242-1250, 2007.
 
16) Zimney A, et al : In vivo evaluation of brain damage in the course of systemic lupus erythematosus using magnetic resonance spectroscopy, perfusion-weighted and diffusion-tensor imaging. Lupus 23 : 10-19, 2014.
 
P.652 掲載の参考文献
1) Berglin E, et al : Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 65 : 453-458, 2006.
PubMed
2) Klimiuk PA et al : Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. J Rheumatol 31 : 238-242, 2004.
 
3) Lanzillo B, et al : Subclinical peripheral nerve involvement in patients With rheumatoid arthritis. Arthritis Rheum 41 : 1196-1202, 1998.
PubMed
4) Bauer W, Clark WS : The systemic manifestations of rheumatoid arthritis. Trans Assoc Am Physicians 61 : 399, 1948.
 
5) Puechal X, et al : Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis. Arhritis Rheum 38 : 1618-1629, 1995.
 
6) Salih AM, et al : Soluble adhesion molecules and anti-endothelial cell antibodies in patients with rheumatoid arthritis complicated by peripheral neuropathy. J Rheumatol 26 : 551-555, 1999.
PubMed
7) Mohan N, et al : Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritis. Arthritis Rheum 44 : 2862-2869, 2001.
PubMed
8) Richez C, et al : Neuropathy resembling CIDP in patients receiving tumor necrosis factor-α blockers. Neurology 64 : 1468-1470, 2005.
 
9) Kaltsonoudis E, et al : Neurological adverse events in patients receiving anti-TNF therapy : a prospective imaging and electrophysiological study. Arthritis Res Ther 16 : R125, 2014.
PubMed
10) 大塚恵美子ほか : リウマチ性肥厚性硬膜炎の一例. 臨床神経 37 : 834-840, 1997.
 
11) 柳下章 : 肥厚性脳硬膜炎の画像診断. 神経内科 55 : 225-230, 2001.
 
12) Baghdadi LR, et al : The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis : a systemic review and meta-analysis. PLoS One 10 : e0117952, 2015.
 
P.659 掲載の参考文献
1) van den Hoogan F, et al : 2013 classification criteria for systemic sclerosis : an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65 : 2737-2747, 2013.
 
2) Man A, et al : The risk of cardiovascular disease in systemic sclerosis : apopulation-based cohort study. Ann Rheum Dis 72 : 1188-1193, 2013.
 
3) Amaral TN, et al : Neurologic involvement in scleroderma : a systematic review. Semin Arthritis Rheum 43 : 335-347, 2013.
PubMed
4) Searles RP, et al : Isolated trigeminal sensory neuropathy : early manifestation of mixed connective tissue disease. Neurology 28 : 1286-1289, 1978.
PubMed
5) Medsger TA, Jr, et al : Skeletal muscle involvement in progressive systemic sclerosis (scleroderma). Arthritis Rheum 11 : 554-568, 1968.
PubMed
6) Follansbee WP, et al : Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma) : a high risk association. Am Heart J 125 : 194-203, 1993.
PubMed
7) Rosato E, et al : Dropped head syndrome and systemic sclerosis. Joint Bone Spine 76 : 301-303, 2009.
PubMed
8) Toledano C, et al : Aldolase predicts subsequent myopathy occurrence in systemic sclerosis. Arthritis Res Ther 14 : R152, 2012.
PubMed
9) Ranque B, et al : A descriptive and prognostic study of systemic sclerosis-associated myopathies. Ann Rheum Dis 68 : 1474-1477, 2009.
PubMed
10) Allanore Y, et al : Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 69 : 218-221, 2010.
 
11) Bhansing KJ, et al : Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis : a descriptive study on clinical features and myopathology. Arthritis Res Ther 16 : R111, 2014.
 
12) Koschik RW, et al : Anti-PM-Scl antibody in patients with systemic sclerosis. Clin Exp Rheumatol 30 : S12-S16, 2012.
PubMed
13) Kaji K, et al : Autoantibodies to RuvBL1 and RuvBL2 : a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement. Arthritis Care Res 66 : 575-584, 2014.
PubMed
P.667 掲載の参考文献
1) Sharp GC, et al : Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 52 : 148-159, 1972.
 
2) Kelly KM, et al : "Endogenous adjuvant" activity of the RNA components of lupus autoantigen Sm/RNP and Ro60. Arthritis Rheum 54 : 1557-1567, 2006.
PubMed
3) Burdt MA, et al : Long-term outcome in mixed connective tissue disease : Longitudinal clinical and serologic findings. Arthritis Rheum 42 : 899-909, 1999.
PubMed
4) 近藤啓文, 岡田純 : 混合性結合組織病臨床調査個人票からのMCTDの疫学的調査, 厚生科学研究費補助金特定疾患対策研究事業混合性結合組織病に関する研究班平成12年度研究報告書, 1998.
 
5) Oxenhandler R, et al : Pathology of skeletal muscle in mixed connective tissue disease. Arthritis Rheum 20 : 985-988, 1977.
PubMed
6) Vianna MAAG, et al : Myositis in mixed connective tissue disease : aunique syndrome characterized by immunohistopathologic elements of both polymyositis and dermatomyositis. Arq Neuropsiquiatr 62 : 923-934, 2004.
 
7) 厚生労働科学研究費補助金難治性疾患克服研究. 事業混合性結合組織病に関する研究班 : 混合性結合組織病の治療ガイドライン, 2005.
 
8) Bennett RM, O'Connell DJ : Mixed connective tisssue disease : a clinicopathologic study of 20 cases. Semin Arthritis Rheum 10 : 25-51, 1980.
PubMed
9) 三森経世ほか : 混合性結合組織病の髄膜炎. 日臨免疫会誌 23 : 647-651, 2000.
 
10) Fujita Y, et al : Aseptic meningitis in mixed connective tissue disease : cytokine and anti-U1RNP antibodies in cerebrospinal fluids from two different cases. Mod Rheumatol 18 : 184-188, 2008.
PubMed
11) Hagen NA et al : Trigeminal sensory neuropathy associated with connective tissue diseases. Neurology 40 : 891-896, 1990.
PubMed
12) 近藤正弘, 村川洋子 : 混合性結合組織病. Clinical Neuroscience 24 : 22-23, 2006.
 
13) Weatherby S, et al : Transverse myelopathy, a rare complication of mixed connective tissue disease : comparison with SLE related transverse myelopathy. J Neurol Neurosurg Psychiatr 68 : 532-533, 2000.
 
P.672 掲載の参考文献
1) Fox RI : Sjogren's syndrome. Lancet 366 : 321-331, 2005.
PubMed
2) Chai J, et al : Neurological manifestation of primary Sjogren's syndrome. Curr Opin Neurol 23 : 509-513, 2010.
PubMed
3) Delalande S, et al : Neurologic manifestations in primary Sjogren's syndrome : a study of 82 patients. Medicine (Baltimore) 83 : 280-291, 2004.
PubMed
4) Garcia-Carrasco M, et al : Primary Sj6gren's syndrome : clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore) 81 : 270-280, 2002.
 
5) Andonopoulos A, et al : The spectrum of neurological in volvement in Sjogren's syndrome. Br J Rheumatol 29 : 21-23, 1990.
 
6) Alexander EL, et al : Neurologic complications of primary Sjogren's syndrome. Medicine (Baltimore) 61 : 247-257, 1982.
PubMed
7) Alexander EL, et al : Anti-Ro (SS-A) autoantibodies in central nervous system disease associated with Sjogren's syndrome (CNS-SS) : clinical, neuroimaging, and angiographic correlates. Neurology 44 : 899-908, 1994.
 
8) Kawagashira Y, et al : Differential, size-dependent sensory neuron involvement in the painful and ataxic forms of primary Sjogren's syndrome-associated neuropathy. J Neurol Sci 319 : 139-146, 2012.
PubMed
9) Mori K, et al : The wide spectrum of clinical manifestations in Sjog ren's syndrome-associated neuropathy. Brain 128 : 2518-2534, 2005.
 
10) Sanahuja J, et al : Primary Sjogren's syndrome with tumefactive central nervous system involvement. AJNR Am J Neuroradiol 29 : 1878-1879, 2008.
PubMed
11) Lennon VA, et al : A serum autoantibody marker of neuromyelitis optica : distinction form multiple sclerosis. Lancet 364 : 2106-2112, 2004.
 
12) Takahashi T, et al : Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO : a study on antibody titre. Brain 130 : 1235-1243, 2007.
 
13) Ishida K, et al : Reccurent aseptic meningitis : a new CSF complication of Sjogren's syndrome. J Neurol 254 : 806-807, 2007.
 
14) 小池春樹 : シェーグレン症候群と末梢神経障害. 脳と神経 65 : 1333-1342, 2013.
 
15) Kondo T, et al : Autoimmune autonomic ganglionopathy with Sjogren's syndrome : significance of ganglionic acetylcholine receptor antibody and therapeutic approach. Auton Neurosci 146 : 33-35, 2009.
PubMed
16) 野口悦正ほか : 2つのことなる機序のニューロパチーをともなったシェーグレン症候群の1例. 臨床神経学 43 : 539-543, 2003.
 
P.679 掲載の参考文献
1) Akman-Demir G, et al : Clinical patterns of neurological involvement in Behget's disease : evaluation of 200 patients. The Neuro-Behget Study Group. Brain 122 : 2171-2182, 1999.
 
2) 広畑俊成 : 神経ベーチェット病の病態. 臨床神経 41 : 1147-1149, 2001.
 
3) Hirohata S, et al : Cerebrospinal fluid interleukin-6 in progressive Neuro-Behget's syndrome. Clin Immunol Immunopathol 82 : 12-17, 1997.
 
4) Hirohata S, et al : Clinical characteristics of neuro-Behget's disease in Japan : a multicenter retrospective analysis. Mod Rheumatol 22 : 405-413, 2012.
 
5) Kikuchi H, et al : Quantitative analysis of brainstem atrophy on magnetic resonance imaging in chronic progressive neuro-Behcet's disease. J Neurol Sci 337 : 80-85, 2014.
PubMed
6) Matsui T, et al : An attack of acute neuro-Behget's disease during the course of chronic progressive neuro- Behget's disease : report of two cases. Mod Rheumatol 20 : 621-626, 2010.
 
7) Hirohata S : Histopathology of central nervous system lesions in Behget's disease. J Neurol Sci 267 : 41-47, 2008.
 
8) Hirohata S, Kikuchi H : Changes in biomarkers focused on differences in disease course or treatment in patient swith neuro-Behget's disease. Intern Med 51 : 3359-3365, 2012.
PubMed
9) Hirohata S, et al : Analysis of various factors on the relapse of acute neurological attacks in Behget's disease. Mod Rheumatol 24 : 961-965, 2014.
 
10) Hirohata S, et al : Low dose weekly methotrexate therapy for progressive neuropsychiatric manifestations in Behget's disease. J Neurol Sci 159 : 181-185, 1998.
 
11) Hirohata S, et al : Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behget's disease. J Neurol Sci 349 : 143-148, 2015.
 
12) Kikuchi H, et al : Effect of infliximab in progressive neuro-Behget's syndrome. J Neurol Sci 272 : 99-105, 2008.
 
13) 廣畑俊成ほか : 神経ベーチェット病の診療のガイドライン. 厚生労働科学研究補助金難治性疾患克服研究事業ベーチェット病に関する調査研究事業平成23-25年度総括・分担研究報告書, p247-252, 2014.
 
14) Borhani Haghighi A, Safari A : Tocilizumab may be a potential addition to our weapons against neuro-Behget's disease. Med Hypotheses 71 : 156-157, 2008.
 
P.684 掲載の参考文献
1) Sweet RD : An acute febrile neutrophilic dermatosis. Br J Dermatol 76 : 349-356, 1964.
PubMed
2) Hisanaga K et al : "Neuro-Sweet disease" : benign recurrent encephalitis with neutrophilic dermatosis. Arch Neurol 56 : 1010-1013, 1999.
PubMed
3) Hisanaga K, et al : Neuro-Sweet disease : Clinical manifestations and criteria for diagnosis. Neurology 64 : 1756-1761, 2005.
PubMed
4) Kokubo Y, et al : Neuro-Sweet disease : report of the first autopsy case. J Neurol Neurosurg Psychiatry 78 : 997-1000, 2007.
 
5) 温井孝昌ほか : 可溶性IL-2受容体値が疾患活動性と相関した神経Sweet病の1例. 臨床神経 54 : 876-881, 2014.
 
6) Kimura A, et al : Longitudinal analysis of cytokines and chemokines in the cerebrospinal fluid of a patient with neuro-Sweet disease presenting with recurrent encephalomeningitis. Intern Med 47 : 135-141, 2008.
PubMed
7) Mizoguchi M, et al : Human leukocyte antigen in Sweet's syndrome and its relationship to Behget's disease. Arch Dermatol 124 : 1069-1073, 1988.
 
8) Mizuki N, et al : Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behget's disease susceptibility loci. Nat Genet 42 : 703-706, 2010,
 
9) Kirino Y, et al : Genome-wide association analysis identifies new susceptibility loci for Behget's disease and epistasis between HLA-B*51 and ERAP1. Nat Genet 45 : 202-208, 2013.
 
10) Krino Y, et al : Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behget disease. Proc Natl Acad Sci USA 110 : 8134-8139, 2013.
 
11) Miyoshi T, et al : Familial Mediterranean fever gene as a possible modifier of Sweet syndrome with chronic myelogenous leukemia. Acta Haematol 120 : 57-62, 2008.
PubMed
12) 木下朋実ほか : コルヒチンが有効なMollaret髄膜炎で, MEFV遺伝子変異をみとめた1例. 臨床神経 54 : 124-129, 2014.
 
13) Hisanaga K : Neuro-neutrophilic disease : neuro-Behget disease and neuro-Sweet disease. Intern Med 46 : 153-154, 2007.
 
14) 中西悦郎ほか : Human leukocyte antigen (HLA) -B54. Cw1を有し, 脳生検により, 神経好中球病がうたがわれた1例. 臨床神経 55 : 13-17, 2015.
 
15) Fukae J, et al : Successful treatment of relapsing neuro-Sweet's disease with corticosteroid and dapsone combination therapy. Clin Neurol Neurosurg 109 : 910-913, 2007.
PubMed
P.691 掲載の参考文献
1) Terushkin V, et al : Neurosarcoidosis : presentations and management. Neurologist 16 : 2-15, 2010.
PubMed
2) Krumholz A, Stern BJ : Neurologic manifestations of sarcoidosis. Handb Clin Neurol 119 : 305-333, 2014.
PubMed
3) 熊本俊秀 : サルコイドーシスと神経障害. 免疫性神経疾患ハンドブック (楠進編), p261-270, 南江堂, 2013.
 
4) 貴田浩志ほか : 第四脳室流出路の閉塞による水頭症をきたした神経サルコイドーシス. 神経内科 73 : 430-432, 2010.
 
5) Saifee TA, et al : Sarcoidosis presenting as acute inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 43 : 296, 2011.
PubMed
6) Niemer GW, et al : Carpal tunnel syndrome in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 18 : 296-300, 2001.
PubMed
7) 中里良彦ほか : 中枢神経サルコイドーシス鑑別診断のための脳脊髄液ACE値. 神経内科 73 : 88-90, 2010.
 
8) 日本サルコイドーシス/肉芽腫性疾患学会ほか : サルコイドーシスの診断基準と診断の手引き-2006. 日呼吸会誌 46 : 768-780, 2008.
 
P.699 掲載の参考文献
1) 川名誠司, 陳科榮 : 皮膚血管炎, 医学書院, 2013.
 
2) Midroni G, Bilbao JM : Biopsy Diagnosis of Peripheral Neuropathy, Butterworth-Heinemann, Oxford, 1995.
 
3) Said G, Lacroix C : Primary and secondary vasculitic neuropathy. J Neurol 252 : 633-641, 2005.
PubMed
4) 岡伸幸 : カラーアトラス末梢神経の病理. 中外医学社, 2010.
 
5) Seo JH, et al : Sensory neuropathy in vasculitis : a clinical, pathologic, and electrophysiologic study. Neurology 63 : 874-878, 2004.
PubMed
6) Collins MP, et al : Peripheral Nerve Society : Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy : executive summary. J Peripher Nerv Syst 15 : 176-184, 2010.
 
7) Bennett DL, et al : The use of nerve and muscle biopsy in the diagnosis of vasculitis : a 5 year retrospective study. J Neurol Neurosurg Psychiatry 79 : 1376-1381, 2008.
PubMed
8) Jamieson PW, et al : Necrotizing angiopathy presenting with multifocal conduction blocks. Neurology 41 : 442-444, 1991.
PubMed
9) 祖父江元ほか : 壊死性血管炎に伴う末梢神経障害の臨床病理学的特徴. 結節性動脈周囲炎2剖検例の検討から. 臨床神経 29 : 209-215, 1989.
 
10) Morozumi S, et al : Spatial distribution of nerve fiber pathology and vasculitis in microscopic polyangiitis-associated neuropathy. J Neuropathol Exp Neurol 70 : 340-348, 2011.
PubMed
11) P2F09前脊髄動脈の血管炎を主体としたANCA関連血管炎の1剖検例・豊田厚生病院神経内科宇佐見恵子 第55回日本神経病理学会総会, 2014.
 
12) Oka N, et al : Two subtypes of Churg-Strauss syndrome with neuropathy : the roles of eosinophils and ANCA. Mod Rheumatol 21 : 290-295, 2011.
PubMed
P.704 掲載の参考文献
1) Cravioto H, Feigin I : Noninfectious granulomatous angiitis with a predilection for the nervous system. Neurology 9 : 599-609, 1959.
PubMed
2) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11. 2013.
 
3) Salvarani C, et al : Adult primary central nervous system vasculitis. Lancet 380 : 767-777, 2012.
PubMed
4) Calabrese LH, Mallek JA : Primary angiitis of the central nervous system. Report of 8 new cases, review of the literature, and proposal for diagnostic criteria. Medicine (Baltimore) 67 : 20-39, 1988.
PubMed
5) Eng JA, et al : Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol 55 : 250-256, 2004.
PubMed
6) Scolding NJ, et al : Aβ-related angiitis : primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain 128 : 500-515, 2005.
 
7) Sakaguchi H, et al : Cerebral amyloid angiopathy-related inflammation presenting with steroidresponsive higher brain dysfunction : case report and review of the literature. J Neuroinflammation 8 : 116, 2011.
PubMed
8) Moore PM : Diagnosis and management of isolated angiitis of the central nervous system. Neurology 39 : 167-173, 1989.
PubMed
9) Salvarani C, et al : Primary CNS vasculitis with spinal cord involvement. Neurology 70 : 2394-2400, 2008.
PubMed
10) Kadkhodayan Y, et al : Primary angiitis of the central nervous system at conventional angiography. Radiology 233 : 878-882, 2004.
PubMed
11) Salvarani C, et al : Primary central nervous system vasculitis with prominent leptomeningeal enhancement : a subset with a benign outcome. Arthritis Rheum 58 : 595-603, 2008.
PubMed
12) Salvarani C, et al : Primary central nervous system vasculitis : comparison of patients with and without cerebral amyloid angiopathy. Rheumatology (Oxford) 47 : 1671-1677, 2008.
PubMed
13) Salvarani C. et al : Rapidly progressive primary central nervous system vasculitis. Rheumatology (Oxford) 50 : 349-358, 2011.
PubMed
14) Molloy ES, et al : Tumour-like mass lesion : an under-recognised presentation of primary angiitis of the central nervous system. Ann Rheum Dis 67 : 1732-1735, 2008.
PubMed
15) Salvarani C, et al : Primary central nervous system vasculitis presenting with intracranial hemorrhage. Arthritis Rheum 63 : 3598-3606, 2011.
PubMed
P.710 掲載の参考文献
1) Hess DC, et al : Anticardiolipin antibodies : a study of frequency in TIA and stroke. Neurology 41 : 525-528, 1991.
PubMed
2) Ruiz-Irastorza G, et al : Antiphospholipid syndrome. Lancet 376 (9751) : 1498-1509, 2010.
PubMed
3) Fujieda Y, et al : Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome. Lupus 21 (14) : 1506-1514, 2012.
PubMed
4) Du VX, et al : From antibody to clinical phenotype, the black box of the antiphospholipid syndrome : Pathogenic mechanisms of the antiphospholipid syndrome. Thromb Res 132 : 319-326, 2013.
PubMed
5) Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Neurology 43 : 2069-2073, 1993.
PubMed
6) Miyakis S, et al : International consensus statement on an update of the classhication criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2) : 295-306, 2006.
 
7) Comellas-Kirkerup L, et al : Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria : a 6-year follow-up study. Blood 116 (16) : 3058-3063, 2010.
 
8) Cervera R, et al : Antiphospholipid syndrome : clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46 : 1019-1027, 2002.
 
9) Arnson Y, et al : The antiphospholipid syndrome as a neurological disease. Semin Arthritis Rheum 40 (2) : 97-108, 2010.
PubMed
10) Zhu DS, et al : Neurological antiphospholipid syndrome : Clinical, neuroimaging, and pathological characteristics. J Neurol Sci 346 : 138-144, 2014.
PubMed
11) 小池隆夫 : 抗リン脂質抗体症候群の治療指針案について, 厚生労働省特定疾患対策研究事業-自己免疫疾患の病因・病態解析と新たな治療法の開発に関する研究報告書, p135-137, 2002.
 
12) Lubbe WF, et al : Fetal survival after prednisone suppression of maternal lupus-anticoagulant. Lancet 1 (8338) : 1361-1363, 1983.
PubMed
13) Khamashta M, et al : The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332 : 993-997, 1995.
PubMed
14) Rosove MH, Brewer PM : Antiphospholipid thrombosis : clinical course after the first thrombotic event in 70 patients. Ann Intern Med 117 (4) : 303-308, 1992.
PubMed
15) Brey RL, et al : Stroke and the antiphospholipid syndrome : consensus meeting Taormina 2002. Lupus 12 (7) : 508-513, 2003.
PubMed
16) Arachchillage DJ, et al : Use of new oral Anticoagulants in antiphospholipid syndrome. Curr Rheumatol Rep 15 : 331-339, 2013.
PubMed
17) Chighizola CB, et al : New oral anticoagulants in thrombotic antiphospholipid syndrome. Lupus 23 : 1279-1282, 2014.
PubMed
18) Erkan D, et al : 14th International congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 13 : 685-696, 2014.
PubMed
19) Finazzi G, et al : A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 3 (5) : 848-853, 2005.
PubMed
P.714 掲載の参考文献
1) 藤井健司 : リウマチ性多発筋痛症の鑑別診断-特に高齢発症関節リウマチとの鑑別について-. 臨床リウマチ 26 : 201-206, 2014.
 
2) Chuang TY, et al : Polymyalgia rheumatica : a 10-year epidemiologic and clinical study. Ann Intern Med 97 : 672-680, 1982.
PubMed
3) Salvarani C, et al : Polymyalgia rheumatica and giant-cell artetitis. Lancet 372 : 234-245, 2008.
PubMed
4) Bird HA, et al : An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 38 : 434-439, 1979.
PubMed
5) Healey LA : Long-term follow-up of polymyalgia rheumatica : evidence for synovitis. Semin Arthritis Rheum 13 : 322-328, 1984.
PubMed
6) Jones JG, Hazleman BL : Prognosis and management of polymyalgia rheumatica. Ann Rheum Dis 40 : 1-5, 1981.
PubMed
7) Nobunaga M, et al : Clinical studies of polymialgia rheumatica. A proposal of diagnostic criteria. Jpn J Med 28 : 452-456, 1989.
 
8) Dasgupta B, et al : 2012 provisional classification criteria for polymyalgia rheumatica : a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 71 : 484-492, 2012.
PubMed
9) Cantini F, et al : Fat suppression magnetic resonance imaging in shoulders of patients with polymyalgia rheumatica. J Rheumatol 31 : 120-124, 2004.
PubMed
10) 大和田高義, 倉沢和宏 : 筋痛を主訴とするリウマチ性疾患-リウマチ性多発筋痛症とその周辺疾患. 脊髄外科 27 : 114-118, 2013.
 
11) Yamashita H, et al : Whole-body fluorodeoxyglucose positron emission tomography/computed tomography in patients with active polymyalgia rheumatica : evidence for distinctive bursitis and large-vessel vasculitis. Mod Rheumatol 22 : 705-711, 2012.
PubMed
12) Hernandez-Rodrigues J, et al : Treatment of polymyalgia rheumatica : asystematic review. Arch Intern Med 169 : 1839-1850, 2009.
 
13) Caporali R, et al : Predonisone plus methotrexate for polymyalgia rheumatica : a randomized, double-blind, placebo-controlled trial. Ann Intern Med 141 : 493-500, 2004.
 
14) van der Veen MJ, et al : Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 55 : 218-223, 1996.
PubMed
15) 田仲敏郎 : PMRの新たな治療戦略-生物学的製剤の可能性. 臨床リウマチ 26 : 224-233, 2014.
 
P.720 掲載の参考文献
1) Susac JO, et al : Microangiopathy of the brain and retina. Neurology 29 : 313-316, 1979.
PubMed
2) Dorr J, et al : Characteristics of Susac syndrome : a review of all reported cases. Nat Rev Neurol 9 : 307-316, 2013.
PubMed
3) Egan RA, et al : Gass plaques and fluorescein leakage in Susac Syndrome. J Neurol Sci 299 : 97-100, 2010.
PubMed
4) Turc G, et al : Skin involvement in Susac's syndrome. J Neurol Sci 305 : 152-155, 2011.
PubMed
5) Susac JO, et al : Susac's syndrome : 1975-2005 microangiopathy/autoimmune endotheliopathy. J Neurol Sci 257 : 270-272, 2007.
PubMed
6) Bienfang DC, et al : Case records of the Massachusetts General Hospital. Case 24-2011. A 36-year-old man with headache, memory loss, and confusion. N Engl J Med 365 : 549-559, 2011.
PubMed
7) Magro CM, et al : Susac syndrome : an organ-specific autoimmune endotheliopathy syndrome associated with anti-endothelial cell antibodies. Am J Clin Pathol 136 : 903-912, 2011.
PubMed
8) Susac JO, et al : MRI findings in Susac's syndrome. Neurology 61 : 1783-1787, 2003.
PubMed
9) Allmendinger AM, et al : CT and MR imaging of Susac syndrome in a young male presenting with acute disorientation. Clin Imaging 34 : 138-142, 2010.
 
10) Kleffner I, et al : A brief review of Susac syndrome. J Neurol Sci 322 : 35-40, 2012.
PubMed
11) Martinez-Thompson JM, et al : Clinical reasoning : a woman with subacute progressive confusion and gait instability. Neurology 83 : e62-67, 2014.
PubMed
12) Kleffner I, et al : Diffusion tensor imaging demonstrates fiber impairment in Susac syndrome. Neurology 70 : 1867-1869, 2008.
PubMed
13) Jarius S, et al : Clinical, para clinical and serological findings in Susac syndrome : an international multicenter study. J Neuroinflammation 11 : 46, 2014.
 
14) Rennebohm RM, et al : Treatment of Susac's Syndrome. Curr Treat Options Neurol 10 : 67-74, 2008.
PubMed
15) Feresiadou A, et al : Recurrence of Susac syndrome following 23 years of remission. Case Rep Neurol 6 : 171-175, 2014.
PubMed
P.727 掲載の参考文献
1) 石田文宏, 中澤英之 : セリアック病. 別冊日本臨牀 消化管症候群 (第2版) 下, p515-517, 日本臨牀社, 2009.
 
2) Bai JC, et al : Celiac disease. World Gastroenterology Organisation Global Guidelines, p 1-25, 2012.
 
3) Sapone A, et al : Spectrum of gluten-related disorders : consensus on new nomenclature and classification, BMC Medicine 10 : 13, 2012.
PubMed
4) Nikpour S : Neurological manifestations, diagnosis, and treatment of celiac disease : A comprehensive review. Iran J Neurol 11 (2) : 59-64, 2012.
PubMed
5) 松永久幸, 三浦総一郎 : セリアック病. 分子消化器病 4 (1) : 47-52, 2007.
Medical*Online
6) Burk K, et al : Neurological symptoms in patients with biopsy proven celiac disease. Mov Dis 16 : 2358-2362, 2009.
 
7) 渡辺知佳子ほか : セリアック病と炎症性腸疾患. 臨床免疫・アレルギー科 61 (1) : 52-56, 2014.
 
8) Ihara M, et al : Gluten sensitivity in Japanese patients with adult-onset cerebellar ataxia. Intern Med 45 (3) : 135-140, 2006.
PubMed
9) 小西哲郎 : セリアック病. 日本臨牀 62 (増刊号1) : 450-455, 2004.
Medical*Online
10) Bushara KO : Neurologic presentation of celiac disease. Gastroenterology 128 : S92-S97, 2005.
PubMed
11) Hadjivassiliou M, et al : Gluten-related neurologic dysfunction. In : Handbook of Clinical Neurology (ed by Biller J, Ferro JM), p 607-619, Elsevier, Amsterdam, 2014.
 
12) Jackson JR, et al : Neurologic and psychiatric manifestations of celiac disease and gluten sensitivity. Psychiatr Q 83 (1) : 91-102, 2012.
PubMed
13) Hu WT, et al : Cognitive impairment and celiac disease. Arch Neurol 63 : 1440-1446, 2006.
PubMed
14) Lichtwark IT, et al : Cognitive impairment in coeliac disease improves on a gluten-free diet and correlates with histological and serological indices of disease. Aliment Pharmacol Ther 40 (2) : 160-170, 2014.
PubMed
15) Collin P, et al : Celiac disease, brain atrophy, and dementia. Neurology 41 : 372-375, 1991.
PubMed
P.733 掲載の参考文献
1) Fenollar F, et al : Whipple's disease. N Engl J Med 356 : 55-66, 2007.
PubMed
2) Black-Schaffer B : The tinctoral demonstration of a glycoprotein in Whipple's disease. Proc Soc Exp Biol Med 72 : 225-227, 1949.
PubMed
3) Yardley JH, Hendrix TR : Combined electron and light microscopy in Whipple's disease. Demonstration of 'bacillary bodies' in the intestine. Bull Johns Hopkins Hosp 109 : 80-98, 1961.
PubMed
4) Relman DA et al : Identification of the uncultured bacillus of Whipple's disease. N Engl J Med 327 : 293-301, 1992.
PubMed
5) Raoult D, et al : Cultivation of the bacillus of Whipple's disease. N Engl J Med 342 : 620-625, 2000.
PubMed
6) Canoso JJ, et al : Whipple's disease and ankylosing spondylitis simultaneous occurrence in HLAB27 positive male. J Rheumatol 5 : 79 -84, 1978.
 
7) Schneider T, et al : Whipple's disease : new aspects of pathogenesis and treatment. Lancet Infect Dis 8 : 179-190, 2008.
PubMed
8) Marth T, Raoult D : Whipple's disease. Lancet 361 : 239-246, 2003.
PubMed
9) Meunier M, et al : Rheumatic and musculoskeletal features of Whipple disease : a report of 29 cases. J Rheumatol 40 : 2061-2066, 2013.
 
10) Kremer S, et al : Diffuse lesions in the CNS revealed by MR imaging in a case of Whipple disease. AJNR Am J Neuroradiol 22 : 493-495, 2001.
 
11) Donmez FY, et al : MRI of recurrent isolated cerebral Whipple's disease. Diagn Interv Radiol 16 : 112-115, 2010.
PubMed
12) Relman DA et al : Identification of the uncultured bacillus of Whipple's disease. N Engl J Med 327 : 293-301, 1992.
PubMed
13) Street S, et al : Tropheryma whippelii DNA in saliva of healthy people. Lancet 354 : 1178-1179, 1999.
PubMed
14) Costello DJ, et al : Case records of the Massachusetts General Hospital. Case 1-2009. A 57-year-old man with progressive cognitive decline. N Engl J Med 360 : 171-181, 2009.
PubMed
15) Feurle GE, et al : The immune reconstitution inflammatory syndrome in whipple disease : a cohort study. Ann Intern Med 153 : 710-717, 2010.
PubMed
P.741 掲載の参考文献
1) Rosenfeld MR, et al : Paraneoplastic syndromes and autoimmune encephalitis. Five new things. Neurol Clin Pract 1 : 215-223, 2012.
 
2) Graus F, et al : Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75 : 1135-1140, 2004.
PubMed
3) Titulaer MJ, et al : Screening for tumors in paraneoplastic syndromes : report of an EFNS Task Force. Eur J Neurol 18 : 19-27, 2011.
 
4) Vincent A, et al : Autoantibodies associated with diseases of the CNS : new developments and future challenges. Lancet Neurol 10 : 759-772, 2011.
PubMed
5) Lang B, et al : Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 2 : 224-226, 1981.
PubMed
6) Motomura M, et al : An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 58 : 85-87, 1995.
PubMed
7) Sillevis Smitt P, et al : Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 342 : 21-27, 2000.
PubMed
8) Margnier R, et al : Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis : a primary autoimmune disease? Arch Neurol 67 : 627-630, 2010.
 
9) Maeda A, et al : Vaccination with recoverin, a cancer-associated retinopathy antigen, induces autoimmune retinal dysfunction and tumor cell regression in mice. Eur J Immunol 32 : 2300-2307, 2002.
PubMed
10) Sommer C, et al : Paraneoplastic stiff-person syndrome : passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet 365 : 1406-1411, 2005.
PubMed
11) Lancaster E, et al : Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology 77 : 1698-1701, 2011.
PubMed
12) Dalmau J, et al : Clinical experience and laboratory investigations in patients with anti NMDAR encephalitis. Lancet Neurol 10 : 63-74, 2011.
PubMed
13) Shams'ili S, et al : An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 253 : 16-20, 2006.
PubMed
14) Dalmau J, et al : Overview the paraneoplastic syndromes of nervous system. UpToDate. [http://www.uptodate.com/contents/overview-of-paraneoplastic-syndromes-of-the-nervous-system]
 
P.746 掲載の参考文献
1) Henson RA, et al : Encephalomyelitis with carcinoma. Brain 88 : 449-464, 1965.
PubMed
2) Dalmau J, Rosenfeld MR : Paraneoplastic syndromes of the CNS. Lancet Neurol 7 : 327-340, 2008.
PubMed
3) Graus F, et al : Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75 : 1135-1140, 2007.
 
4) Shirafuji T, et al : Anti-Hu-associated paraneoplastic encephalomyelitis with esophageal small cell carcinoma. Intern Med 51 : 2423-2427, 2012.
PubMed
5) Graber JJ, Nolan CP : Myelopathies in patients with cancer. Arch Neurol 67 : 298-304, 2010.
PubMed
6) Graus F, et al : Anti-Hu-associated paraneoplastic encephalomyelitis : analysis of 200 patients. Brain 124 : 1138-1148, 2001.
PubMed
7) Pittock SJ, Lennon VA : Aquaporin-4 autoantibodies in a paraneoplastic context Arch Neurol 65 : 629-632, 2008.
 
8) Glantz MJ, et al : The radiographic diagnosis and treatment of paraneoplastic central nervous system disease. Cancer 73 : 168-175, 1994.
PubMed
9) Flanagan EP, et al : Paraneoplastic isolated myelopathy : clinical course and neuroimaging clues. Neurology 76 : 2089-2095, 2011.
PubMed
P.751 掲載の参考文献
1) Graus F, et al : Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75 : 1135-1140, 2004.
PubMed
2) Brierley JB, et al : Subacute encephalitis of later adult mainly affecting the limbic areas. Brain 83 : 357-368, 1960.
 
3) Corsellis JAN, et al : "Limbic encephalitis" and its association with carcinoma. Brain 91 : 481-496, 1968.
 
4) Alamowitch S, et al : Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain 120 : 923-928, 1997.
PubMed
5) Voltz R et al : A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med 340 : 1788-1795, 1999.
PubMed
6) Dalmau J, Rosenfeld MR : Overview of paraneoplastic syndromes of the nervous system. Up To Date. [http://update.com/content/overview-of-paraneoplastic-syndromes-of-the-nervous-system]
 
7) Gultekin SH, et al : Paraneoplastic limbic encephalitis : neurological symptoms, immunological find-ings and tumour association in 50 patients. Brain 123 : 1481-1494, 2000.
 
8) Foster AR, Caplan JP : Paraneoplastic limbic encephalitis. Psychosomatics 50 : 108-113, 2009.
PubMed
9) 田中惠子 : 傍腫瘍性神経症候群と抗神経抗体. 臨床神経学 50 : 371-378, 2010.
 
10) Dalmau J, et al : Clinical analysis of anti-Ma2-associated encephalitis. Brain 127 : 1831-1844, 2004.
PubMed
11) Muehlschlegel S, et al : Paraneoplastic chorea with leukoencephalopathy presenting with obsessive-compulsive and behavioral disorder. Mov Disord 20 : 1523-1527, 2005.
PubMed
12) Dalmau J, et al : Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 10 : 63-74, 2011.
PubMed
13) Lawn ND, et al : Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc 78 : 1363-1368, 2003.
PubMed
14) 河村満ほか : ヒトの時間認知機構の解明-神経心理学的アプローチ. Brain and Nerve 65 : 949-955, 2013.
 
15) Schnider A : Orbitofrontal reality filtering. Front Behav Neurosci 7 : 1-8, 2013.
 
16) Hirai T, et al : Limbic lobe of the human brain : evaluation with turbo fluid-attenuated inversionrecovery. Radiology 215 : 470-475, 2000.
PubMed
17) Ances BM, et al : Treatment-responsive limbic encephalitis identified by neuropil antibodies : MRI and PET correlates. Brain 128 : 1764-1777, 2005.
PubMed
18) Shams'ili S, et al : An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 253 : 16-20, 2006.
PubMed
P.756 掲載の参考文献
1) Brain WR, et al : Subacute cortical cerebellar degeneration and its relation to carcinoma. J Neurol Neurosurg Psychiatry 14 : 59-75, 1951.
PubMed
2) Voltz R : Paraneoplastic neurological syndromes : an update on diagnosis, pathogenesis, and therapy. Lancet Neurol 1 : 294-305, 2002.
PubMed
3) Honnorat J, Antoine JC : Paraneoplastic neurological syndromes. Orphanet J Rare Dis 2 : 22-31, 2007.
PubMed
4) Vernino S : Paraneoplastic cerebellar degeneration. Handb Clin Neurol 103 : 215-223, 2012.
PubMed
5) Shams'ili S, et al : Paraneoplastic cerebellar degeneration associated with antineuronal antibodies : analysis of 50 patients. Brain 126 (Pt 6) : 1409-1418, 2003.
 
6) Rojas-Marcos I, et al : Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. Medicine (Baltimore) 82 : 216-223, 2003.
PubMed
7) Pittock SJ, et al : Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 56 : 715-719, 2004.
 
8) Sillevis Smitt P, et al : Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 342 : 21-27, 2000.
PubMed
9) de Graaff E, et al : Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol 71 : 815-824, 2012.
PubMed
10) Graus F, et al : P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 59 : 764-766, 2002.
PubMed
11) Verschuuren J, et al : Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yoassociated paraneoplastic cerebellar degeneration. Acta Neuropathol 91 : 519-525, 1996.
PubMed
12) Sakai K et al : Isolation of a complementary DNA clone encoding an autoantigen recognized by an anti-neuronal cell antibody from a patient with paraneoplastic cerebellar degeneration. Ann Neurol 28 : 692-698, 1990.
PubMed
13) Albert ML, et al : Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 47 : 9-17, 2000.
PubMed
14) Tanaka M, et al : Cytotoxic T cells against a peptide of Yo protein in patients with paraneoplastic cerebellar degeneration and anti-Yo antibody. J Neurol Sci 168 : 28-31, 1999.
PubMed
15) Tanaka K, et al : Passive transfer and active immunization with the recombinant leucine-zipper (Yo) protein as an attempt to establish an animal model of paraneoplastic cerebellar degeneration. J Neurol Sci 127 : 153-158, 1994.
PubMed
P.761 掲載の参考文献
1) Leypoldt F, Wandinger KP : Paraneoplastic neurological syndromes. Clin Exp Immunol 175 : 336-348, 2014.
PubMed
2) McKeon A, Pittock SJ : Paraneoplastic encephalomyelopathies : pathology and mechanisms. Acta Neuropathol 122 : 381-400, 2011.
PubMed
3) Melzer N, et al : Paraneoplastic and non-paraneoplastic autoimmunity to neurons in the central nervous system. J Neurol 260 : 1215-1233, 2013.
PubMed
4) Giometto B, et al : Paraneoplastic neurologic syndrome in the PNS Euronetwork database : a European study from 20 centers. Arch Neurol 67 : 330-335, 2010.
PubMed
5) Blaes F : Paraneoplastic brain stem encephalitis. Curr Treat Options Neurol 15 : 201-209, 2013.
PubMed
6) Saiz A, et al : Anti-Hu-associated brainstem encephalitis. J Neurol Neurosurg Psychiatry 80 : 404-407, 2009.
PubMed
7) Pittock SJ, et al : Anti-neuronal nuclear autoantibody type 2 : paraneoplastic accompaniments. Ann Neurol 53 : 580-587, 2003.
PubMed
8) Dalmau J, et al : Clinical analysis of anti-Ma2-associated encephalitis. Brain 127 : 1831-1844, 2004.
PubMed
9) Peterson K et al : Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-YO antibody-positive patterns. Neurology 42 : 1931-1937, 1992.
 
10) Vernino S, Lennon VA : New Purkinje cell antibody (PCA-2) : marker of lung cancer-related neurological autoimmunity. Ann Neurol 47 : 297-305, 2000.
PubMed
11) Pittock SJ, et al : Amphiphysin autoimmunity : paraneoplastic accompaniments. Ann Neurol 58 : 96-107, 2005.
PubMed
12) Tan KM, et al : Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 70 : 1883-1890, 2008.
PubMed
13) Mundiyanapurath S, et al : GABA-B-receptor antibodies in paraneoplastic brainstem encephalitis. J Neuroimmunol 15 : 88-91, 2013.
 
14) 長山成美ほか : 亜急性小脳変性症, Lambert-Eaton筋無力様症候群および脳幹脳炎を合併した抗P/Q型VGCC抗体陽性肺小細胞癌の1例. BRAIN and NERVE-神経研究の進歩 60 : 1470-1474, 2008.
 
15) Jubelt B, et al : Rhombencephalitis/brainstem encephalitis. Curr Neurol Neurosci Rep 11 : 543-552, 2011.
PubMed
P.766 掲載の参考文献
1) 松本英之, 宇川義一 : オプソクローヌス・ミオクローヌス症候群. Brain Nerve 62 : 365-369, 2010.
 
2) Wong A : An update on opsoclonus. Curr Opin Neurol 20 : 25-31, 2007.
PubMed
3) Alabduljalil T, Behbehani R : Paraneoplastic syndromes in neuro-ophthalmology. Curr Opin Ophthalmol 18 : 463-469, 2007.
PubMed
4) Dalmau J, Rosenfeld MR : Paraneoplastic syndromes of the CNS. Lancet Neurol 7 : 327-340, 2008.
PubMed
5) Hasegawa S, et al : A nationwide survey of opsoclonus-myoclonus syndrome in Japanese children. Brain Dev, 2014. [Epub ahead of print]
 
6) Kambe T, et al : A mild form of adult-onset opsoclonus-myoclonus syndrome associated with antiglutamate receptor antibodies. JAMA Neurol 70 : 654-655, 2013.
PubMed
7) Korfei M, et al : Functional characterisation of autoantibodies from patients with pediatric opsoclonus-myoclonus-syndrome. J Neuroimmunol 170 : 150-157, 2005.
PubMed
8) Zee DS. Robinson DA : A hypothetical explanation of saccadic oscillations. Ann Neurol 5 : 405-414, 1979.
PubMed
9) Wong AM, et al : Opsoclonus in three dimensions : oculographic, neuropathologic and modelling correlates. J Neurol Sci 189 : 71-81, 2001.
PubMed
10) Graus F, et al : Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75 : 1135-1140, 2004.
PubMed
11) Pranzatelli MR, et al : Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 28 : 585-593, 2006.
PubMed
12) Armstrong MB, et al : Delayed, recurrent opsoclonus-myoclonus syndrome responding to plasmapheresis. Pediatr Neurol 33 : 365-367, 2005.
PubMed
13) Mitchell WG, et al : Longitudinal neurodevelopmental evaluation of children with opsoclonus-ataxia. Pediatrics 116 : 901-907, 2005.
PubMed
14) Bataller L, et al ; Spanish Opsoclonus-Myoclonus Study Group : Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 124 : 437-443, 2001.
PubMed
15) 松本英之 : 抗てんかん薬の選択. Modern Physician 33 : 1054, 2013.
 
P.775 掲載の参考文献
1) Sawyer RA, et al : Blindness caused by photoreceptor degeneration as a remote effect of cancer. Am J Ophthalmol 81 : 606-613, 1976.
PubMed
2) Milam AH, et al : Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. Invest Ophthalmol Vis Sci 34 : 91-100, 1993.
PubMed
3) Polans AS, et al : A photoreceptor calcium binding protein is recognized by autoantibodies obtained from patients with cancer-associated retinopathy. J Cell Biol 112 : 981-989, 1991.
PubMed
4) Duncan LM, et al : Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res 58 : 1515-1520, 1998.
PubMed
5) Morgans CW, et al : TRPM1 is required for the depolarizing light response in retinal ON-bipolar cells. Proc Natl Acad Sci USA 106 : 19174-19178, 2009.
PubMed
6) Koike C, et al : TRPM1 is a component of the retinal ON bipolar cell transduction channel in the mGluR6 cascade. Proc Natl Acad Sci USA 107 : 332-337, 2010.
PubMed
7) Nakamura M, et al : TRPM1 mutations are associated with the complete form of congenital stationary night blindness. Mol Vis 16 : 425-437, 2010.
PubMed
8) Dhingra A, et al : Autoantibodies in melanoma-associated retinopathy target TRPM1 cation channels of retinal ON bipolar cells. J Neurosci 31 : 3962-3967, 2011.
 
9) Kondo M, et al : Identification of autoantibodies against TRPM1 in patients with paraneoplastic retinopathy associated with ON bipolar cell dysfunction. PLoS One 6 (5) : e19911, 2011.
PubMed
10) Ueno S, et al : Degeneration of retinal on bipolar cells induced by serum including autoantibody against TRPM1 in mouse model of paraneoplastic retinopathy. PLoS One 8 (11) : e81507, 2013.
PubMed
11) Keltner JL, et al : Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome : eleven new cases and a review of 51 previously published cases. J Neuroophthalmol 21 : 173-187, 2001.
 
P.780 掲載の参考文献
1) Rosenfeld MR Posner JB : Paraneoplastic motor neuron disease. Adv Neurol 56 : 445-459, 1991.
PubMed
2) Corcia P, et al : Is there a paraneoplastic ALS? Amyotroph Lateral Scler Frontotemporal Degener 6 : 1-6, 2014.
 
3) Voltz R : Paraneoplastic neurological syndromes : an update on diagnosis, pathogenesis, and therapy. Lancet Neurol 1 : 294-305, 2002.
PubMed
4) Giometto B, et al : Paraneoplastic neurologic syndrome in the PNS Euronetwork database : a European study from 20 centers. Arch Neurol 6 : 330-335, 2010.
 
5) Briani C, et al : Spectrum of paraneoplastic disease associated with lymphoma. Neurology 76 : 705-710, 2011.
PubMed
6) Stich O, et al : Absence of paraneoplastic antineuronal antibodies in sera of 145 patients with motor neuron disease. J Neurol Neurosurg Psychiatry 78 : 883-885, 2007.
PubMed
7) Ferracci F, et al : A novel antineuronal antibody in a motor neuron syndrome associated with breast cancer. Neurology 53 : 852-855, 1999.
 
8) Berghs S, et al : Autoimmunity to beta IV spectrin in paraneoplastic lower motor neuron syndrome. Proc Natl Acad Sci USA 98 : 6945-6950, 2001.
PubMed
9) Liu YJ, et al : Aberrant activation of AMP-activated protein kinase contributes to the abnormal distribution of HuR in amyotrophic lateral sclerosis. FEBS Lett 589 : 432-439, 2015.
 
10) Henkel JS, et al : Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med 5 : 64-79, 2013.
PubMed
11) Tani T, et al : Regulatory T cells in paraneoplastic neurological syndromes. J Neuroimmunol 196 : 166-169, 2008.
PubMed
12) Graus F, et al : Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75 : 1135-1140, 2004.
PubMed
13) Forsyth PA, et al : Motor neuron syndromes in cancer patients. Ann Neurol 41 : 722-730, 1997.
PubMed
14) Gordon PH, et al : Lymphoproliferative disorders and motor neuron disease : an update. Neurology 48 : 1671-1678, 1997.
PubMed
15) Schold SC, et al : Subacute motor neuronopathy : a remote effect of lymphoma. Ann Neurol 5 : 271-287, 1979.
PubMed
P.786 掲載の参考文献
1) Koike H, et al : Paraneoplastic neuropathy : wide-ranging clinicopathological manifestations. Curr Opin Neurol 24 : 504-510, 2011.
PubMed
2) Koike H, Sobue G : Paraneoplastic neuropathy. Handb Clin Neurol 115 : 713-726, 2013.
PubMed
3) Graus F, et al : Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75 : 1135-1140, 2004.
PubMed
4) Giometto B, et al : Paraneoplastic neurologic syndrome in the PNS Euronetwork database : a European study from 20 centers. Arch Neurol 67 : 330-335, 2010.
PubMed
5) Oki Y, et al : Ataxic vs painful form of paraneoplastic neuropathy. Neurology 69 : 564-572, 2007.
PubMed
6) Graus F, et al : Anti-Hu-associated paraneoplastic encephalomyelitis : analysis of 200 patients. Brain 124 : 1138-1148, 2001.
PubMed
7) Tomita M, et al : Clinicopathological features of neuropathy associated with lymphoma. Brain 136 : 2563-2578, 2013.
PubMed
8) Vigliani MC, et al : Risk of cancer in patients with Guillain-Barre syndrome (GBS). A population-based study. J Neurol 251 : 321-326, 2004.
PubMed
9) Joint Task Force of the EFNS and the PNS : European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. J Peripher Nerv Syst 15 : 185-195, 2010.
PubMed
10) Antoine JC, et al : Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a miXed axonal and demyelinating peripheral neuropathy. Ann Neurol 49 : 214-221, 2001.
PubMed
11) Koike H, et al : Demyelinating neuropathy and autoimmune hemolytic anemia in a patient with pancreatic cancer. Intern Med 52 : 1737-1740, 2013.
 
12) Fain O, et al : Vasculitides associated with malignancies : analysis of sixty patients. Arthritis Rheum 57 : 1473-1480, 2007.
PubMed
13) Koike H, et al : The spectrum of immune-mediated autonomic neuropathies : insights from the clinicopathological features. J Neurol Neurosurg Psychiatry 84 : 98-106, 2013.
PubMed
14) Chinn JS, Schuffler MD : Paraneoplastic visceral neuropathy as a cause of severe gastrointestinal motor dysfunction. Gastroenterology 95 : 1279-1286, 1988.
PubMed
15) van Broekhoven F, et al : Human chorionic gonadotropin treatment of anti-Hu-associated paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 81 : 1341-1344, 2010.
PubMed
P.791 掲載の参考文献
1) Stertz O : Polymyositis. Berl Klin Wochenschr 53 : 489, 1916.
 
2) Barnes BE, Mawr B : Dermatomyositis and malignancy. A review of the literature. Ann Intern Med 84 : 68-76, 1976.
PubMed
3) Azuma K et al : Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis. Mod Rheumatol 21 : 178-183, 2011.
PubMed
4) Zampieri S, et al : Polymyositis, dermatomyositis and malignancy : a further intriguing link. Autoimmun Rev 9 : 449-453, 2010.
PubMed
5) Sigurgeirsson B, et al : Risk of cancer in patients with dermatomyositis or polymyositis. A polulation-based study. N Engl J Med 326 : 363-367, 1992.
 
6) Buchbinder R, et al : Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 134 : 1087-1095, 2001.
PubMed
7) Chow WH. et al : Cancer risk following polymyositis and dermatomyositis : anationwide cohort study in Denmark. Cancer Causes Control 619-13, 1995.
 
8) Catherine LH, et al : Frequency of specific cancer types in dermatomyositis and polymyositis : a population-based study. Lancet 357 : 96-100, 2001.
 
9) Cai C, et al : Regional ischemic immune myopathy : a paraneoplastic dermatomyopathy. J Neuropathol Exp Neurol 73 : 1126-1133, 2014.
PubMed
10) Wang J, et al : Meta-analysis of the association of dermatomyositis and polymyositis with cancer. Br J Dermatol 169 : 838-847, 2013.
PubMed
11) Kaji K, et al : Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis : an association with malignancy. Rheumatology (Oxford) 46 : 25-28, 2007.
PubMed
12) Trallero-Araguas E, et al : Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis : a systemic review and meta-analysis. Arthritis Rheum 64 : 523-532, 2012.
 
13) Ichimura Y, et al : Anti-NXP-2 autoantibodies in adult patients with idiopathic inflammatory myopathies : possible association with malignancy. Ann Rheum Dis 71 : 710-713, 2012.
 
14) Fiorentino DF, et al : Most patients with cance卜associated dermatomyositis have antibodyes nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum 65 : 2954-2962, 2013.
 
P.797 掲載の参考文献
1) 本村政勝, 福田卓 : Lambert-Eaton筋無力症候群. BRAIN and NERVE 63 : 745-754, 2011.
 
2) 本村政勝,福田卓 : イオンチャネルと神経免疫疾患-Lambert-Eaton筋無力症候群と小脳失調. 神経免疫 17 : 257-261, 2009.
 
3) Takamori M : Lambert-Eaton myasthenic syndrome : search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis. J Neuroimmunol 201-202 : 145-152, 2008.
 
4) Titulaer MJ, et al : Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol 29 : 902-908, 2011.
PubMed
5) Nakao YK. et al : Seronegative Lambert-Eaton myasthenic syndrome : study of 110 Japanese patients. Neurology 59 : 1773-1775, 2002.
PubMed
6) Titulaer MJ, et al : The Lambert-Eaton myasthenic syndrome 1988-2008 : a clinical picture in 97 patients. J Neuroimmunol 201-202 : 153-158, 2008.
 
7) O'Neill JH, et al : The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 111 : 577-596, 1988.
PubMed
8) Wirtz PW, et al : The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands. Neurology 63 : 397-398, 2004.
PubMed
9) Wirtz PW, et al : Associated autoimmune disease in patients with the Lambert-Eaton myasthenic syndrome and their families. J Neurol 251 : 1255-1259. 2004.
PubMed
10) Lennon VA, et al : Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 332 : 1467-1474, 1995.
PubMed
11) Motomura M, et al : Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci 147 : 35-42, 1997.
 
12) Takamori M, et al : Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome. J Neurol Sci 133 : 95-101, 1995.
PubMed
13) Titulaer MJ, et al : SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome : frequency and relation with survival. J Clin Oncol 27 : 4260-4267, 2009.
PubMed
14) Titulaer MJ, et al : Lambert-Eaton myasthenic syndrome : from clinical characteristics to therapeutic strategies. Lancet Neurol 10 : 1098-1107, 2011.
PubMed
15) Wirtz PW, et al : HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. J Neuroimmunol 159 : 230-237, 2005.
PubMed
16) Gutmann L, et al : The Eaton-Lambert syndrome and autoimmune disorders. Am J Med 53 : 354-356, 1972.
PubMed
17) Wirtz PW, et al : Associated autoimmune disease in patients with the Lambert-Eaton myasthenic syndrome and their families. J Neurol 251 : 1255-1259, 2004.
PubMed
18) Odabashi Z, et al : Postexercise facilitation of reflexes is not common in Lambert-Eaton myasthenic syndrome. Neurology 59 : 1085-1087, 2002.
 
19) Oh SJ, et al : Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 32 : 515-520, 2005.
PubMed
20) Lorenzoni PJ, et al : Non-paraneoplastic Lambert-Eaton myasthenic syndrome : a brief review of 10 cases. Arq Neuropsiquiatr 68 : 849-854, 2010.
PubMed
21) Pellkofer HL, et al : Managing non-paraneoplastic Lamert-Eaton myasthenic syndrome : clinical characteristics in 25 German patients. J Neuroimmunol 217 : 90-94, 2009.
 
22) AAEM Quality Assurance Committee : Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome : summary statement. Muscle Nerve 24 : 1236-1238, 2001.
PubMed
23) Tim RW, et al : Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients. Ann NY Acad Sci 841 : 823-826, 1998.
PubMed
24) Hatanaka Y, Oh SJ : Ten-second exercise is superior to 30-second exercise for post-exercise facilitation in diagnosing Lambert-Eaton myasthenic syndrome. Muscle Nerve 37 : 572-575, 2008.
PubMed
25) Johnston I, et al : Heterogeneity of calcium channel autoantibodies detected using a small-cell lung cancer line derived from a Lambert-Eaton myasthenic syndrome patient. Neurology 44 : 334-338, 1994.
PubMed
26) Takamori M, et al : Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome. J Neurol Sci 133 : 95-101, 1995.
PubMed
27) Takamori M, et al : Synaptotagmin can cause an immune-mediated model of Lambert-Eaton myasthenic syndrome in rats. Ann Neurol 35 : 74-80, 1994.
PubMed
28) Takamori M, et al : Antibodies to calcium channel and synaptotagmin in Lambert-Eaton myasthenic syndrome. Am J Med Sci 319 : 204-208, 2000.
PubMed
29) Takamori M, et al : Autoantibodies against M1 muscarinic acetylcholine receptor in myasthenic disorders. Eur J Neurol 14 : 1230-1235, 2007.
PubMed
30) Sabater L, et al : SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 70 : 924-928, 2008.
PubMed
31) Martin-Moutot N, et al : Distinct evolution of calcium channel antibody types in Lambert-Eaton myasthenic syndrome. J Neuroimmunol 197 : 47-53, 2008.
PubMed
32) Iwasa K, et al : LEMS IgG binds to extracellular determinants on N-type voltage-gated calcium channels, but does not reduce VGCC expression. Ann NY Acad Sci 998 : 196-199, 2003.
 
33) 岩佐和夫 : 神経筋接合部自己免疫疾患の病態に迫る. 金沢大十全医会誌 117 : 14-17, 2008.
Medical*Online
34) Sabater L, et al : SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 70 : 924-928, 2008.
PubMed
35) Stich O, et al : SOX1 antibodies in sera from patients with paraneoplastic neurological syndromes. Acta Neurol Scand 125 : 326-331. 2012.
PubMed
36) Tschernatsch M, et al : Anti-SOX1 antibodies in patients with paraneoplastic and non-paraneoplastic neuropathy. J Neuroimmunol 226 : 177-180, 2010.
PubMed
37) Vural B, et al : Frequency of SOX group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. Cancer 103 : 2575-2583, 2005.
 
38) Titulaer MJ, et al : Screening for small-cell lung cancer : a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 26 : 4276-4281, 2008.
PubMed
39) Wirtz PW : The Lambert-Eaton myasthenic syndrome : clinical, epidemiological and immunological studies, p 48-49, Febodruk B. V, Netherlands, 2005.
 
40) Newsom-Davis J : A treatment algorithm for Lambert-Eaton myasthenic syndrome. Ann NY Acad Sci 841 : 817-822, 1998.
PubMed
41) Molgo J, et al : Potency of 3, 4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur J Pharmacol 61 : 25-34, 1980.
PubMed
42) Wu ZZ, et al : Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunit. J Biol Chem 284 : 36453-36461, 2009.
PubMed
43) Keogh M, et al : Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Datebase Syst Rev CD003279, 2011.
 
44) Sanders DB, et al : A randomized trial of 3, 4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 54 : 603-607, 2000.
PubMed
45) Lindquist S, Stangel M : Update on treatment options for Lambert-Eaton myasthenic syndrome : focus on use of amifampridine. Neuropsychiatr Dis Treat 7 : 341-349, 2011.
PubMed
46) Tarr TB, et al : Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome. J Neurosci 33 : 10559-10567, 2013.
PubMed
47) Chalk CH, et al : Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 40 : 1552-1556, 1990.
PubMed
48) Maddison P, et al : Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 353 : 117-118, 1999.
PubMed
49) Maddison P, et al : Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. J Neurol Neurosurg Psychiatry 70 : 212-217, 2001.
PubMed
50) Wirtz PW, et al : P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer. J Neuroimmunol 164 : 161-165, 2005.
PubMed
51) Scagliotti G : Proteasome inhibitors in lung cancer. Crit Rev Oncol Hematol 58 : 177-189, 2006.
PubMed
52) Subklewe M, et al : Dendritic cell maturation stage determines susceptibility to the proteasome inhibito bortezomib. Hum Immunol 68 : 147-155, 2007.
 
53) Gomez AM, et al : Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenic gravis. J Immunol 186 : 2503-2513, 2011.
PubMed
54) Gomez AM, et al : Targeting plasma cells with proteasome inhibitors : possible roles in treating myasthenia gravis? Ann NY Acad Sci 1274 : 48-59, 2012.
PubMed
55) Newsom-Davis J, Murray NM : Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 34 : 480-485, 1984.
PubMed
56) Palace J, et al : A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenic gravis. Myasthenia Gravis Study group. Neurology 50 : 1778-1783, 1998.
 
57) Bain PG, et al : Effects of intravenous immunoglobulin on muscle weakness and calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 47 : 678-683, 1996.
PubMed
58) Motomura M, et al : Apheresis treatment in Lambert-Eaton myasthenic syndrome. Ther Apher 4 : 287-290, 2000.
PubMed
59) Pellkofer HL, et al : Favorable response to rituximab in a patient with anti-VGCC positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction. Muscle Nerve 40 : 305-308, 2009.
 
60) Maddison P, et al : The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 82 : 671-673, 2011.
PubMed
61) Mason WP, et al : Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 120 : 1279-1300, 1997.
PubMed
62) Lorenzoni PJ, et al : Cerebellar ataxia in non-paraneoplastic Lambert-Eaton myasthenic syndrome. J Neurol Sci 270 : 194-196, 2008.
PubMed
63) Clouston PD, et al : Paraneoplastic cerebellar degeneration. III. Cerebellar degeneration, cancer, and the Lambert-Eaton myasthenic syndrome. Neurology 42 : 1944-1950, 1992.
PubMed
64) Graus F, et al : P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 59 : 764-766, 2002.
PubMed
65) Fukuda T, et al : Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol 53 : 21-28, 2003.
PubMed
66) Liao YJ, et al : Anti-Ca2+ channel antibody attenuates Ca2+ currents and mimics cerebellar ataxia in vivo. Proc Natl Acad Sci USA 105 : 2705-2710, 2008.
PubMed
P.804 掲載の参考文献
1) Arimura K, et al : Isaacs' syndrome as a potassium channelopathy of the nerve. Muscle Nerve Suppl 11 : S55-58, 2002.
PubMed
2) Hart IK, et al : Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain 125 : 1887-1895, 2002.
PubMed
3) Newsom-Davis J, Mills KR : Immunological associations of acquired neuromyotonia (Isaacs' syndrome). Report of five cases and literature review. Brain 116 : 453-469, 1993.
PubMed
4) Arimura K et al : The origin of spontaneous discharges in acquired neuromyotonia. A Macro EMG study. Clin Neurophysiol 116 : 1835-1839, 2005.
PubMed
5) Sinha S, et al : Autoimmune aetiology for acquired neuromyotonia (Isaacs' syndrome). Lancet 338 : 75-77, 1991.
PubMed
6) 有村公良, 渡邊修 : 免疫介在性ニューロミオトニア (Isaacs症候群). Brain and Nerve 62 : 401-410, 2010.
 
7) Klein CJ, et al : Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping. JAMA Neurol 70 : 229-234, 2013.
PubMed
8) Liguori R, et al : Morvan's syndrome : clinical and serological observation in 29 cases. Brain 124 : 2417-2426, 2001.
 
9) Vincent A, et al : Potassium channel antibody-associated encephalopathy : apotentially immunotherapy-responsive form of limbic encephalitis. Brain 127 : 701-712, 2004.
 
10) 渡邊修 : VGKC関連抗体. Brain and Nerve 65 : 401-411, 2013.
 
11) Irani SR, et al : Antibodies to kvl potassium channel complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 133 : 2734-2748, 2010.
 
12) Nagado T, et al : Potassium current suppression in patients with peripheral nerve hyperexcitability. Brain 122 : 2057-2066, 1999.
PubMed
13) Kuwabara S, Misawa S : Acquired and genetic channelopathies : in vivo assessment of axonal excitability. Exp Neurol 263 : 368-371, 2015.
PubMed
14) Ahmed A, Simmons Z : Isaacs syndrome : A review. Muscle Nerve, 2015. [Epub ahead of print]
 
15) Tan KM, et al : Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 70 : 1883-1890, 2008.
PubMed
P.809 掲載の参考文献
1) Walusinski O, Honnorat J : Augustin Morvan (1819-1897), a little-known rural physician and neurologist. Rev Neurol (Paris) 169 : 2-8, 2013.
PubMed
2) Liguori R et al : Morvan'ssyndrome : peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 124 : 2417-2426. 2001.
 
3) Irani SR, et al : Morvan syndrome : clinical and serological observations in 29 cases. Ann Neurol 72 : 241-255, 2012.
PubMed
4) Irani SR et al : Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 133 : 2734-2748, 2010.
 
5) 渡邊修 : VGKC関連抗体. BRAIN NERVE 65 : 401-411, 2013.
 
6) Vincent A, et al : Autoantibodies associated with diseases of the CNS : new developments and future challenges. Lancet Neurol 10 : 759-772, 2011.
PubMed
7) Poliak S, et al : Caspr2, a new member of the neurexin superfamily, is localized at the juxtaparanodes of myelinated axons and associates with K+ channels. Neuron 24 : 1037-1047, 1999.
 
8) Lancaster E, et al : Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 69 : 303-311, 2011.
PubMed
9) Sharma S, Sharma P : Morvan syndrome : after scrotal sac drainage and chemical instillation in hydrocele. Neurol India 61 : 300-302, 2013.
PubMed
10) Vincent A, Irani SR : Caspr2 antibodies in thymoma. J Thorac Oncol 50 : 5277-5280, 2010.
 
11) Klein CJ, et al : Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping. JAMA Neurol 70 : 229-234, 2013.
PubMed
12) El-Bitar MK, et al : Morvan syndrome following B-cell lymphoma. J Child Neurol 25 : 1038-1041, 2010.
PubMed
13) Ong E, et al : Dramatic improvement after rituximab in a patient with paraneoplastic treatment-refractory Morvan syndrome associated with anti-CASPR2 antibodies. Eur J Neurol 20 : e96-97, 2013.
 
P.816 掲載の参考文献
1) Moersch FP, Woltman HW : Progressive fluctuating muscular rigidity and spasm ("stiff-man" syndrome) ; report of a case and some observations in 13 other cases. Proc Staff Meet Mayo Clin 31 : 421-427, 1956.
PubMed
2) Gordon EE, et al : Acritical survey of stiff-man syndrome. Am J Med 42 : 582-599, 1967.
 
3) Solimena M, et al : Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy. and type I diabetes mellitus. N Engl J Med 318 : 1012-1020, 1988.
 
4) McKeon A, et al : Stiff-man syndrome and variants : clinical course, treatments, and outcomes. Arch Neurol 69 : 230-238, 2012.
PubMed
5) 石井亜紀子 : Stiff-person症候群とその他の脊髄症. 脳神経 62 : 377-385, 2010.
 
6) Barker RA, et al : Review of 23 patients affected by the stiff man syndrome : clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 65 : 633-640, 1998.
PubMed
7) Brown P, et al : The stiff leg syndrome. J Neurol Neurosurg Psychiatry 62 : 31-37, 1997.
PubMed
8) 松本英之, 宇川義一 : Stiff-person症候群. Brain Medical 20 : 283-289, 2008.
Medical*Online
9) Ishizawa K, et al : Large motor neuron involvement in Stiff-man syndrome : aqualitative and quantitative study. Acta Neuropathol 97 : 63-70, 1999.
 
10) Solimena M, De Camilli P : Autoimmunity to glutamic acid decarboxylase (GAD) in Stiff-Man syndrome and insulin-dependent diabetes mellitus. Trends Neurosci 14 : 452-457, 1991.
PubMed
11) Meinck HM, Thompson PD : Stiff man syndrome and related conditions. Mov Disord 17 : 853-866, 2002.
PubMed
12) Raju R, et al : Analysis of GAD65 autoantibodies in Stiff-Person syndrome patients. Immunology 175 : 7755-7762, 2005.
PubMed
13) Saiz A, et al : Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies : diagnostic clues for this association. Brain 131 : 2553-2563, 2008.
PubMed
14) De Camilli P, et al : The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. J Exp Med 178 : 2219-2223, 1993.
PubMed
15) Sommer C, et al : Paraneoplastic stiff-person syndrome : passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet 365 : 1406-1411, 2005.
PubMed
16) Butler MH, et al : Autoimmunity to gephyrin in Stiff-Man syndrome. Neuron 26 : 307-312, 2000.
PubMed
17) Hutchinson M, et al : Progressive encephalomyelitis, rigidity, and myoclonus : a novel glycine receptor antibody. Neurology 71 : 1291-1292, 2008.
PubMed
18) Carvajal-Gonzalez A, et al : Glycine receptor antibodies in PERM and related syndromes : characteristics, clinical features and outcomes. Brain 137 : 2178-2192, 2014.
PubMed
19) McKeon A, et al : Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol 70 : 44-50, 2013.
PubMed
20) McCabe DJ, et al : Paraneoplastic "stiff person syndrome" with metastatic adenocarcinoma and anti-Ri antibodies. Neurology 62 : 1402-1404, 2004.
PubMed
21) Raju R, et al : Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome. Brain 129 : 3270-3276, 2006.
PubMed
22) Dalakas MC, et al : Stiff person syndrome : quantification, specificity, and intrathecal synthesis of GAD65 antibodies. Neurology 57 : 780-784, 2001.
PubMed
23) Levy LM, et al : Brain gamma-aminobutyric acid changes in stiff-person syndrome. Arch Neurol 62 : 970-974, 2005.
PubMed
24) Perani D, et al : PET evidence of central GABAergic changes in stiff-person syndrome. Mov Disord 22 : 1030-1033, 2007.
PubMed
25) Duddy ME, Baker MR : Stiff person syndrome. Front Neurol Neurosci 26 : 147-165, 2009.
PubMed
26) Koerner C, et al : Stiff-person syndromes : motor cortex hyperexcitability correlates with anti-GAD autoimmunity. Neurology 62 : 1357-1362, 2004.
PubMed
27) Nakane S, et al : Successful treatment of stiff person syndrome with sequential use of tacrolimus. J Neurol Neurosurg Psychiatry 84 : 1177-1180, 2013.
PubMed
28) Lorish TR, et al : Stiff-man syndrome updated. Mayo Clin Proc 64 : 629-636, 1989.
PubMed
29) Dalakas MC : Advances in the pathogenesis and treatment of patients with stiff person syndrome. Curr Neurol Neurosci Rep 8 : 48-55, 2008.
PubMed
30) Dalakas MC : Stiff person syndrome : advances in pathogenesis and therapeutic interventions. Curr Treat Options Neurol 11 : 102-110, 2009.
PubMed
31) Espay AJ, Chen R : Rigidity and spasms from autoimmune encephalomyelopathies : stiff-person syndrome. Muscle Nerve 34 : 677-690, 2006.
PubMed
32) Dalakas MC, et al : High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 345 : 1870-1876, 2001.
PubMed
33) Penn RD, Mangieri EA : Stiff-man syndrome treated with intrathecal baclofen. Neurology 43 : 2412, 1993.
PubMed
34) Hao W, et al : Plasmapheresis and immunosuppression in stiff-man syndrome with type 1 diabetes : a 2-year study. J Neurol 246 : 731-735, 1999.
PubMed
35) Harding AE, et al : Plasma exchange and immunosuppression in the stiff man syndrome. Lancet 2 : 915, 1989.
PubMed
36) Meinck HM : Stiff man syndrome. CNS Drugs 15 : 515-526, 2001.
PubMed
37) Squintani G, et al : Efficacy of pregabalin in a case of stiff-person syndrome : clinical and neurophysiological evidence. J Neurol Sci 314 : 166-168, 2012.
 
38) Ruegg SJ, et al : Levetiracetam improves paroxysmal symptoms in a patient with stiff-person syndrome. Neurology 62 : 338, 2004.
 
39) Baker MR, et al : Treatment of stiff person syndrome with rituximab. J Neurol Neurosurg Psychiatry 76 : 999-1001, 2005.
PubMed

VII 特論

P.824 掲載の参考文献
1) Okuno T, et al : The role of immune semaphorins in multiple sclerosis. FEBS Lett 585 : 3829-3835, 2011.
PubMed
2) Takamatsu H, Kumanogoh A : Diverse roles for semaphorin-plexin signaling in the immune system. Trends Immunol 33 : 127-135, 2012.
PubMed
3) Delgoffe GM, et al : Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature 501 : 252-256, 2013.
PubMed
4) Kumanogoh A, et al : Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2. Nature 419 : 629-633, 2002.
PubMed
5) Nakatsuji Y, et al : Elevation of Sema4A implicates Th cell skewing and the efficacy of IFN-β therapy in multiple sclerosis. J Immunol 188 : 4858-4865, 2012.
 
6) Koda T, et al : Sema4A inhibits the therapeutic effect of IFN-β in EAE. J Neuroimmunol 268 : 43-49, 2014.
 
7) Yong VW, et al : Interferon beta in the treatment of multiple sclerosis : mechanisms of action. Neurology 51 : 682-689, 1998.
PubMed
8) Axtell RC, et al : T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 16 : 406-412, 2010.
PubMed
9) Nakatsuji Y, et al : Roles of Sema4A in multiple sclerosis and interferon-β therapy efficacy. Clin Exp Neuroimm 4 : 274-282, 2013.
 
10) Kappos L, et al : Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis : a3-year follow-up analysis of the BENEFIT study. Lancet 370 : 389-397, 2007.
PubMed
11) Rio J, et al : Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 59 : 344-352, 2006.
PubMed
12) Giraudon P, et al : Semaphorin CD100 from activated T lymphocytes induces process extension collapse in oligodendrocytes and death of immature neural cells. J Immunol 172 : 1246-1255, 2004.
 
13) Kikutani H, Kumanogoh A : Semaphorins in interactions between T cells and antigen-presenting cells. Nat Rev Immunol 3 : 159-167, 2003.
PubMed
14) Okuno T, et al : Roles of Sema4D-plexin-Bl interactions in the central nervous system for pathogenesis of experimental autoimmune encephalomyelitis. J Immunol 184 : 1499-1506, 2010.
 
15) Smith ES, et al : SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease. Neurobiol Dis 73C : 254-268, 2014.
 
P.833 掲載の参考文献
1) Poser S, et al : Acute demyelinating disease. Classification and non-invasive diagnosis. Acta Neurol Scand 86 : 579-585, 1992.
PubMed
2) Lucchinetti CF, et al : Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 131 : 1759-1775, 2008.
PubMed
3) Yapici Z, et al : Bilateral demyelinating tumefactive lesions in three children with hemiparesis. J Child Neurol 17 : 655-660, 2002.
PubMed
4) Xia L, et al : Tumefactive demyelinating lesions : nine cases and a review of the literature. Neurosurg Rev 32 : 171-179, 2009.
 
5) Altintas A, et al : Clinical and radiological characteristics of tumefactive demyelinating lesions : follow-up study. Mult Scler 18 : 1448-1453, 2012.
PubMed
6) 清水優子 : Tumefactive Demyelinating Disease. MS Frontier 2 : 45-48, 2013.
Medical*Online
7) Kobayashi M, et al : Gadolinium enhancement patterns of tumefactive demyelinating lesions : correlations with brain biopsy findings and pathophysiology. J Neurol 261 : 1902-1910, 2014.
PubMed
8) Masdeu JC, et al : Multiple sclerosis-when and how to image. American College of Radiology. ACR Appropriateness Criteria. Radiology 215 (Suppl) : 547-562, 2000.
 
9) Kim DS, et al : Distinguishing tUmefactive demyelinating lesions from glioma or central nervous system lymphoma : added value of unenhanced CT compared with conventional contrast-enhanced MR imaging. Radiology 251 : 467-475, 2009.
PubMed
10) Cha S, et al : Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions. AJNR Am J Neuroradiol 22 : 1109-1116, 2001.
PubMed
11) Given CA 2 nd, et al : The MRI appearance of tumefactive demyelinating lesions. AJR Am J Roentgenol 182 : 195-199, 2004.
 
12) Cianfoni A, et al : Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy. AJNR Am J Neuroradiol 28 : 272 -277, 2007.
 
13) Schiepers C, et al : Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis. Mult Scler 3 : 8-17, 1997.
PubMed
14) Hardy TA, et al : Tumefactive demyelination : an approach to diagnosis and management. J Neurol Neurosurg Psychiatry 84 : 1047-1053, 2013.
PubMed
15) Fan X, et al : Rituximab for tumefactive inflammatory demyelination : a case report. Clin Neurol Neurosurg 114 : 1326-1328, 2012.
PubMed
16) Haupts MR, et al : Fulminant tumefactive multiple sclerosis : therapeutic implications of histopathology. J Neurol 255 : 1272-1273, 2008.
PubMed
17) Visser F, et al : Tumefactive multiple sclerosis lesions under fingolimod treatment, Neurology 79 : 2000-2003, 2012.
PubMed
18) Pilz G, et al : Tumefactive MS lesions under fingolimod : a case report and hterature review. Neurology 81 : 1654-1658, 2013.
PubMed
19) Jander S, et al : Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler 18 : 1650-1652, 2012.
PubMed
20) Saez JC, et al : Plasma membrane channels formed by connexins : their regulation and functions. Physiol Rev 83 : 1359-1400, 2003.
PubMed
21) Ransom B, et al : New roles for astrocytes (stars at last). Trends Neurosci 26 : 520-522, 2003.
PubMed
22) Takeuchi H, et al : Blockade of microglial glutamate release protects against ischemic brain injury. Exp Neurol 214 : 144-146, 2008.
PubMed
23) Takeuchi H, et al : Blockade of gap junction hemichannel suppresses disease progression in mouse models of amyotrophic lateral sclerosis and Alzheimer's disease. PLOS ONE 6 : e21108, 2011.
PubMed
24) Masaki K, et al : Connexin 43 astrocytopathy linked to rapidly progressive multiple sclerosis and neuromyelitis optica, PLOS ONE 8 : e72919, 2013.
PubMed
25) Masaki K, et al : Extensive loss of connexins in Balosdisease : evidence for an auto-antibody-independent astrocytopathy via impaired astrocyte-oligodendrocyte/myelin interaction. Acta Neuropathol 123 : 887-900, 2012.
PubMed
26) Saiki S, et al : Extensive hemispheric lesions with radiological evidence of blood-brain barrier integrity in a patient with neuromyelitis optica. J Neurol Sci 284 : 217-219, 2009.
 
27) Matsushita T, et al : Extensive vasogenic edema of anti-aquaporin-4 antibody-related brain lesions. Mult Scler 15 : 1113-1117, 2009.
 
28) Boulay AC, et al : Immune quiescence of the brain is set by astroglial connexin 43. J Neurosci 35 : 4427-4439, 2015.
PubMed
29) Ftinfschilling U, et al : Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature 485 : 517-521, 2012.
 
P.840 掲載の参考文献
1) Allen IC, et al : The NLRP3 inflammasome mediates in vivo innate immunity to innuenza A virus through recognition of viral RNA. Immunity 30 : 556-565, 2009.
PubMed
2) Misawa T, et al : Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol 14 : 454-460, 2013.
PubMed
3) Subramanian N, et al : The adaptor MAVS promotes NLRP3 mitochondrial localization and inflammasome activation. Cell 153 : 348-361, 2013.
PubMed
4) Schroder K, Tschopp J : The inflammasomes. Cell 140 : 821-832, 2010.
PubMed
5) Brodsky IE, Monack D : NLR-mediated control of inflammasome assembly in the host response against bacterial pathogens. Semin Immunol 21 : 199 -207, 2009.
 
6) Tschopp J, Schroder K : NLRP3 inflammasome activation : The convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 10 : 210-215, 2010.
PubMed
7) Inoue M, Shinohara ML : The role of interferon-beta in the treatment of multiple sclerosis and experimental autoimmune encephalomyelitis in the perspective of inflammasomes. Immunology 139 : 11-18, 2013.
PubMed
8) Inoue M, Shinohara ML : NLRP3 inflammasome and MS/EAE. Autoimmune Dis 2013 : 859145, 2013.
PubMed
9) Gris D, et al : NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J Immunol 185 : 974-981, 2010.
 
10) Jha S, et al : The inflammasome sensor NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18. J Neurosci 30 : 15811-15820, 2010.
PubMed
11) Inoue M, et al : NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 109 : 10480-10485, 2012.
 
12) Inoue M, et al : Interferon-beta therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome. Sci Signal 5 : ra38, 2012.
PubMed
13) Shi FD, et al : IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-gamma by NK cells. J Immunol 165 : 3099 -3104, 2000,
 
14) Coll RC, et al : A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 21 : 248-255, 2015.
PubMed
15) Shinohara ML, et al : Engagement of the type I lnterferon receptor on dendritic cells inhibits T helper 17 cell development : role of intracellular osteopontin. Immunity 29 : 68-78, 2008.
 
P.845 掲載の参考文献
1) Pollinger B, et al : Spontaneous relapsing-remitting EAE in the SJL/J mouse : MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J Exp Med 206 : 1303-1316, 2009.
PubMed
2) Bettelli E, et al : Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest 116 : 2393-2402, 2006.
 
3) Tomassini V, et al : Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Mult Scler 13 : 1086-1094, 2007.
PubMed
4) Brilot F, et al : Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 66 : 833-842, 2009.
PubMed
5) Probstel AK et al : Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 77 : 580-588, 2011.
PubMed
6) Mader S, et al : Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 8 : 184, 2011.
PubMed
7) Kitley J, et al : Myelin-Oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79 : 1273-1277, 2012.
PubMed
8) Reindl M, et al : The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 9 : 455-461, 2013.
PubMed
9) Baumann M, et al : Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry 86 : 265-272, 2015.
 
10) Kitley J, et al : Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies : a comparative study. JAMA Neurol 71 : 276-283, 2014.
PubMed
11) Rostasy K, et al : Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler 19 : 1052-1059, 2013.
 
12) Tanaka M, Tanaka K : Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system. J Neuroimmunol 270 : 98-99, 2014.
PubMed
13) Tsuburaya RS, et al : Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in a Japanese boy with recurrent optic neuritis. Brain Dev 37 : 145-148, 2015.
 
14) Ikeda K, et al : Severe demyelination but no astrocytopathy in clinically de丘nite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody. Mult Scler 21 : 656-659, 2015.
 
15) Heftberger R, et al : Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler. (in press)
 
16) Marignier R, et al : Aquaporin-4 antibody-negative neuromyelitis optica : distinct assay sensitivity-dependent entity. Neurology 80 : 2194-2200, 2013.
PubMed
17) Sato DK, et al : Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82 : 472-481, 2014.
 
18) Zamvil SS, Slavin AJ : Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm 2 : e62, 2015.
PubMed
19) Schirmer L, et al : Differential loss of KIR4.1 immunoreactivity in multiple sclerosis lesions. Ann Neurol 75 : 810-828, 2014.
PubMed
20) Mayer MC, Meinl E : Glycoproteins as targets of autoantibodies in CNS inflammation : MOG and more. Ther Adv Neurol Disord 5 : 147-159, 2012.
PubMed
21) Morell P, Quarles R : Myelin formation, structure and biochemistry. In : Basic Neurochemistry : Molecular, Cellular and Medical Aspects, 6th ed (ed by Siegel GJ, et al), p 69-94, Lippincott-Raven, Philadelphia, 1999.
 
P.852 掲載の参考文献
1) He L, Hannon GJ : MicroRNAs : small RNAs with a big role in gene regulation. Nat Rev Genet 5 : 522-531, 2004.
PubMed
2) Fabian MR, et al : Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 79 : 351-379, 2010.
PubMed
3) Otaegui D, et al : Differential micro RNA expression in PBMC from multiple sclerosis patients. PLoS One 4 : e6309. 2009.
PubMed
4) Junker A, et al : MicroRNA profiling of multiple sclerosis lesions identifies modulator of the regulatory protein CD47. Brain 132 : 3342-3352, 2009.
PubMed
5) Moore CS, et al : miR-155 as a multiple sclerosis-relevant regulator of myeloid cell polarization. Ann Neurol 74 : 709-720, 2013.
PubMed
6) Guerau-de-Arellano M, et al : Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity. Brain 134 : 3575-3586, 2011.
 
7) Gandhi R et al : Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol 73 : 729-740, 2013.
PubMed
8) De Felice B, et al : Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β. BMC Med Genomics 7 : 26, 2014.
 
9) Mufioz-Culla M, et al : Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. Mult Scler 20 : 1851-1859, 2014.
 
10) Hu R, et al : MicroRNA-155 confers encephalogenic petential to Th17 cells by promoting effector gene expression. J Immunol 190 : 5972-5980, 2013.
 
11) Saba R, et al : MicroRNA-146a : a dominant, negative regulator of the innate immune response. Front Immunol 21 : 578, 2014.
 
12) Du C, et al : MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol 10 : 1252-1259, 2009.
PubMed
13) Li Z, Rana TM : Therapeutic targeting of microRNAs : current status and fUture challenges. Nat Rev Drug Discov 13 : 622-638, 2014.
PubMed
P.859 掲載の参考文献
1) Coles AI, et al : Alemtuzumab vs. interferon beta-la in early multiple sclerosis. N Engl J Med 359 : 1786-1801, 2008.
 
2) Coles AJ, et al : Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy : a randomized controlled phase 3 triaL Lancet 380 : 1829-1839, 2012.
PubMed
3) Cohen JA, et al : Alemtuzumab versus interferon beta la as first-line treatment for patients with relapsing-remitting multiple sclerosis : a randomized controlled phase 3 trial. Lancet 380 : 1819-1828, 2012.
 
4) Chen JT, et al : Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol 63 : 254 -262, 2008.
 
5) Coles AJ, et al : Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 78 : 1069-1078, 2012.
PubMed
6) Penderis J, et al : Impaired remyelination and depletion of oligodendrocyte progenitors does not occur following repeated episodes of focal demyelination in the rat central nervous system. Brain 126 : 1382-1391, 2003.
 
7) Barkhof F, et al : Remyelinated lesions in multiple sclerosis : magnetic resonance image appearance. Arch Neurol 60 : 1073-1081, 2003.
PubMed
8) Goldschmidt T, et al : Remyelination capacity of the MS brain decreases with disease chronicity. Neurology 72 : 1914-1921, 2009.
PubMed
9) Lee Y, et al : Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 487 : 443-448, 2012.
PubMed
10) Makinodan M, et al : Oligodendrocyte plasticity with an intact cell body in vitro. PLoS One 8 : e66124, 2013.
PubMed
11) Wolswijk G : Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J Neurosci 18 : 601-609, 1998.
PubMed
12) Charles P, et al : Re-expression of PSA-NCAM in demyelinated axons : an inhibitor of remyelination in multiple sclerosis? Brain 125 : 1972-1979, 2002.
PubMed
13) John GR, et al : Multiple sclerosis : re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat Med 8 : 1115-1121, 2002.
PubMed
14) Back SA, et al : Hyaluronan accumulates in demyelinated lesions and inhibit oligodendrocyte progenitor maturation. Nat Med 11 : 966-972, 2005.
PubMed
15) Kotter MR, et al : Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. J Neurosci 26 : 328-332, 2006.
PubMed
16) Skripuletz T, et al : Astrocytes regulate myelin clearance through recruitment of microglia during cuprizone-induced demyelination. Brain 136 : 147-167, 2013.
PubMed
17) Lampron A, et al : Inefficient clearance of myelin debris by microglia impairs remyelinating processes. J Exp Med 212 : 481-495, 2015.
PubMed
18) Miron VE, et al : M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci 16 : 1211-1218, 2013.
PubMed
19) Mi S, et al : LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci 8 : 745-751, 2005.
PubMed
20) Kwon HS, et al : Myocilin is involved in NgR1/Lingo-1-mediated oligodendrocyte differentiation and myelination of the optic nerve. J Neurosci 34 : 5539-5551, 2014.
PubMed
21) Foote AK, et al : Inflammation stimulates remyelination in areas of chronic demyelination. Brain 128 : 528-539, 2005.
PubMed
22) Clarner T. et al : Corticosteroids impair remyelination in the corpus callosum of cuprizone-treated mice. J Neuroendocrinol 23 : 601-611, 2011.
PubMed
23) Barnett MH, et al : Relapsing and remitting multiple sclerosis : pathology of the newly forming lesion. Ann Neurol 55 : 458-468, 2004,
PubMed
24) Fancy SP, et al : Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev 23 : 1571-1585, 2009.
PubMed
25) Nakahara J, et al : Abnormal expression of TIP30 and arrested nucleocytoplasmic transport within oligodendrocyte precursor cells in multiple sclerosis. J Clin Invest l l9 : 169-181, 2009.
 
26) Yang W, et al : TIP30 inhibits oligodendrocyte precursor cell differentiation via cytoplasmic sequestration of Olig1. Glia 63 : 684-698, 2015.
PubMed
27) Shen S, et al : Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat Neurosci 11 : 1024-1034, 2008.
PubMed
28) Preston M, et al : Digestion products of the PH20 hyaluronidase inhibit remyelination. Ann Neurol 73 : 266-280, 2013.
PubMed
29) Mi S, et al : LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOGinduced experimental autoimmune encephalomyelitis. Nat Med 13 : 1228-1233, 2007.
PubMed
30) Zhang J, et al : Fingolimod treatment promotes proliferation and differentiation of oligodendrocyte progenitor cells in mice with experimental autoimmune encephalomyelitis. Neurobiol Dis 76 : 57-66, 2015.
PubMed
31) Deshmukh VA, et al : Aregenerative approach to the treatment of multiple sclerosis. Nature 502 : 327-332, 2013.
 
32) Abiraman K, et al : Anti-muscarinic adjunct therapy accelerates functional human oligodendrocyte repair. J Neurosci 35 : 3676-3688, 2015.
PubMed
P.867 掲載の参考文献
1) The Medical Letter日本語版補足データより. [http://www.medmk.com/mm/add/mp_multiple_sclerosis.htm]
 
2) 池上直己 : 効率性についての政策選択. 医療の政策選択, p1-34, 勁草書房, 1992.
 
3) 荻野美恵子 : 早期治療の政策および医療経済学的側面. 神経治療 30 : 722-729, 2013.
Medical*Online
4) Tanaka E, et al : Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA. Mod Rheumatol 23 (4) : 742-751, 2013.
PubMed
5) http://www.rheuma-net.or.jp/rheuma/rm400/library/pdf/guidelinelto4.pdf
 
6) 荻野美恵子 : 厚生労働科学研究費補助金 難治性疾患克服研究事業「難治性疾患の医療費構造に関する研究」平成21年度 総括・分担研究報告書, p312, 2010.
 
7) 荻野美恵子 : 難治性免疫性神経疾患における高額薬剤の使用について-包括医療において負のインセンティブが働いているか? -北里医学 44 : 7-12, 2014.
Medical*Online
8) 荻野美恵子 : 医療経済学的視点からみた多発性硬化症治療の課題 : アクチュアル 脳・神経疾患の臨床 最新アプローチ 多発性硬化症と視神経脊髄症 (辻省次編), p292-302, 中山書店, 2012.
 
9) Noyes K, et al : Cost-effectiveness of disease-modifying therapy for multiple sclerosis : a population-based study. Neurology 77 : 355-363, 2011.
PubMed
10) Goodin DS, et al : Cause of death in MS : long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study. BMJ Open 2 (6). pii : eOO1972. doi : 10.1136/bmjopen-2012-001972. Print 2012.
 
11) 多発性硬化症治療ガイドライン2010 (「多発性硬化症治療ガイドライン」作成委員会編, 日本神経学会, 日本神経免疫学会, 日本神経治療学会監), p11-15, 医学書院, 2010.
 
12) Massacesi L, et al : Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis : a multicentre randomized non-inferiority trial. PLoS One 9 (11) : e113371, 2014.
PubMed
13) Hartung DM, et al : The cost of multiple sclerosis drugs in the US and the pharmaceutical industry : too big to fail? Neurology 84 : 2185-2192, 2015.
PubMed
P.874 掲載の参考文献
1) Astrom KE, et al : Progressive multifocal leuko-encephalopathy ; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 81 : 93-111, 1958.
PubMed
2) Padgett BL, et al : Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1 : 1257-1260. 1971.
PubMed
3) Takao M : [Targeted therapy and progressive multifocal leukoencephalopathy (PML) : PML in the era of monoclonal antibody therapies]. Brain Nerve 65 : 1363-1374, 2013.
PubMed
4) Warnke C, et al : Natalizumab and progressive multifocal leukoencephalopathy : what are the causal factors and can it be avoided? Arch Neurol 67 : 923-930, 2010.
PubMed
5) Clifford DB, et al : Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis : lessons from 28 cases. Lancet Neurol 9 : 438-446, 2010.
PubMed
6) Bloomgren G, et al : Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366 : 1870-1880, 2012.
PubMed
7) Bellizzi A, et al : New insights on human polyomavirus JC and pathogenesis of progressive multifocal leukoencephalopathy. Clin Dev Immunol 2013 : 839719, 2013,
PubMed
8) Monaco MC, et al : Detection of JC virus DNA in human tonsil tissue : evidence for site of initial viral infection. J Virol 72 : 9918-9923, 1998.
PubMed
9) Keene DL, et al : Monoclonal antibodies and progressive multifocal leukoencephalopathy. Can J Neurol Sci 38 : 565-571, 2011.
PubMed
10) Yachnis A, Rivera-Zengotita M : Multiple screlosis. In : High-yield Pathology Neuropathology (ed by Yachnis A, Rivera-Zengotita M), Elsevier Saunders, Philadelphia, 2013.
 
11) Berger JR, et al : PML diagnostic criteria : consensus statement仕om the AAN Neuroinfectious Disease Section. Neurology 80 : 1430-1438, 2013.
 
12) 厚生労働科学研究費補助金 難治性疾患等克服研究事業 (難治性疾患克服研究事業) プリオン病及び遅発性ウイルス感染症に関する調査研究班 進行性多巣性白質脳症 (Progressive Multifocal Leukoencephalopathy : PML) 診療ガイドライン2013, 2013.
 
13) Wattjes MP, Barkhof F : Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. Curr Opin Neurol 27 : 260-270, 2014.
PubMed
14) Harrison DM, et al : Immune reconstitution is not a prognostic factor in progressive multifocal leukoencephalopathy. J Neuroimmunol 238 : 81-86, 2011.
 
15) Yousry TA, et al : Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 72 : 779-787, 2012.
PubMed
16) Rudick R, et al : Natalizumab : bench to bedside and beyond. JAMA Neurol 70 : 172-182, 2013.
PubMed
17) Rudick RA, et al : Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354 : 911-923, 2006.
PubMed
18) Langer-Gould A, et al : Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353 : 375-381, 2005.
 
19) Kleinschmidt-DeMasters BK, Tyler KL : Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353 : 369-374, 2005.
PubMed
20) Van Assche G, et al : Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353 : 362-368, 2005.
PubMed
21) Plavina T, et al : Anti-JC virus antibody levels in serum or plasma fUrther define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76 : 802-812, 2014.
 
22) Major EO, et al : JC viremia in natalizumab-treated patients with multiple sclerosis. N Engl J Med 368 : 2240-2241, 2013.
PubMed
23) Marshall IJ, et al : Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter/enhancer of JC virus and supports viral activity. J Gen Virol 91 : 3042-3052, 2010.
 
24) Tuccori M, et al : Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy. Oncologist 15 : 1214-1219, 2010.
PubMed
25) Sano Y, et al : RituXimab-associated progressive multifocal leukoencephalopathy derived from non-Hodgkin lymphoma : neuropathological findings and results of mefioquine treatment. Intern Med 54 : 965-970, 2015,
 
26) Kleinschmidt-DeMasters BK, et al : Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol 71 : 604-617, 2012.
PubMed
27) Johnson T, Nath A : Immune reconstitution inflammatory syndrome and the central nervous system. Curr Opin Neurol 24 : 284-290, 2011.
PubMed
28) Tan IL, et al : Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 77 : 1061-1067, 2011.
PubMed
29) Boster AL, et al : Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab. JAMA Neurol 70 : 398-402, 2013.
 
30) Clifford DB, et al : Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 68 : 1156-1164, 2011.
PubMed
31) Linda H, von Heijne A : Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy. Front Neurol 4 : 11, 2013.
PubMed
32) Phan-Ba R, et al : MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy. J Neurol Neurosurg Psychiatry 83 : 224- 226, 2012.
 
33) Mc Govern EM, Hennessy MJ : Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab. J Neurol 260 : 665-667, 2013.
PubMed
34) Clifford DB, et al : A study of mefloquine treatment for progressive multifocal leukoencephalopathy : results and exploration of predictors of PML outcomes. J Neurovirol 19 : 351-358, 2013.
 
35) Tan CS, Koralnik IJ : Progressive multifocal leukoencephalopathy and other disorders caused by JC virus : clinical features and pathogenesis. Lancet Neurol 9 : 425-437, 2010.
PubMed
36) Khatri BO, et al : Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 72 : 402-409, 2009.
PubMed
37) Hunt D, Giovannoni G : NataHzumab-associated progressive multHbcal leucoencephalopathy : a practical approach to risk profiling and monitoring. Pract Neurol 12 : 25-35, 2012.
PubMed
38) Koralnik IJ, et al : JC virus granule cell neuronopathy : a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol 57 : 576-580, 2005.
PubMed
39) Hemmaway C, et al : Cerebellar Cladophialophora bantiana infection in a patient with marginal zone lymphoma treated with immunochemotherapy including rituximab. Br J Haematol 154 : 423, 2011.
 
40) Fine AJ, et al : Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients. Clin Infect Dis 57 : 849-852, 2013.
PubMed
41) Young JD, McGwire BS : Infliximab and reactivation of cerebral toxoplasmosis. N Engl J Med 353 : 1530-1531, 2005.
PubMed
42) Kothary N, et al : Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 65 : 546-551, 2011,
PubMed
43) Kumar D, et al : A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. Arthritis Rheum 62 : 3191-3195, 2010.
 
44) Ray M, et al : A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab. Ann Rheum Dis 73 : 1429-1430, 2014.
 
45) Martin SI, et al : Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 43 : 16-24, 2006.
PubMed
46) von Geldern G, et al : PML-IRIS in a patient treated with brentuximab. Neurology 79 : 2075-2077, 2012.
 
47) Fredericks C, et al : A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab. Lupus 23 : 711-713, 2014.
 
P.882 掲載の参考文献
1) Confavreux C, et al : Rate of pregnancy related relapses in multiple sclerosis. N Engl J Med 339 : 285-291, 1998.
PubMed
2) Lu E, et al : Disease-modifying drugs for multiple sclerosis in pregnancy : a systematic review. Neurology 79 : 1130-1135, 2012.
PubMed
3) Amato MP, et al : Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis. Neurology 75 : 1794-1802, 2010.
 
4) Salminen HJ, et al : Glatiramer acetate in pregnancy : preliminary safety and birth outcomes. J Neurol 257 : 2020-2023, 2010.
PubMed
5) Lu E, et al : Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs. Mult Scler 18 : 460-467, 2012.
PubMed
6) Giannini M, et al : Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis : a prospective observational multicentric study. BMC Neurol 12 : 124, 2012.
PubMed
7) ノバルティスファーマ (株) ジレニア(R) 適正使用ガイド (藤原一男監), 2014年6月作成.
 
8) バイオジェン・アイデック (株) タイサブリ(R) 点滴静注300mg適正使用ガイド (吉良潤一監), 2014年12月作成.
 
9) Haghikia A, et al : Natalizumab use during the third trimester of pregnancy. JAMA Neurol 71 : 891-895, 2014.
PubMed
10) 大橋高志ほか : 視神経脊髄炎 (NMO) における免疫吸着療法の検討. 東京女子医科大学雑誌 78 (臨時増刊号) : 94-98, 2008.
 
11) Achiron K, et al : Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol 251 : 1133-1137, 2004.
 
12) Haas J : High dose MG in the postpartum period for prevention of exacerbations in MS. Mult Scler Suppl 2 : S18-S20, 2002.
 
13) Correale J, et al : Increase in multiple sclerosis activity after assisted reproduction technology. Ann Neurol 72 : 682-694, 2012.
PubMed
14) Portaccio E, et al : Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology 77 : 145-150, 2011.
 
15) Bourre B, et al : Pregnancy and neuromyelitis optica. Neurology 78 : 875-879, 2012.
PubMed
16) Kim W, et al : Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology 78 : 1264-1267, 2012.
PubMed
17) Shimizu Y, et al : Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder. Mult Scler, 2015. [Epub ahead of print]
 
18) 日本神経治療学会治療指針作成委員会 : 標準的神経治療 : 視神経脊髄炎 (NMO). 神経治療 30 : 777-793, 2013.
 
19) Pellkofer HL, et al : Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab. Mult Scler 15 : 1006-1008, 2009.
 
20) Ringelstein M, et al : Neuromyelitis optica and pregnancy during therapeutic B cell depletion : infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum. Mult Scl 19 : 1544-1547, 2013.
 
21) Kalidindi M, et al : Myasthenia gravis and pregnancy. J Obstet Gynaecol 27 : 30-32, 2007.
PubMed
22) 神崎昭浩, 本村政勝 : 抗MuSK抗体陽性の重症筋無力症の妊婦例と新生児一過性重症筋無力症児例. 臨床神経 51 : 188-191, 2011.
 
23) 村島温子 : 妊娠希望者・妊婦・授乳婦への対応. 内科 112 : 77-80, 2013.
 
24) Petri M : The Hopkins Lupus Pregnancy Center : ten key issues in management. Rheum Dis Clin North Am 33 : 227-235, 2007.
PubMed
25) 関節リウマチ治療におけるメトトレキサート (MTX) 診療ガイドライン2011年版 (日本リウマチ学会MTX診療ガイドライン策定小委員会編), p 40-41, 羊土社, 2011.
 

書評

最近チェックした商品履歴

Loading...